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ABSTRACT 
The incidence of oesophageal adenocarcinoma (OAC) is increasing at an alarming rate in 
the Western World. Despite advances in surgical technique and patient selection, overall 
survival remains abysmal. Understanding the molecular and genetic events in the 
evolution of OAC is crucial to improving outcome. The role of iron in the carcinogenesis of 
OAC is supported by epidemiological and experimental evidence. Oesophageal cancers 
are iron loaded and aggressively capture systemic iron to potentiate a malignant 
phenotype. This project aimed to establish that OAC cells are also capable of acquiring 
haem and to explore the potential of iron chelation therapy in the treatment of 
oesophageal cancer. 
Haem import proteins are sequentially over expressed in the evolution of OAC. Culturing 
OAC cells with supplementary haem significantly enhances viability, proliferation, 
migration and anchorage independent growth. Abrogation of haem import protein 
expression reverses the stimulatory effect of supplementary haem and significantly 
reduces tumour burden in-vivo. Different classes of iron chelators exhibit potent in-vitro 
and in-vivo anti-neoplastic action in oesophageal malignancy. Iron chelators demonstrate 
chemo-sensitising properties and are able to overcome chemo-resistance. 
Haem import proteins are potential therapeutic targets in the treatment of oesophageal 
malignancy. Iron chelation therapy represents an effective, predictable and well tolerated 
adjunct to standard chemotherapy and should be considered for clinical trial. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Oesophageal Cancer 
Oesophageal cancer is responsible for 5% of all cancer deaths in the UK and is the sixth 
most common cancer in Western populations1. There are two major histological subtypes 
of oesophageal cancer, squamous cell carcinoma (SCC) and adenocarcinoma (OAC). SCC 
and OAC differ substantially with respect to patterns of incidence and aetiological factors; 
however, both are associated with an extremely poor overall five year survival rate of just 
10%2,3. The incidence of OAC has risen alarmingly over the past 25 years and is finally 
starting to become the focus of clinical and laboratory based research4,5. Surgical 
resection is the only curative treatment for OAC, however, the majority of patients 
present with advanced disease or are unsuitable for radical intervention3. Of the minority 
that undergo surgery, the outlook remains bleak with only 20-30% surviving two years3. 
Oesophagectomy carries a 30 day mortality rate of 5-10% and the associated morbidity 
impacts on quality of life scores for three years before returning to pre-operative levels6. 
Locally advanced disease and undiagnosed metastatic spread greatly contribute to failure 
of treatment with curative intent3. High rates of loco-regional and distant recurrence has 
led to much interest in pre-operative (neoadjuvant) combination chemotherapy with 
response rates of up to 30-40%3,7. Cisplatin and 5-flurouracil (5-FU) based chemotherapy, 
combined with surgery, increases overall survival by 6% at five years, compared to 
surgery alone7. 
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Figure 1.1 Disease free and overall survival from oesophageal adenocarcinoma - long 
term results of Medical Research Council OE02 oesophageal cancer trial 
Figure A: Disease free survival and figure B: Overall survival determined by surgery alone 
(S) or neoadjuvant chemotherapy followed by surgery (CS). All patients considered 
potentially curable at allocation. CS: two cycles of combination Cisplatin and 5-
fluorouracil before surgery. 
Adapted from Allum et al7 
 
Despite the addition of neoadjuvant chemotherapy and refinement of surgical technique, 
the vast majority of patients still die from overwhelming malignant disease progression. It 
would appear that further advances in treatment will be governed by understanding the 
molecular events involved in oesophageal cancer evolution and the development of novel 
therapeutic strategies where side effects, complications and mortality associated with 
existing forms of treatment can be minimised. 
The focus of this body of work is principally OAC, however, oesophageal SCC is largely 
included throughout to reflect the importance of this histological entity and the 
considerable overlap in clinical oncological and surgical treatment of OAC and SCC. 
 3 
 
1.2 Epidemiology of oesophageal cancer 
The incidence of OAC has dramatically increased over the last 25 years and is now rising 
faster than any other malignant disease in Western nations8-12. The magnitude of such an 
increase is truly alarming considering the extremely poor survival rate, advanced stage at 
presentation, lack of therapeutic options, deficient knowledge of the disease process and 
an underfunded research programme. 
In the USA the absolute incidence of OAC increased approximately seven-fold, from 3.6 
million in 1973 to 25.6 per million in 200513,14. From the early 2000s the annual increase 
in cases has just started to show signs of slowing from an average of 8.2% to 1.3%14. 
Upon sub-classification of OAC stage at presentation, there is a drop off in the numbers 
of early stage disease that accounts for this seeming improvement, whereas the 
incidence of late regional or metastatic cases continues unabated14. This may be 
explained by improved staging techniques, leading to greater detection of regional lymph 
nodes or metastatic lesions, termed stage migration14. 
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Figure 1.2 Stage-specific incidence trends in oesophageal adenocarcinoma 1973-2006 
Adapted from Pohl et al14. 
 
For the majority of the early twentieth century, OAC was a rare entity representing only 
0.8-3.7% of all oesophageal cancers15-19. In contrast, recent publications from the United 
States4,20, United Kingdom21, Switzerland22 and Australia23 demonstrate that 30-70% of all 
oesophageal cancers are adenocarcinomas. Within Western populations, there is a fair 
degree of heterogeneity in annual incidence, for example, the United Kingdom has nearly 
twice the incidence of OAC (5-8.7/100,000) as the United States (3.7/100 000) and other 
European countries with annual reported cases varying in incidence by up to 30%24-26. 
In contrast to the West, the Middle East and Asia-Pacific has seen very little in the way of 
an OAC epidemic27. SCC retains its predominance as the major histological subtype, 
principally in the lower third of the oesophagus27,28. Regions with a high incidence of SCC 
tend to be less prosperous with some geographical locations yielding an extremely dense 
disease prevalence, up to 1:1000 adults28. One such area, the so-called “Asian 
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oesophageal cancer belt” stretches from Eastern Turkey, through Iran and southern areas 
of the former Soviet Union28-30. 
1.3 Risk factors for oesophageal malignancy 
The contrasting spectrum of risk factors for OAC and oesophageal SCC suggest markedly 
different pathological origins. A large study from the United States, examining the racial 
preponderances of the two histological subtypes, confirmed previous observations that 
oesophageal SCC was much more common in those of Afro-Caribbean  origin (SCC >90%, 
OAC 5%) compared to Caucasians (SCC 32%, OAC 66%), typically males31. Consumption of 
alcohol and smoking is much more prevalent in American Afro-Caribbeans31 and 
conversely, prevalence of Barrett’s metaplasia (BM) is low (BM is the major risk factor for 
OAC; discussed in more detail below)31,32. Tobacco and alcohol are extremely strong 
synergistic risk factors for SCC whereas tobacco alone is only weakly associated with OAC 
(2.5 times risk of non-smokers)33-35. Smoking cessation decreases the relative risk of SCC 
within a decade, however the modest increase in relative risk of OAC persists36. 
Diet appears to play a moderate role in oesophageal cancer risk. Akin to many cancers, 
the incidence of oesophageal malignancy is inversely proportional to fruit and vegetable 
intake37. Evidence supporting micronutrient intake is less robust with a modest benefit 
seen in high incidence areas of China, following micronutrient supplementation37,38. 
Chronic thermal injury, from consuming hot drinks, may increase risk but this is largely 
tempered by tea drinking; especially green tea in China37,39,40. Areas of intensely high SCC 
incidence, such as Linxian, China, are associated with dietary nitrosamines41. 
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Nitrosamines are highly carcinogenic and widely used in Asia and the Far East for food 
preservation41. 
Obesity increases the risk of OAC 2-3-fold but is not associated with an increased risk of 
SCC42-44. Obesity has been proposed as an indirect risk factor for OAC by increasing the 
risk of gastro-oesophageal reflux disease (GORD) and BM. However, some studies have 
shown the impact of obesity on OAC incidence to be independent for GORD42,43,45. 
Chronic inflammation seems to have a central role in the development of OAC46. 
Abdominal obesity (visceral fat) is increasingly being recognised as causing low level 
systemic inflammation, characterised by increased plasma levels of pro-inflammatory 
cytokines and receptors, such as interleukin-6, tumour necrosis factor-α and its receptor, 
C-reactive protein and leptin42,46-48. 
Helicobacter pylori has been associated with several benign and malignant 
gastrointestinal diseases48,49. H. pylori causes non-cardia gastric adenocarcinoma and 
gastric MALT lymphoma48,49. Specific eradication therapy and casual exposure to 
antibiotics has led to a marked decrease in H. pylori colonisation in Western countries48. 
The pattern of increasing OAC incidence and reducing incidence of non-cardia gastric 
adenocarcinoma fits geographically with H. Pylori eradication, drawing a tentative 
conclusion that the organism may have a protective role against OAC48,50-52. One 
proposed mechanism is acidification of refluxing gastric content in patients with GORD 
secondary to loss of the inhibitory effect of H. pylori on gastric acid production52. 
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1.4 Barrett’s oesophagus and gastro-oesophageal reflux 
Barrett’s oesophagus describes an acquired condition in which squamous epithelium of 
the distal oesophagus is replaced by metaplastic columnar epithelium53-55. BM is the most 
significant risk factor for the development of OAC with a relative risk of 30-120 compared 
to BM free subjects55-58. Dysplasia in BM, particularly high grade, is considered a 
precursor for invasive OAC59,60. 
BM is likely to represent a tissue response to the chronic reflux of acidified bile into the 
oesophagus55. GORD affects 40% of adults in the United States and BM is thought to 
develop in 5-20% of patients with chronic GORD61,62. Despite the high prevalence of BM, 
the absolute risk of developing invasive OAC on an individual basis is minimal. Estimates 
of cancer risk in BM are variable, ranging from 0.5-1% of patients with BM per year63-65. 
Recent meta-analysis of larger longitudinal studies placed the risk for progression to OAC 
at 0.5% per year66. Publication bias may play a role in over estimating the incidence of 
BM, favouring small studies with a tendency to over estimate cancer risk66. The 
relationship between severity and longevity of GORD symptoms, compared to OAC risk, 
has been characterised by a series of case-control studies55,67,68. Severe and prolonged 
GORD symptoms (>20 years) produced an odds ratio of 43.5 for developing OAC, 
compared to a cohort with short-term minor symptoms55. No association between GORD 
and SCC risk has been noted55. Despite the association between GORD and developing 
OAC, a lack of symptoms does not eliminate the risk of developing OAC with as many as 
40% of cases presenting with no appreciable history of GORD55. Endoscopic surveillance 
of patients with BM is recommended with the intention to identify early and potentially 
curable cancers60,69. However, the very low absolute risk of developing OAC brings into 
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question the value, cost effectiveness and timing interval of sequential endoscopies60,70. 
Furthermore, observer variation in histological diagnosis and sampling bias compound 
the difficulty in assessing the risk of progression to invasive OAC71. 
 
1.5 Barrett’s metaplasia – dysplasia – adenocarcinoma sequence 
The molecular evolution of BM to OAC is similar to the well established paradigm of the 
colorectal adenoma-carcinoma sequence72,73. A progressive alteration from benign BM, 
through stages of dysplasia and ultimately Barrett’s associated OAC can be observed74. 
The degree of dysplasia is proportional to the risk of malignant transformation74. Subjects 
with benign BM (non-dysplastic) and low grade dysplasia (LGD) have minimal risk of 
malignant progression, whereas those with high grade dysplasia (HGD) experience 
disease progression of up to 10% per annum58,60,74. Data on disease progression is 
compromised by random sampling biopsy techniques that leave the majority of mucosa 
unsampled and therefore the potential for small foci or mosaic areas of more advanced 
dysplasia to remain undetected74. Indeed, a series of surgical resection specimens 
demonstrated concurrent undetected OAC in 50% of patients with HGD, adding 
significantly to the argument that patients with HGD should undergo prophylactic 
oesophagectomy75,76. Furthermore, progression of disease is not necessarily orderly or 
inexorable74. Patients with benign BM may progress to HGD or OAC without LGD and 
patients with LGD or HGD can regress to a non-dysplastic status77. A high degree of inter-
observer variation exists in the histological diagnosis of LGD, at least in part accounting 
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for the apparent ability of benign BM to transform directly to HGD78. The histological 
diagnosis of HGD is consistently far more reliable and reproduceable79. 
Given the relatively high mortality and morbidity associated with oesophagectomy, 
attempts to identify cases of HGD that will rapidly progress to OAC have been the subject 
of investigation76,80. Features of HGD that herald malignant transformation include 
increased expression of Ki-67, abnormalities of DNA content or loss of tumour suppressor 
genes such as p5360,81. New treatment modalities including endoscopic mucosal resection 
and radiofrequency ablation have long term curative potential and may negate the need 
for radical oesophageal surgery82-84. 
 
1.6 The molecular and genetic basis for the progression of Barrett’s metaplasia to 
adenocarcinoma 
The replacement of distal oesophageal squamous mucosa with BM and the potential for 
evolution through dysplasia to invasive OAC is associated with accumulative molecular 
and genetic aberrations. A generic feature of malignancy is the abrogation or loss of 
regulatory proteins governing the cell cycle and avoidance of apoptosis85. Molecular 
alterations are described at various stages of OAC tumourigenesis including point 
mutations, loss of heterozygosity and hypermethylation at multiple tumour suppressor 
gene loci such as p16, APC, Rb, p27, and k-ras86. The origin and pertinent aberrations 
involved in the BM-dysplasia-OAC sequence are discussed in more detail below. 
1.6.1 Cellular origin of Barrett’s metaplasia The exact origin of the progenitor cells 
leading to BM is a matter for conjecture. However, BM may arise from the stem cells of 
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squamous mucosa or associated glandular ducts, which in the presence of an acid milieu, 
differentiate into unique glandular phenotypes distinct from adjacent gastric mucosa73,87. 
An alternative explanation, using a rodent model of BM, suggests that progenitor cells 
arise from the bone marrow74,87,88. The mechanisms by which these cells differentiate 
and the factors leading to the propagation of columnar, instead of squamous mucosa, are 
still largely unknown74. 
1.6.2 p16 Loss of cell cycle control at the G1/S checkpoint appears to be a critical and 
early step in the progression of BM86,89. G1/S transition is modulated by cyclin dependent 
kinases (CDKs) and cyclin dependent kinase inhibitors (CDKIs)90. The p16 gene encodes 
the CDKI, p16, which acts ultimately to inhibit phosphorylation of the retinoblastoma 
gene product (pRb) and subsequent G1/S progression, by limitation of the CDK 4/6-cyclin 
D complex91. p16 hypermethylation has been demonstrated in 75% of BM and 90% of 
dysplasia arising within BM and is considered to be integral to pathological 
progression92,93. 
1.6.3 Adenomatous polyposis coli (APC) APC protein is essential to the control of the 
canonical oncogenic Wnt signalling pathway where the APC-axin-GSK complex 
phosphorylates β-catenin, mediating its destruction94. Loss of APC function results in an 
accumulation of nuclear β-catenin, leading to activation of downstream effects including 
increased expression of the oncogenes c-Myc and cyclin D195. The APC protein also binds 
to the ends of microtubules that form the spindle apparatus during chromosome 
segregation96. Thus, APC abrogation could mediate chromosomal instability during 
metaphase89,96. In contrast to point mutations that are classically seen in colorectal 
malignancies, hypermethylation of the promoter region of the APC gene is strongly 
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associated with silencing of its expression in OAC. APC hypermethylation occurs early in 
the metaplasia-dysplasia-OAC sequence and has been described in 39% of BM and 92% of 
OAC resection specimens97,98. 
1.6.4 p53 The p53 suppressor protein is involved in multiple central cellular processes, 
including transcription, DNA repair, genomic stability, cell cycle control and 
apoptosis99,100. The major function of p53 is arresting the cell cycle at the G1 and G2 check 
points, in the presence of DNA damage101. If DNA irregularities are not successfully 
repaired then the cell is destined for apoptosis101. p53 is the most commonly mutated 
gene in human cancers and appears to occur relatively early in the metaplasia-dyplasia-
OAC progression with p53 inactivation noted in 60% of BM, 66% of BM associated 
dysplasia and 88% of OAC99,102-104. p53 loss appears to follow abrogation of p16 in almost 
all resection specimens of OAC and is a major mutation in oesophageal SCC103,105,106. 
1.6.5 p27 The CDKI, p27, is a negative regulator of the cell cycle and is highly expressed 
during the quiescent G0 and pre-replicative G1 phases
107. p27 degradation is required for 
the cell to enter S phase107. Loss of p27 is associated with aggressive behaviour in a 
variety of tumour types and p27 protein suppression has been observed in 83% of OAC 
and 50% of BM associated HGD107,108. High levels of p27 mRNA expression suggests post-
transcriptional modification of the protein in OAC cells107. 
1.6.6 Cyclin D1 Cyclin D1 positively regulates transmission of the cell cycle through the 
G1/S interface by promoting CDK4 and CDK6 and inactivating pRb
109-111. Over expression 
of this proto-oncogene has been observed in a variety of cancers, including oesophageal 
SCC112.  Cyclin D1 is over expressed in 46% of BM biopsies and is associated with a 6-7 
fold increase in progression to OAC113,114. 
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1.6.7 Retinoblastoma gene (Rb) The Rb gene product (pRb) halts the cell cycle at G1/S 
with a requirement to be phosphorylated to allow progression to S, G2 and M
115,116. pRb is 
also linked to apoptotic pathways mediated by p53117. Loss of heterozygosity and 
expression of the Rb gene are seen in the development of retinoblastoma and several 
other cancers115. The Rb gene locus appears to be aberrant in 36-48% of OAC and has 
been observed in BM118-121. 
1.6.8 K-ras The K-ras proto-oncogene encodes a highly conserved protein involved with 
growth and differentiation signal transduction122. K-ras mutations have been identified in 
40% of BM associated HGD and 30% of OAC123. Although thought to be an early event in 
the development gastrointestinal cancers, K-ras mutations have not been detected in 
non-dysplasic BM122-124. 
1.6.9 Bcl-2 In addition to cellular proliferation, malignant cells can exhibit avoidance of 
apoptosis. The Bcl-2 oncogene is able to repress a number of apoptotic programs by 
inhibiting activation of caspases that dismantle the cell through protease activity125,126. 
Weak bcl-2 expression is seen in oesophagitis uncomplicated by BM. However, BM and 
BM associated LGD exhibit marked bcl-2 over expression (72% and 100% of biopsies) 
suggesting an early role for bcl-2 deregulation in the BM-dysplasia-carcinoma 
sequence127. Bcl-2 expression in HGD and OAC is much less frequent, indicating that 
established OAC avoids apoptosis via alternative mechanisms127. 
1.6.10 Cell adhesion and interaction in the malignant progression of oesophageal 
adenocarcinoma Tumour infiltration and metastatic spread is strongly influenced by the 
ability to modify adhesions between cells and the supporting extracellular matrix128. E-
cadherins are calcium dependent transmembrane glycoproteins responsible for cell 
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adhesion in epithelial tissues128,129. Cadherins are anchored to the axin cytoskeleton 
maintaining cell-cell contact, signal transduction and cell polarity130. Loss of E-cadherin 
aids cell invasion and has been proposed as an important suppressor of malignant activity 
in numerous cancers131,132. Progressive loss of E-cadherin expression has been observed 
through the BM-dysplasia-OAC sequence and further loss of E-cadherin, in established 
OAC, is associated with poor differentiation and lymph node metastasis128,133,134. 
1.6.11 The role of growth factors in the malignant progression of oesophageal 
adenocarcinoma Signalling pathways that mediate the normal functions of growth 
factors are commonly subverted in cancer. OAC is no exception and is associated with a 
number of growth factor aberrations135. Epidermal growth factor receptor (EGFR) 
activation results in a cascade of cellular responses associated with cell division, 
proliferation and angiogenesis135. EGFR is over expressed in 55% of OAC cases and has 
been correlated with poor survival135. The c-erbB-2 oncogene codes for a transmembrane 
growth factor receptor with ligands including, Neu-differentiating factor and heregulin136-
138. Over expression in human cancers is associated with increased risk of metastasis and 
amplification of the gene has been suggested as an important prognostic marker in 
OAC135,139,140. Over expression of c-erbB-2 occurs in between 16-25% of OAC cases and 
first appears in the late stages of dysplasia135,141. 
1.6.12 Immortalisation of cells in the progression of oesophageal adenocarcinoma 
Telomeres are highly conserved specialised structures at the ends of eukaryotic 
chromosomes that slowly shorten with each round of replication142. Telomeric shortening 
ultimately leads to cell death, limiting proliferation and aiding cell senescence143. 
Telomerase activity confers immortalisation to cells by maintaining telomeric length and 
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facilitating accumulation of genetic defects143. Increasing telomerase activity is widely 
evident in the progression from BM to invasive OAC144. 
1.6.13 Other genes involved in the malignant progression of oesophageal 
adenocarcinoma Repeated reflux of acidified bile into the lower oesophagus can 
promote mucosal oxidative stress and induce transcription of genes associated with 
malignant progression55. Inducible nitric oxide synthase (iNOS) is over expressed in 76% 
of BM and 80% of OAC biopsies145. Nitric oxide is a potent ROS, capable of inducing DNA 
mutations146. BM, when exposed to acidified bile, is known to express the 
endoperoxidase cyclo-oxygenase-2 (COX2); downstream effects include expression of the 
apoptosis avoidance oncogene Bcl-2, inhibition of immune surveillance and promotion of 
angiogenesis147. 
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Figure 1.3 Summary of the genetic basis for progression through the Barrett’s 
Metaplasia-dysplasia-adenocarcinoma sequence 
LOH - loss of heterozygosity; Rb - retinoblastoma gene; Mdm - murine double minute; 
APC - adenomatous polyposis coli gene; Bcl - B cell lymphoma; VEGF - vascular 
endothelial growth factor; VEGFR - vascular endothelial growth factor receptor; EGF - 
epidermal growth factor; COX - cycloxygenase; iNOS - inducible nitric oxide synthase; k-
ras - Kirsten rat sarcoma 
Reproduced with the kind permission of Dr JK Roberts, University of Birmingham, UK. 
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1.7 The role of iron in malignant progression of oesophageal adenocarcinoma 
The weight of epidemiological and experimental evidence associating iron with cancer 
incidence and progression is mounting148-155. Global variation in the incidence of cancer 
has been attributed to environmental influences, including dietary preferences148. Diets 
high in red and processed meats have been associated with carcinogenesis at numerous 
anatomical sites, most thoroughly explored in the case of colorectal 
adenocarcinoma148,153,156-162. The presence of heterocyclic amines, polycyclic aromatic 
hydrocarbons and N-nitroso compounds in consumed meat, created during high 
temperature cooking methods or preservation techniques, have been extensively 
evaluated as risk factors for the development of gastric adenocarcinoma and OAC148,163. 
More recently, in a large prospective trial, high red meat consumption, independent of 
cooking or preservation technique, was associated with OAC and oesophageal SCC149. 
Furthermore, haem and iron derived from dietary meat has been significantly correlated 
with oesophageal and gastric adenocarcinoma occurrence164. 
Whole body iron stores slowly accumulate with ageing, as intake gradually exceeds 
loss165. Cohort studies have correlated a replete iron state with increased risk of cancer 
mortality151,154,166. The genetic disorder hereditary haemochromatosis, characterised by 
excessive gastrointestinal absorption and storage of iron, is strongly associated with 
hepatocellular carcinoma and other non-hepatic malignancies, including oesophageal and 
colorectal cancer152,155. A randomised trial, allocating patients to regular venesection or 
control, found a significant correlation between reduced ferritin levels in venesected 
patients and reduced overall risk of developing visceral malignancy over a 4 year 
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period167. More specifically, increased frequency of blood donation is associated with a 
decreased incidence of OAC among men with a latency period of 3-7 years168. 
In addition to epidemiological evidence, animal studies have started to yield experimental 
evidence implicating iron in OAC carcinogenesis150,169,170. Investigators produced a rat 
model of GORD to explore the association between BM and OAC in humans150. GORD was 
reproduced with a surgical oesophagogastro-duodenal anastomosis, however 
development of OAC was an infrequent event and the rats developed anaemia150. In an 
attempt to prevent anaemia, intra-peritoneal injections of iron dextran were 
administered whereupon, it was observed that animals receiving supplementary iron had 
a very high incidence of BM and OAC (91% and 73%, respectively, at 31 weeks)170. Iron 
supplemented rats demonstrated progressive epithelial cell proliferation, hyperplasia, 
inflammation and iron deposition in the distal oesophagus, compared to control 
counterparts170. The investigators’ resolve further advanced the cause by assigning rats to 
four experimental arms: non-operated controls +/- iron dextran supplementation; 
oesophagogastro-duodenal anastomosis +/- supplementary iron dextran169. After 40 
weeks, the rats were culled. All non-operated controls showed no evidence of BM, 
dysplasia or OAC. In the surgical GORD models, 53% of non-supplemented rats developed 
BM compared to 78% of the iron supplemented cohort. OAC was present in 26% and 54% 
of non-supplemented and iron supplemented GORD models, respectively. Histologically, 
all tumours were adenocarcinoma and of larger volume in the iron supplemented 
cohort169. Iron deposition and evidence of over expression of oxidative response genes 
was noted in the distal oesophagus of all rats with oesophagogasto-duodenal reflux but 
much more marked in the presence of supplementary iron. The investigators concluded 
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that iron, in the presence of GORD, was driving oxidative stress and initiating metaplasia, 
dysplasia and invasive adenocarcinoma169. 
Studies of ex-vivo human OAC and associated dysplastic BM, have shown that progression 
to invasive OAC is associated with increased expression of the iron import proteins, 
transferrin receptor 1 (TfR1), divalent metal transporter 1 (DMT1) and duodenal 
cytochrome b (Dcytb)171. Protein expression of the iron efflux protein ferroportin (FPN) 
was paradoxically increased in OAC however; FPN localisation was cytoplasmic, 
representing functional loss of iron export. These changes were not just confined to late 
stage disease but evident in the early change of low to high grade Barrett’s dysplasia. The 
authors postulated that over expression of iron transport proteins was unlikely to 
represent increased luminal iron uptake, rather the acquisition of systemic iron, through 
TfR1 mediated endocytosis171. Gross OAC iron content was significantly raised, compared 
to associated dysplastic BM, suggesting paradoxical over expression of TfR1 and DMT1  
potentially mediated by an aberration of the iron regulatory protein/iron responsive 
element (IRP-IRE) system, which is responsible for regulating cell iron content and 
discussed in more detail below171. Alternatively, these proteins may have been 
modulated by other factors that, despite normal IRP-IRE iron sensing, skew the balance 
towards induced expression171. One suggested factor was c-MYC, an oncogene reported 
to induce TfR1 and iron regulatory protein 2 (IRP2), whilst repressing H-ferritin 
expression172,173. c-MYC expression has previously been demonstrated in BM174. Indeed, 
the authors compared mRNA expression of c-MYC and TfR1 in OAC and found a positive 
correlation, suggesting c-MYC mediated TfR1 induction rather than an IRE-IRP mediated 
TfR1 suppression171. These observations, mirrored those of earlier work on colorectal 
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adenocarcinoma where iron transport proteins were up-regulated, promoting 
paradoxical cancer cell iron loading175,176. Furthermore, in-vitro culture of OAC cell lines 
with supplementary iron prompted avid proliferation and significant gross intracellular 
iron loading compared to control. TfR1 mRNA expression was significantly suppressed 
and H-ferritin protein levels increased on iron loading in keeping with an IRE-IRP 
mediated response171. 
 
 
1.8 Iron and potential mechanisms underlying carcinogenesis 
Molecular mechanisms underlying the initiation or promotion of carcinogenesis, 
secondary to systemic and cellular iron loading, are likely to be driven by multiple 
downstream effects. 
Iron is essential for all organisms and is the most abundant metal in humans with the 
average adult containing approximately 4g177. The highly reactive and toxic nature of free 
iron makes its abundance something of an enigma. However, it is this reactivity that lends 
iron a vital and diverse biochemical role in: catalysing enzymatic reactions, energy 
metabolism, oxygen transport and DNA synthesis178. Electron transfer is easily 
accomplished between ferric and ferrous iron and in the presence of oxidative stress, 
ferrous iron can reduce oxygen to produce superoxide and subsequently, hydroxyl radical 
formation (Fenton reaction)178. Hydroxyl radicals are very potent reactive oxygen species 
(ROS) with the ability to indiscriminately oxidise nucleic acids, proteins and initiate lipid 
peroxidation178,179. In order to safely access the redox potential of iron, biological 
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processes require iron to be continuously complexed with protein180. In-vitro studies, 
have clearly shown that iron can induce oxidative damage to DNA and furthermore, rat 
models of GORD suggest that iron mediated oxidative stress is central to oesophageal 
carcinogenesis; exemplified by marked over expression of oxidative stress responsive 
genes169-171,181,182. 
 
Fe2+ + H2O2 → Fe
3+ + OH• + OH-  
 Fe3+ + H2O2 → Fe
2++ OOH• + H+ 
 
Figure 1.4 The Fenton reactions 
In states of oxidative stress Fe2+ ferrous and Fe3+ ferric iron undergo electron transfer 
generating OH• hydroxyl and OOH• peroxide free radicals 
 
The antioxidant β-carotene can prevent or even reverse BM and has been 
epidemiologically associated with decreased risk of OAC183. The severity of oesophagitis is 
positively correlated with evidence of mucosal oxidative stress and most intensely 
displayed in BM184. It has been postulated that supplementary systemic iron, in rats with 
iatrogenic GORD, leaks via capillary permeability into inflamed tissue and explains the 
presence of free iron deposition in oesophagitis181. Systemic iron, bound to the soluble 
protein transferrin (Tf) in the serum, may also be endocytosed by macrophages and 
translocated to areas of inflammation and deposited185. 
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Iron is essential for cellular metabolism and is intrinsic to cell growth and replication186. It 
has long been known that iron plays a crucial role in the conversion of ribonucleotides to 
deoxyribonucleotides, a rate limiting step in DNA synthesis, catalysed by ribonucleotide 
reductase (RNR)187,188. Recent analysis of cell cycle regulation has implicated iron in the 
control of numerous checkpoints including, p53, p27kip1, cyclin D1 and CDK2186,189-192. Iron 
depletion classically arrests the cell cycle at G1/S
193,194. It follows that a selective 
advantage is conferred upon cancer cells that are able acquire iron in greater quantities, 
to drive the cell cycle and enhance proliferation. This is reflected by the overexpression of 
TfR1, greater up-take of iron from Tf and high expression of RNR in malignant 
transformation171,195-197. 
Inorganic iron and haem have both been shown to induce Wnt signalling, a major 
oncogenic signalling pathway in carcinogenesis176,198. Investigators propose a role for iron 
in the regulation of β-catenin, allowing nuclear accumulation and activation of Wnt target 
genes, including the oncogene, c-MYC176. This phenomenon appeared to be dependent 
on the background loss of functioning APC, a common finding in gastrointestinal cancers, 
suggesting that excess iron could exacerbate tumorigenesis176. Protein encoded by the c-
MYC proto-oncogene is a transcription factor that can activate or repress the expression 
of target genes. c-MYC has been shown to repress the expression of H-ferritin and 
stimulate expression of IRP2 and thus increase the intracellular iron pool; whether this is 
the driver for iron loading in OAC is yet to confirmed173. In addition, E-cadherin, a cell 
adhesion molecule commonly repressed in epithelial carcinogenesis and associated with 
Wnt signalling, has also been shown to be down-regulated in cellular iron loading, aiding 
cellular invasion and metastasis175,199,200.  
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1.9 Dietary iron 
Dietary iron exists in two main forms: inorganic iron, derived from fruit, cereals and 
vegetables and organic iron, principally derived from meat in the form of haem (ferrous 
protoporphyrin IX), which is released following digestion of haemoglobin and 
myoglobin180. The amount of iron absorbed from the diet is dependent on the content of 
inorganic and organic iron, bioavailability and iron status of the consumer201. Differences 
in the bioavailability of iron can lead to a 10-fold variation in iron absorption. Certain 
dietary constituents such as ascorbic acid can increase absorption, whereas phytate, 
calcium and polyphenols inhibit bioavailability201. 
 
 
 
 
Figure 1.5 Haem – ferrous protoporphyrin IX 
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1.10 Absorption, storage and transport of inorganic iron  
The absorption of iron occurs almost entirely in the duodenum202. Dietary inorganic iron 
is in the form of ferric iron (Fe3+) complexes and must be reduced to ferrous iron (Fe2+) 
before active transport across the brush border of the enterocyte202. Iron reduction is 
performed by a brush border surface ferric reductase protein, known as duodenal 
cytochrome b (Dcytb)202. Ferrous iron is then imported, via the divalent metal transporter 
(DMT1), to be stored bound to ferritin, utilised  within the enterocyte or systemically 
exported via ferroportin (FPN), a basolateral iron transporter203,204. FPN mediated export 
is facilitated by ferroxidase activity of the ceruloplasmin homologue hephaestin; 
producing ferric iron, in preparation for systemic transport bound to serum transferrin 
(Tf)177,205-207. Serum Tf is secreted by hepatocytes and has two iron binding sites, each 
capable of binding a single atom of ferric iron178. Nearly all inorganic iron is bound to Tf in 
the circulation, exhibiting a large degree of redundant capacity as only 30% of binding 
sites are normally occupied (Tf is termed holo or diferric Tf when iron loaded and apo-Tf 
when unoccupied)178. All non-enterocyte cells, requiring iron, express TfR1 which 
selectively binds diferric Tf178,208. The TfR-Tf complex is endocytosed and by a process of 
endosomal acidification ferric iron is released and the receptor complex re-cycled209. 
Released ferric iron is reduced to ferrous by the ferrireductase, steap3 and transported 
out of the endosome, via DMT1, to be utilised or stored in the cell bound to ferritin210,211. 
1.10.1 Duodenal cytochrome b (Dcytb) Dcytb is a plasma membrane b-type cytochrome 
with ferric reductase activity and is highly expressed on the apical border of human 
duodenal enterocytes adjacent to DMT1202,212. Dcytb mRNA and protein levels are up-
regulated by several independent stimulators of iron absorption, including chronic 
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anaemia, iron deficiency and hypoxia202. Dcytb mRNA lacks a definable IRE suggesting 
that iron dependent regulation is via an unconventional mechanism202. The physiological 
role or contribution made by Dcytb to iron absorption is debatable. In murine studies, 
involving Dcytb silencing, animals did not become iron deficient when fed a balanced 
diet213. It is possible that dietary constituents, such as ascorbate are responsible for ferric 
iron reduction, marginalising the role of Dcytb213. 
1.10.2 Divalent metal transporter 1 (DMT1) The biological function of DMT1 was 
determined through phenotypic analysis of the microcytic anaemia (mk) mouse and 
Belgrade rat; both have spontaneous mutations in DMT1 genes and develop severe 
impairment of iron transport function210,214,215. DMT1 appears to mediate the absorption 
of numerous divalent metals (Fe2+, Zn2+, Mn2+, Co2+, Cd2+, Cu2+ N2+ and Pb2+), although its 
prime role is ferrous iron transport203. Transcription of the DMT1 gene involves two splice 
variants at the 5’-end and a further two variants at the 3’-end216,217. The 5’-end variants 
produce DMT1A, found on the apical border of the enterocyte and DMT1B, which is more 
ubiquitously expressed in the TfR1 endosome where it is responsible for liberating 
endocytosed iron from Tf218. One of the 3’end untranslated region (UTR) splice variants 
contains an IRE (DMT1 IRE+ve) that is able to bind IRP and appears to respond to cellular 
iron levels in-vitro214,219. 
1.10.3 Ferritin Ferritins are highly conserved in species from bacteria and plants to 
man178. Human ferritin is a hetropolymer composed of 24 subunits. These subunits, 
designated H for heavy and L for light (alternatively for heart and liver), have a molecular 
weight of 21K and 19.5KDa, respectively. Heavy polymers predominate in the heart and 
striated muscle whereas light ferritin polymers are more abundant in the liver178. Despite 
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the differing contributions, both heavy and light chains are required for normal function; 
heavy chain knock-out mice die in-utero220. 
The vast majority of ferritin is found in the cytoplasm of cells. If intracellular iron exceeds 
requirements, ferritin is able to capture and compartmentalise free iron to prevent ROS 
generation and subsequent cellular damage178,221. The internalisation and storage of iron 
within ferritin is a complex process. Firstly two Fe2+ irons are bound by H-chain 
ferroxidase centres and rapidly oxidised forming transient diferric intermediates. The 
resulting Fe3+ irons are freed from the ferroxidase and transferred to a nucleation centre 
on the inner surface of the ferritin shell222. Iron mineralisation then occurs to produce 
polynuclear cores of ferrihydrite (5Fe2O3)
223. The exact mechanism of iron liberation from 
ferritin is poorly understood but may involve lysosomal degradation224. 
Ferritin mRNA contains a 5’–UTR IRE allowing translational control of ferritin protein by 
the IRE-IRP system, dependent on intracellular labile iron concentration225-227. 
1.10.4 Ferroportin (FPN) Ferroportin is the sole cellular efflux protein for iron and is 
principally localised on the basolateral membrane of duodenal enterocytes204. FPN is also 
expressed at other sites of major iron efflux, namely the liver, spleen, placental 
trophoblast and macrophages228. FPN is a highly conserved protein and is essential for 
maintaining extracellular iron homeostasis; total FPN deficiency is universally lethal in-
utero, blocking placental iron transport229. FPN function is governed by the systemic iron 
regulatory hormone hepcidin. In high iron states, elevated serum hepcidin levels bind to 
FPN resulting in phosphorylation, internalisation and degradation230,231. In this manner, 
iron efflux from enterocytes is prohibited, curtailing contribution to the systemic iron 
pool. Iron efflux is also prevented from the liver and macrophages leading to 
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sequestration180,229. In addition to systemic control by hepcidin, labile iron within the 
enterocyte can regulate FPN expression at a local level. FPN mRNA contains a 5’-UTR IRE, 
bringing FPN mRNA translation under control of the IRE-IRP regulatory system. However, 
the exact interaction of the IRE-IRP system with FPN mRNA is not clear204,232. 
Iron exporting cells have no significant alternative to the FPN iron efflux pathway, 
underlining the fundamental role of the hepcidin-FPN interaction in systemic iron 
homeostasis. The excessively high intestinal iron absorption, characteristic of the 
haemochromatosis group of diseases, results from inappropriately high FPN activity 
because of either hepcidin deficiency or FPN mutation, rendering it insensitive to 
degradation233,234. At the other end of the spectrum, haemoglobin production can be 
impaired as a result of inflammatory cytokine induced hepcidin excess, trapping recycled 
iron within the liver and macrophages229,235. 
1.10.5 Hephaestin Hephaestin is co-localised on the basolateral border of the enterocyte 
with FPN205,236. Hephaestin was cloned as the defective gene in sex-linked anaemic (sla) 
mice237. The sla mouse develops microcytic anaemia as a result of diminished transfer of 
iron across the basolateral membrane of the mature enterocyte237. Hephaestin has 
extensive homology with the copper containing serum ferroxidase ceruloplasmin and is 
thought to assist in the efflux of iron across the basolateral border of enterocytes by 
oxidising ferrous to ferric iron, ready for systemic transport bound to Tf206,207. The 
regulation of hephaestin appears to be in response to systemic and intracellular iron 
status by expression of the homeobox transcription factor CDX2206,238. 
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1.10.6 Transferrin receptor (TfR1) (CD71) The transferrin receptor is an essential protein 
involved in cellular iron up-take and regulation of cell growth209,239. TfR1 is a 
transmembrane glycoprotein, existing principally as a homodimer of 90,000 KDa subunits 
joined by two disulphide bonds240. Each monomer consists of a large extracellular C-
terminal domain that contains the Tf binding site, a single pass transmembrane domain 
and an intracellular N-terminal domain that requires glycosylation for receptor 
functionality240. 
Diferric Tf binds TfR1, prompting receptor mediated endocytosis and subsequent 
internalisation of the complex bound by clathrin-coated pits209.  A reduction in 
endosomal pH induces a conformational change in Tf, leading to iron release and an 
increased affinity of apo-Tf for its receptor241. The apo-Tf-TfR1 complex is then returned 
to the cell surface whereupon apo-Tf is released209. Ferric iron is reduced to ferrous iron 
by the actions of steap3211 and subsequently exported from the endosome via DMT1B210. 
TfR1 expression is principally regulated at the post transcriptional level, in response to 
intracellular iron status209,242. The large 3’ UTR of the TfR1 transcript contains 5 IREs 
which are recognised by both IRP1 and IRP2; without recognition and binding, TfR1 mRNA 
is degraded, decreasing TfR1 protein expression242. 
TfR1 is ubiquitously expressed at low levels on many cell types but is especially well 
represented on cells with a high rate of proliferation such as the basal epidermis243. A 
second transferrin receptor (TfR2) has been identified and displays some homology to 
TfR1 except in the N-terminal domain244. In contrast to TfR1, TfR2 is not regulated in 
response to intracellular iron levels209, being entirely without IREs and its expression is 
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limited to hepatocytes and small bowel enterocytes244,245. TfR2 appears to have a 
significant role in sensing systemic iron status and control of hepcidin production246. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Iron and haem transport proteins in the human enterocyte 
Dietary inorganic iron (mostly ferric) is reduced by the actions of the ferric reductase 
Dcytb and reducing agents in the diet to yield Fe2+ which enters the enterocyte via the 
divalent metal transporter 1 (DMT1). Haem is transported from the lumen by haem-
carrier protein 1 (HCP1) and broken down by haem-oxygenase 1 (HO-1) to liberate Fe2+ to 
join the common labile iron pool. Intracellular haem or the by-product of haem 
metabolism, bilirubin (bil), may be effluxed from the enterocyte back to the lumen by the 
feline leukaemic virus receptor (FLVCR) or the breast cancer resistance protein (BCRP) to 
prevent toxicity. If body iron stores are high, iron may be diverted into ferritin to be 
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stored and lost when the enterocyte is shed at the villous tip. Alternatively, iron passes 
into the labile iron pool and is subsequently processed for efflux via ferroportin (FPN) as 
Fe2+. Exiting iron is re-oxidised to Fe3+ through hephaestin (heph) to enable loading on to 
transferrin (Tf) for systemic distribution. Potential exists for intact haem to be effluxed 
through the basolateral membrane by FLVCR or BCRP to the systemic circulation. 
Modified from Sharp and Srai247. 
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1.11 Cellular regulation of iron transport and storage proteins 
The role of iron in a variety of metabolic processes necessitates that cellular levels are 
tightly controlled186. Cellular iron concentration is elegantly regulated by the interaction 
between two iron regulatory proteins (IRP1 and IRP2) and iron responsive elements 
(IREs)248,249. IRPs are ubiquitously expressed members of the aconitase gene family and 
register iron availability mainly through direct interactions with iron in the 
cytosol242,249,250. IREs are highly conserved stem-loop IRP binding structures, found on 
either the 5’ or 3’-UTRs of mRNA encoding proteins involved with iron metabolism248,250. 
The IRP-IRE interaction provides a mechanism for post-transcriptional regulation and 
subsequent expression of iron transport or storage proteins250. In iron depleted cells, IRPs 
bind to IREs, either repressing mRNA translation or stabilising mRNA to prolong its half-
life 242,250 . IRP binding to a 3’-UTR promotes mRNA translation by stabilisation whereas, 
5’-UTR binding marks mRNA for degradation, preventing translation248,250. DMT1 and 
TfR1 exhibit 3’-UTR IREs, increasing protein expression and iron influx, during low iron 
states. In contrast, ferritin and FPN have 5’-UTR IREs reducing storage capacity and 
preventing iron efflux248,250. Although IRP1 and IRP2 are similar in structure, IRP2 
regulation appears to be post translational, mediated by proteasomal degradation251. In 
addition, the relative contribution of IRP1 and IRP2 to cellular iron homeostasis varies. 
Under normal levels of oxygen tension, IRP2 is the principal protein to bind mRNA; IRP1 is 
dominant during conditions of oxidative stress252. 
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Figure 1.7 The IRE-IRP regulatory system 
Proteins involved in iron storage, iron transport, erythroid haem synthesis and TCA cycle 
are regulated by the interaction of IRPs with IREs. The binding of IRPs to a single IRE in the 
5’ –UTR region of mRNA blocks translation, whereas, IRP binding to multiple IREs in the 3’ 
–UTR region stabilises TfR1 mRNA and increases protein expression. 
IRP: iron regulatory protein; IRE: iron-responsive element; TCA: tri-carboxylic acid. 
Adapted from Hentze et al253. 
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1.12 Systemic regulation of iron 
A stable systemic iron state is required for normal biochemical function and avoidance of 
toxicity. Systemic iron homeostasis can be achieved by control of three major iron fluxes: 
absorption of dietary iron; regulation of iron storage (principally in the liver); and 
recycling of senescent erythrocytes by macrophages233. There is no excretory pathway for 
iron apart from the small, theoretical loss of iron sequestered in enterocytes which are 
lost to the bowel lumen during mucosal regeneration233,254. 
 
 
 
 
 
 
 
 
Figure 1.8 Homeostatic regulation of plasma iron 
Ferroportin functions as a hepcidin-regulated valve that controls the efflux of recycled, 
dietary and stored iron into plasma transferrin. 
Adapted from Ganz233. 
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The identification of a master iron regulatory hormone, hepcidin, has been the catalyst to 
unravelling mammalian iron homeostasis255. Hepcidin was discovered by chance during 
an attempt to knock-out an adjacent gene in murine studies. The mice inexplicably 
developed systemic iron overload, mimicking the phenotype of hereditary 
hemochromatosis256. Hepcidin is a small polypeptide secreted by hepatocytes, circulated 
in the serum and excreted in urine255,257. An increase in serum hepcidin reduces Tf 
saturation and conversely, decreased circulating hepcidin, increases Tf saturation258. 
Hepcidin acts by binding to FPN, triggering tyrosine phosphorylation, internalisation and 
lysosomal degradation259,260. Loss of functioning FPN from the basolateral surface of 
enterocytes blocks the systemic export of dietary iron from the duodenum258. Similarly, 
reticuloendothelial iron, derived mainly from senescent erythrocytes, remains 
sequestered and unavailable for haemopoiesis235,258. Hepcidin is homeostatically 
regulated by iron, erythropoietic activity and inflammation261. Hepcidin production is 
increased in states of iron excess and suppressed in iron deficiency anaemia261. Hepcidin 
is likely to be regulated by both circulating holo-Tf and intracellular iron stores261. The 
bone morphogenetic protein (BMP) pathway has gained eminence as the critical 
regulator of hepcidin expression, acting via a common mediator, Smad4, that in turn, up-
regulates transcription of HAMP, the gene encoding hepcidin262. BMP signalling can be 
modulated by co-receptors, in particular, hemojuvelin (HJV); a common cause of juvenile 
hemochromatosis in HJV gene mutations263. In addition to the BMP/HJV pathway, other 
factors are necessary for hepcidin regulation, these include TfR1, TfR2 and HFE261. Tf 
bound iron stabilises TfR2 and causes HFE to displace from TfR1 and shift to TfR2246. The 
HFE-TfR2 complex then interacts with the HJV-BMP receptor (BMPR) potentiating HAMP 
transcription and hepcidin secretion264. Mutations in TfR2 and HFE genes can cause adult 
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onset hemochromatosis261. The regulation of hepcidin expression, by erythropoietic 
activity, is not clearly delineated, however soluble proteins (growth differentiation factor 
15) produced by developing erythroblasts in the bone marrow reduce hepcidin 
production265. Hepcidin is decreased by hypoxia, possibly through alterations in the 
hypoxia-inducible factor (HIF) pathway266. Hepcidin synthesis is rapidly increased in 
infection and inflammation by the production of IL-6. IL-6 is a prominent inducer of 
hepcidin by a STAT3 dependent process267. The sequestration of iron, in the 
reticuloendothelial system, during infection or inflammation is part of the innate immune 
system, depriving infecting pathogens of iron required for replication268. Indeed, hepcidin 
was originally described for its antimicrobial properties (hepatic bactericidal protein)231. 
In chronic inflammatory processes, hepcidin production is responsible for the associated 
anaemia of chronic disease267. 
 
1.13 Absorption, transport and metabolism of haem iron 
Haem and porphyrins have fundamental roles in many cellular processes. Haem is a 
complex of iron and protoporphyrin IX and is an important co-factor in oxygen transport, 
iron storage (haemoglobin and myoglobin), mitochondrial electron transport, steroid 
metabolism and signal transduction269,270. Haem iron is the most bio-available form of 
iron from the gastrointestinal tract and is absorbed with far greater affinity than 
inorganic iron, contributing significantly to body iron stores271. The duodenum is the 
principle site of dietary haem absorption, aided by the relatively low pH of gastric acid, 
which prevents haem forming insoluble aggregates272. Conventionally, haem was thought 
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to diffuse across biological membranes due to its lipophilic nature, however it is now 
appreciated that haem and porphyrins carry anionic side chains that produce a negative 
charge, inhibiting entry to biological compartments by diffusion alone273. Haem is 
therefore transported into the enterocyte in an active energy dependent manner by the 
apically located haem carrier protein 1 (HCP1)274. HCP1 is also expressed in the liver and 
proximal tubule of the kidney, potentially to scavenge free haem275. 
In a similar manner to free iron, haem is capable of inducing ROS formation by the Fenton 
reaction and is therefore toxic to cells in excessive amounts270. Within the enterocyte, 
haem is degraded to release ferrous iron, biliverdin and carbon monoxide by the action of 
haem oxygenase 1 (HO1)276. Free ferrous iron is then readily incorporated into the 
inorganic iron regulatory pathway bound to ferritin or exported via FPN270. Very little 
dietary haem is exported from enterocytes intact, although haem efflux pathways have 
recently been recognised270. Haem excretory pathways are currently thought to be 
protective mechanisms, exporting excess haem to prevent acute toxicity, rather than a 
process for systemic haem distribution, in a manner analogous to inorganic iron efflux by 
FPN270. Two haem efflux proteins have been reported, namely, Feline leukaemic virus, 
subgroup C receptor (FLVCR) and breast cancer resistance protein (BCRP)270. FLVCR 
appears to have a major role in protecting developing erythroid cells from haem toxicity 
during maturation and has since been recognised to be highly expressed in tissues 
involved in haem trafficking namely, hepatocytes, macrophages and duodenum270,277. The 
regulation of FLVCR expression remains unknown, although could potentially be 
regulated by a transcription factor that senses intracellular haem concentration270. BCRP 
is abundantly expressed by enterocytes at an apical location; positioned perfectly for 
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effluxing dietary carcinogens back into the intestinal lumen278,279. The exact role and 
contribution of FLVCR and BRCP to intestinal haem trafficking and regulation is still to be 
determined. 
Mitochondrial iron metabolism is a complex and incompletely understood process. 
Mitochondria are the principal site of cellular haem synthesis253,279. In murine 
erythroblasts, iron appears to be transported into mitochondria by the transporter 
mitoferrin280. Iron is utilised for haem production which is required to be transported 
across the mitochondrial membrane for insertion into proteins such as cytochromes281. 
FLVCR, BRCP and the ABC-mitochrondrial erythroid transporter (ABC-me) are candidates 
for exporting this newly synthesised mitochrondrial haem into the cytoplasm273,282,283. 
Erythroid precursors require efficient iron acquisition for adequate haemoglobin (Hb) 
production. This is achieved primarily through recycling of iron through 
erythrophagocytosis of senescent erythrocytes and to a lesser degree, dietary iron 
acquisition281. Circulating erythrocytes represent a huge potential source of haem iron 
and undergo degradation within the liver, spleen and marrow. Iron from phagocytosed 
erythrocytes is liberated from haem by the action of HO1 and enters the systemic iron 
pool in an orderly fashion via FPN, to be acquired by erythroid precursors through TfR1 
mediated endocytosis274. However, approximately 10-20% of erythrocytes are lost to 
intravascular haemolysis, releasing free Hb into the systemic circulation284. Free Hb is 
ultimately scavenged by the liver, as the principal organ of detoxification, storage and 
buffering of systemic iron285. Free Hb can bind to haptoglobin (Hp), a α2 acid acute phase 
glycoprotein produced in the liver and endocytosed, as an Hb-Hp complex, by the Hb 
scavenger receptor CD163286. The endocytosed Hb-Hp complex is broken down to 
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produce haem, globin and unconjugated bilirubin by hepatocytes or macrophages287-289. 
Free Hb is also oxidised to methaemoglobin, which dissociates to form free haem285. The 
toxic potential of free haem requires it to be protein bound within the circulation. This 
function is performed by haemopexin, a 60kDa β-globulin also excreted by the liver290. 
Haemopexin is another acute phase reactant and has the highest affinity for haem of all 
proteins285,291. Once bound to haemopexin, the haem-haemopexin complex is 
endocytosed by a receptor-mediated mechanism, in the liver, akin to the diferric TfR1 
mediated up-take of inorganic iron285,292. A recent report has identified the human 
haemopexin receptor as the low-density lipoprotein receptor-related protein LRP1 (CD91) 
that is highly expressed in the liver292. The functional overlap between Hp and 
haemopexin highlights the importance of haem scavenging to iron homeostasis and the 
prevention of systemic toxicity293. 
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Figure 1.9 Overview of systemic haem and inorganic iron metabolism 
Haem is trafficked between developing erythrocytes, senescent erythrocytes, 
hepatocytes and scavenging macrophages. Haem is produced in the mitochrondria of 
developing erythrocytes and incorporated into haemoglobin (Hb) or effluxed to prevent 
haem toxicity by the feline leukaemic virus receptor (FLVCR) or breast cancer resistance 
protein (BCRP). Free extracellular haem is rapidly complexed to haemopexin (Hx) to 
prevent formation of reactive oxygen species. Senescent erythrocytes are either 
endocytosed directly by macrophages to metabolise Hb or undergo intravascular 
haemolysis. Free Hb released during haemolysis, is rapidly complexed to haptoglobin (Hp) 
and scavenged by liver and macrophage expressed haptoglobin receptors (CD163) or 
oxidised to release free haem which complexes with haemopexin. Haemopexin bound 
haem is scavenged by low-density lipoprotein receptor related protein (LRP1) expressed 
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by the liver and metabolised via haem-oxygenase 1 (HO1) to release Fe2+ that is either 
exported through ferroportin (FPN) or stored in ferritin. Fe2+ exported from the liver and 
macrophages is bound to transferrin (Tf) and joins the circulating pool of transferrin 
bound iron from the diet that is available to all systemic (non-enterocyte lineages) via 
transferrin receptor 1 (TfR1) mediated endocytosis. Haem may also be exported from the 
liver by BCRP and potentially exported intact from enterocytes via the actions of BCRP 
and FLVCR. 
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1.13.1 Haem-carrier protein 1 (HCP1) (SLC46A1)(PCFT/HCP1) HCP1 was first isolated 
from a mouse duodenum, utilising suppression subtractive hybridisation274. The search 
for an enterocytes-based protein, capable of transporting haem, was sparked by an 
earlier observation that haem is imported intact across the enterocyte brush border294. 
HCP1 is highly hydrophobic, contains nine transmembrane domains and has considerable 
homology to the bacterial metal tetracycline transporters, as members of the major 
facilitator superfamily 274. HCP1, when functionally expressed in Xenopus oocytes, 
demonstrates an ability to carry haem in a temperature-dependent and saturable 
manner274. Furthermore, HCP1 dependent import of haem is blocked in the presence of 
HCP1 antibody and appears specific for the porphyrin ring274. HCP1 mRNA expression is 
strongly regulated by hypoxia and relatively insensitive to changes in iron stores274,285,295. 
However, the protein is post-translationally regulated by redistribution between the 
apical and cytosolic compartments, depending in iron status; iron deficient mice exhibit 
apical localisation, and in iron replete states, HCP1 is confined to the cytosolic 
compartment274. The mechanism behind HCP1 distribution is yet to be elucidated285. 
HCP1 has very recently been described to bind and transport folate, with high affinity, 
across the duodenal brush border and placenta296,297. Patients suffering from hereditary 
familial folate malabsorption are homozygous for a mutation in the HCP1 gene and the 
protein has recently been re-named the proton coupled folate transporter/haem carrier 
protein 1 (PCFT/HCP1)296. 
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1.13.2 Low-density lipoprotein receptor related protein (LRP1) (CD91) (Haemopexin 
receptor) LRP1 is an extremely diverse protein that consists of five domains: the ligand 
binding cystein rich repeats; the epidermal growth factor receptor like cystein repeats; 
YWTD domains; membrane spanning segment and a cytoplasmic tail298. It has long been 
known as a multifunctional scavenger and signalling receptor that recognises a host of 
different ligands via multiple binding clusters298. At least 30 different ligands, drawn from 
several families of proteins, are represented including lipoproteins, proteinases, bacterial 
toxins, extracellular matrix proteins and inhibitor complexes298. In addition, an increasing 
number of cytoplasmic proteins have been found to interact with the tail of LRP1 to 
mediate rapid endocytosis of the receptor298,299. LRP1 is highly expressed in the liver and 
brain, originally suggesting its main role to be related to lipoprotein metabolism, 
reasoned not solely by location but also by virtue of its ability to bind chylomicron 
remnants300 and apoE, which is closely associated with Alzheimer’s disease301.However, 
LRP1 appears to have another specific role involving scavenging systemic haem. The 
haem-haemopexin complex is endocytosed by isolated hepatocytes in a manner similar 
to TfR1 mediated up-take of inorganic iron285,291,302. Extensive ligand affinity studies292 
have identified LRP1 as the responsible protein. LRP1 also exerts effects on certain serine 
proteinases and metalloproteinases, promoting it as an important regulator of 
extracellular proteolytic activity with implications for wound repair, tumour invasion and 
cellular migration298,303,304. 
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Ligand 
 
Ligand function 
ApoE 
Lipoprotein lipase 
Hepatic lipase 
Lipoprotein metabolism and transport 
tPA Fibrinolysis, signalling function in brain 
uPA Cell migration, wound healing 
Factors IXa, VIIIa, VIIa/TFP1 Coagulation 
MMP-13 and MMP-9 Angiogenesis and metastasis 
Spingolipid activator protein (SAP)  
Pregnancy zone protein 
α2M 
Pan-proteinase inhibitors, infection 
Complement C3 Infection  
PAI-1 Regulates tPA/uPA activity 
C1 inhibitor Regulates C1r/C1s activity 
Antithrombin III 
TFPI 
Heparin cofactor II 
Regulates clotting 
α1-antitrypsin Regulates neutrophil elastase 
APP Role unclear 
Thrombospondin 1 TGF-β activation, matrix cell 
interactions 
Thrombospondin 2 
Pseudomonas exotoxin A 
Collagen assembly, matrix cell 
interactions 
Lactoferrin Antibacterial 
Rhinovirus  
RAP Chaperone 
HSP-96 Chaperone 
HIV-Tat protein Transcriptional activation 
 
 
Table 1.1 The numerous and diverse ligands associated with LRP1 
List adapted from Hvidberg292 
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1.13.3 Feline leukaemic virus, subgroup C receptor (FLVCR) FLVCR was originally 
identified as the cell surface receptor for feline leukaemic virus which causes fatal 
erythrocyte aplasia in cats285,305. FLVCR was subsequently described in humans to export 
cytoplasmic haem from developing erythroid cells, protecting them from haem toxicity, 
acting as a safety valve273. FLVCR-null mice lack definitive erythropoiesis and die in mid 
gestation277. FLVCR mediated haem export is time and temperature dependent273. 
Antibody mediated inhibition of FLVCR decreases haem export, impeding maturation and 
ultimately leading to apoptosis273. FLVCR appears to mediate unidirectional haem 
transport and does not reverse its export function even when intracellular haem levels 
are depleted273. The expression of FLVCR on cell lines derived from hepatocyte and 
intestinal lineages, where haem biosynthesis or trafficking occurs, adds credence to the 
hypothesis that FLVCR is instrumental in maintaining haem homeostasis at these 
sites273,306. More recently, FLVCR has been described on the surface of macrophages, 
facilitating the export of haem derived from ingested senescent erythrocytes277. FLVCR is 
a member of the Major Facilitator Superfamily and shares a degree of structural 
homology with HCP1273,307,308. The regulation of FLVCR expression is yet to be 
ascertained, however, expression is down-regulated when globin synthesis increases273. 
FLVCR, in a similar manner to BCRP, may act as a supplement for haem regulation by HO1 
in the relatively hypoxic conditions found within the bone marrow, especially as the 
action of HO1 is largely oxygen dependent285. Very recently, a further receptor with 
marked homology to FLVCR1 has been reported. Named FLVCR2, this protein appears to 
have the potential to import haem in-vitro, however, the exact role of FLVCR2 is still to be 
elucidated309. 
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1.13.4 Breast cancer resistance protein (BCRP) (ABCG2, MXR and ABCP) BCRP is a 
member of the ATP-binding cassette transporter superfamily310,311. BCRP is expressed 
abundantly on the apical membrane of normal intestinal and colonic epithelium278 where 
its function is thought to be integral to the efflux of diet derived carcinogens279,312. 
Similarly, BCRP has a role in detoxifying drugs, toxins and metabolites which flux across 
the hepatic canalicular membranes, proximal renal tubules and placenta313. This 
protective role can be turned to the advantage of malignant cells where membrane-
embedded BCRP is able to limit the intracellular concentrations of chemotherapy agents, 
conferring a degree of chemoresistance310,314. A BCRP -/- murine model provided 
evidence for the ability of BCRP to efflux protoporphyrins, conferring cellular protection 
from photosensitivity282. Down-regulation of BCRP in colorectal cancer may explain its 
particular propensity to accumulate phototoxins with subsequent susceptibility to red 
light induced apoptosis (photodynamic therapy)312. 
BCRP has only one ABC cassette, in a single peptide of 70 KDa, that consists of six putative 
transmembrane domains315. BCRP has several regulatory elements in its promoter region 
including a hypoxia response element316. BCRP transcription is partly regulated by HIF1 
and AKt1, an upstream regulator of HIF1, that can signal BCRP to locate on the plasma 
membrane316. The regulation of BCRP expression by HIF and its ability to transport haem 
under hypoxic conditions, confers cellular survival benefit during hypoxic stress285,317. The 
action of BCRP probably reduces the generation of ROS by haem and also prevents 
mitochondrial damage leading to apoptosis285,318. 
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1.14 Iron chelation as a potential anti-neoplastic therapeutic modality 
Iron is essential for cellular metabolism, participating in a wide variety of cellular 
functions such as electron transport, energy metabolism, DNA synthesis and modulation 
of the molecules involved in cell cycle regulation191,319-322. Rapidly proliferating cancer 
cells are particularly susceptible to iron deprivation; in part due to the expression of the 
iron dependent enzyme RNR, promoting iron chelation as an attractive potential anti-
neoplastic treatment strategy319,322-324. RNR is essential for the conversion of 
ribonucleotides into deoxyribonucleotides and represents a rate limiting step in DNA 
synthesis322. RNR consists of two subunits: an R1 subunit tasked with binding 
ribonucleotides and allosteric effectors and an R2 subunit, containing a tyrosyl radical 
that is stabilised by iron187,188,322,325.  Without a constant supply of oxygen and labile iron, 
RNR rapidly becomes inactivated322,325. The overall result is a change in the expression of 
cyclins and CDK proteins, essential for cell cycle progression, causing cell arrest in G1/S 
phase and apoptosis319. The RNR inhibitor hydroxyurea  (HU) has long been used in 
clinical practice as an agent for treating chronic myelocytic leukemia, although limited by 
a short biological half life and poor affinity to RNR, HU demonstrates the clinical 
effectiveness of RNR inhibition in malignant disorders325-327.  Akin to all chemotherapeutic 
agents, clinical use of iron chelators as anti-neoplastic agents depends on at least some 
selectivity for inhibiting neoplastic cells, compared to benign parental lineages323,325,328. 
Indeed, the differences in iron metabolism between normal and neoplastic cells are 
quantitative rather than qualitative; comparison of a number of key enzymes shows RNR 
to have the greatest increase in activity between neoplastic and benign tissue325,329,330. 
Although, malignancy specific iron dependent pathways must exist; iron chelators have 
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been shown to inhibit the canonical Wnt/β-catenin oncogenic pathway in colorectal 
adenocarcinoma lineages, in an iron dependent manner331. A number of therapeutic 
strategies, based on iron deprivation, have been attempted including dietary iron 
restriction, anti-TfR1 antibodies and various iron chelating compounds319,323,325,332. Iron 
chelators alter cellular iron homeostasis either by preventing iron acquisition or if lipid 
soluble, binding the intracellular labile iron pool322,333. Broadly, iron chelators can be 
divided into three categories: naturally occurring iron chelators; clinically established 
chelators and experimental agents. 
 
 
 
Figure 1.10 Molecular structures of iron chelators Deferasirox, DFO and Dp44mT 
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1.15 Naturally occurring chelators 
Epidemiological evidence has long been established for the inverse relationship between 
dietary fibre intake and colorectal carcinoma334-336 and more recently, distal gastric 
adenocarcinomas337. Intuitively, increased dietary fibre increases colonic transit time and 
limits mucosal exposure to potential dietary carcinogens338. Fibre exhibits the ability to 
bind numerous toxic agents within the gastrointestinal tract339,340. 
Alginates, derived from seaweeds and brown algae, are another group of organic 
compounds that bind iron and various heavy metals341. Alginates are salts of alginic acid 
and are composed of linear polysaccharides containing various quantities of 1,4-linked β-
D-mannuronic and α-L-gluronic acid residues, arranged in irregular blocks along the 
chain342. Alginate, derived from Sargassum Fluitans, binds 0.99 mmolFe2+/g and 
sequesters 66 atoms of Fe3+ per chain343,344. In the gastrointestinal tract, alginate binds 
iron rendering it unavailable for absorption345. In a study of ileostomy patients receiving 
supplemental oral alginate, iron excreted via the ileostomy, was greater than the oral 
intake at +12 µM Fe compared to control (no alginate) at -8 µM Fe345. Epidemiological 
evidence, mainly from Japan,  associates a high intake of dietary seaweed with decreased 
incidence of various tumours including colorectal adenocarcinoma, oesophageal  SCC and 
breast cancer346-348. Seaweed extracts have also been demonstrated in-vitro to induce 
apoptosis in gastric carcinoma derived cell lines and induce chemo-sensitivity in human 
malignant lymphoid cells to etoposide349,350. 
Phytic acid is a major component of cereals and pulses351 with the ability to bind and 
maintain iron in the Fe3+ state, preventing the creation of destructive ROS for seed 
preservation352. In a rat model, additional dietary phytic acid decreased colonic cell 
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proliferation and in those exposed to the carcinogen, azoxymethane, supplementary 
phytic acid significantly reduced tumour burden353,354. Most pertinently, induced 
colorectal carcinogenesis in a rat model, using 1,2 dimethylhydrazine,  was significantly 
augmented by supplementary iron and then subsequently suppressed with the addition 
of phytic acid355. 
 
1.16 Clinically established iron chelators 
Iron chelators have been used for many years in the treatment of iron overload disorders. 
The clinically established iron chelators Desferrioxamine and Deferasirox are hereby 
discussed with reference to potential anti-neoplastic activity. 
1.16.1 Desferrioxamine (DFO) Desferrioxamine is the archetypal iron chelator used in 
clinical practice for the treatment of iron overload diseases, such as β-thalassemia, for 
over thirty years. DFO is a hexadentate siderophore, produced by Streptomyces Pilosus, 
that has a very high affinity for Fe3+, resulting in a stable 1:1 complex. Once bound, iron is 
metabolically inactive and does not produce ROS325,356. Although clinically effective at 
promoting iron excretion, DFO is orally inactive and requires administration by a long 
subcutaneous/parenteral infusion (12-24 hours/day, 5-6 days/week) due to a short 
plasma half life so long term compliance with treatment is challenging357. DFO exhibits 
relatively low lipophilicity and therefore has limited access to intracellular iron pools358. 
Despite the disadvantages of DFO, it has been shown to have marked anti-proliferative 
activity in a number of cellular in-vitro studies, animal models and some therapeutic 
effect in clinical trials325,328,359-362.  DFO has a potent cytotoxic effect on neuroblastoma 
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cells whilst exerting very little effect on normal benign cell lines, suggesting a heightened 
sensitivity to iron deprivation in malignant cells, compared to benign parent 
tissue325,360,361. Furthermore, bone marrow cells, as a classical model of rapidly dividing 
benign tissue, were quantified as being ten-fold less sensitive to DFO than neuroblastoma 
cells360. Breast cancer cells incubated with DFO exhibit reduced proliferation and 
increased apoptosis362and in a Fisher rat model of breast cancer, DFO significantly 
inhibited xenograft growth363.  In further examples of the therapeutic action of DFO in 
animal models, DFO treatment induced significant regression in hepatocelluar carcinoma 
xenografts and prolonged the life of mice with L1210 leukemia325,364. More pertinently, 
within the clinical setting, administration of a five day course of DFO, delivered as an 8 
hour IV infusion at 150 mg/Kg/day, resulted in a very prompt 50% reduction in malignant 
bone marrow infiltration in seven of nine participants with advanced neuroblastoma365. 
In the same trial, a single patient demonstrated a 48% reduction in tumour burden and 
encouragingly, in marked contrast to conventional chemotherapy, no toxic side effects 
were recorded365. Following on from this success, when DFO therapy was combined with 
standard cytotoxic drugs in the treatment of patients with stage III or IV neuroblastoma, 
objective responses were observed in 12 of 13 patients366. Expanded further, 
combination therapy with DFO in a large cohort of some 57 patients with neuroblastoma 
resulted in 24 complete responses, 5 very good responses, 21 partial, 3 minor and 4 had 
progressive disease367. It must be stressed, however, that these clinical trials had a single 
arm with no controls. Limited in-vitro evidence exists to suggest that DFO has a 
synergistic effect on neuroblastoma cell viability in combination with doxorubicin368. 
Haematological malignancies also appear to be sensitive to DFO exposure with numerous 
reports of marked improvements in the haematological profiles of patients with a broad 
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spectrum of highly proliferative malignancies: a neonate with refractory lymphoid 
leukaemia responded to DFO with blast cell reduction and several fold increase in 
haematological progenitor cells369. Combined with low dose cytosine arabinoside, DFO 
caused significant leukaemic cytoreduction369 and DFO administration to a patient in a 
chronic blast crisis induced a major reduction in circulating blast count370. 
DFO arrests cells in the G1/S phase of the cell cycle
189,194,371. The action of DFO on the cell 
cycle is complex but appears to be mediated by a decrease in the hyperphosphorylated 
form of pRb via suppression of cyclins D1, D2 and D3 which bind with CDK 4 to 
phosphorylate pRb189. In addition, cyclins A and B1 are also decreased in contrast to the 
action of the RNR inhibitor hydroxyurea, which increased the expression of all cyclins, 
suggesting that DFO does not directly inhibit RNR189. 
1.16.2 Deferasirox (Exjade® / ICL670, Novartis Pharma AG, Basel, Switzerland) 
Deferasirox is a recently licensed once-daily, oral iron chelator approved for the 
treatment of transfusional iron overload372,373. Deferasirox is a hydroxyphenyl-triazole 
class of tridentate chelator; two molecules are required to form a stable complex with 
each iron (Fe3+) atom. The active molecule (ICL670) is highly lipophilic and 99% albumin 
bound. Deferasirox has a high and specific affinity for Fe3+ (approximately 14 and 21 
times greater than its affinity for copper [Cu2+] and zinc [Zn2+], respectively)372,374. The 
long half-life means that Deferasirox can be taken once daily (standard dose of 20–30 
mg/kg/day) and the oral formulation confers ease-of-use ideal for self-administration at 
home (Novartis Pharmaceuticals Corporation; Deferasirox Prescribing information). 
 51 
 
In-vivo animal pharmacokinetic studies demonstrate that Deferasirox is rapidly absorbed 
and can efficiently and selectively mobilise iron from various organ systems including 
hepatocytes and cardiomyocytes374,375. The main metabolic pathway for Deferasirox is 
glucuronidation with subsequent biliary excretion. Consequently, Deferasirox and 
metabolites are primarily excreted in the faeces with a remainder eliminated by renal 
filtration (Novartis Pharmaceuticals Corporation 2009). 
The impact of oral Deferasirox on normal iron absorption was evaluated in a rat model 
and no appreciable impairment of homeostatic mechanisms of dietary iron uptake was 
demonstrated374,375. Deferasirox was generally well tolerated across a wide range of 
doses in toxicology studies with no data prohibiting administration to humans. 
Phase 1 clinical trials for use in iron overloaded individuals showed that the serum 
concentration of Deferasirox is proportional to the dose administered376. Unbound 
Deferasirox had a mean half-life of 11–19 hours, supporting the once-daily dosing 
regimen used throughout the clinical trial programme376. Deferasirox plasma levels were 
also shown to be maintained within a therapeutic range over a 24-hour period (20 
mg/kg/day: peak levels ~60–100µmol/L, trough levels ~15–20µmol/L), providing constant 
chelation activity377. 
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Figure 1.11 Mean plasma concentrations (+ SD) of Deferasirox are proportional to dose 
Adapted from Raffin el al376. 
 
The proof of concept for Deferasirox in humans was achieved by a dose escalation study 
in patients with β-thalassemia and transfusional iron overload that demonstrated a 
chelation efficiency of up to 20.5%,377 establishing an effective dose between 20–30 
mg/kg/day. Data from subsequent phase II and III comparative studies in transfusion 
dependent β-thalassemia patients, provided evidence that Deferasirox efficacy is 
comparable with DFO378,379. 
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Deferasirox has been shown to be generally well tolerated in adults and children with a 
variety chronic anemias379. A total of 652 patients received Deferasirox during core 
clinical trials; none experienced drug related neutropenia or agranulocytosis, which has 
been observed during treatment with other chelators379-381. The most frequent adverse 
events reported during chronic treatment with Deferasirox include transient mild to 
moderate gastrointestinal disturbances and skin rashes. These events rarely required 
drug discontinuation and many resolved spontaneously379. Mild, non-progressive 
increases in serum creatinine (generally within upper limit of normal) were observed in 
34% of patients, although these are not thought to be clinically significant as they were 
temporary and reversible. 
Post marketing experience of Deferasirox has involved very rare cases of renal and liver 
failure in patients with multiple co-morbidities. In addition, a small number of patients 
have developed a cytopenia which could be associated with Deferasirox treatment but all 
had advanced haematological disease (Novartis Pharmaceuticals Corporation; Deferasirox 
prescribing information). 
Over the past few years, encouraged by the antiproliferative effects of other chelators, 
ease of dosing and apparent lack of serious side effects, the potential cytotoxic effects of 
Deferasirox have come under scrutiny. Investigations are currently confined to in-vitro 
studies with the exception of a limited number of clinical observational reports involving 
haematological malignancies322,382-387. Deferasirox was found to exhibit a greater in-vitro 
cytotoxic effect on the human hepatoma cell line HUH7 than the hexadentate 
hydroxyquinoleine chelator, O-trensox387. Specifically Deferasirox decreased cellular 
viability, inhibited DNA replication and induced DNA fragmentation. Interestingly, in 
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contrast to O-trensox and other chelators, Deferasirox induced cell cycle blockade during 
S phase rather than G1
387.  Furthermore, much higher concentrations of Deferasirox were 
required to induce cytotoxicity in primary hepatocyte cultures compared to hepatoma 
cells (25µM versus >200µM) suggesting that malignant lines are more sensitive to 
Deferasirox exposure than benign tissues, an observation previously seen with DFO, 
Deferiprone and O-trensox360,384,387. Deferasirox has also been shown as a potent iron 
dependent inhibitor of the canonical Wnt/β-catenin oncogenic signalling pathway in 
colorectal lineages, although the exact mechanism and iron dependent enzymes involved 
are yet to be elucidated331. 
Experimental tridentate Fe3+ chelators, structurally similar to Deferasirox (2,6-Bis-
hydroxyamino-1,3,5-triazine [BHT family]), were synthesised as potential anti-neoplastic 
agents322. Characteristics of the BHT derived chelators that conferred cytotoxic activity 
were: strong binding of Fe3+ along with high Fe3+/Fe2+ selectivity resulting in a low redox 
potential of the formed complex, limiting uncontrolled formation of ROS in normal cells; 
rigidity of the ligand resulting in size selectivity towards iron binding; and balanced 
hydrophobicity of the ligand, allowing it to be soluble in aqueous media and retain 
membrane permeability322,388,389. Substantially higher anti-proliferative activity has been 
achieved with tridentate chelators based on semicarbazone and semithiocarbazone such 
as Triapine390-392, however these agents have a relatively high Fe2+/Fe3+ potential and are 
capable of redox cycling to produce ROS. The resulting hydroxyl radicals are capable of 
directly attacking cellular components resulting in DNA damage, lipid peroxidation and 
protein oxidation322,333,393. 
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The usefulness of iron chelation therapy in transfusion dependent myelodysplastic 
syndromes is debated but some authors suggest that it may induce a marginal survival 
benefit385. Intriguingly, haematologists noticed that patients treated with Deferasirox 
developed rapid improvement in haemoglobin levels and in some cases the need for 
recurrent blood transfusions relented383,386,394. Nuclear factor – κB (NF– κB) plays a 
pivotal role in the pathogenesis of myelodysplastic syndromes and haematological 
malignancies by regulating several fundamental cellular processes such as apoptosis, 
proliferation, differentiation and tumour migration382,386. The possible action of 
Deferasirox on the NF– κB pathway was assessed by taking samples of peripheral blood 
from patients with myelodysplastic disorders and incubating them with 50 µM 
Deferasirox for 18 hours386. NF– κB activity was found to be dramatically reduced in 
samples showing high basal activity. The addition of ferric hydroxyquinoline during 
incubation did not reinstate NF– κB activity suggesting that the effect produced by 
Deferasirox is independent of chelation induced iron deprivation386. In addition, inhibition 
of the NF– κB pathway was seen solely with Deferasirox and not alternative chelators, 
despite the anticipated reduction in ROS. The authors concluded that Deferasirox 
inhibition of NF– κB should be further explored given that normal haematological cell 
lines lack activation of NF– κB with potential for selective therapy386. 
Deferasirox appears to induce other changes in cell physiology not seen with other 
chelators. Human hepatoma cells exhibit a marked reduction in polyamine synthesis, 
normally highly expressed in rapidly dividing tumour cells, when exposed to Deferasirox, 
possibly by inhibition of ornithine decarboxylase387,395. Deferasirox also appears to have 
anti-proliferative effects on myeloid leukaemia cells, perhaps due to suppression of 
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signalling through the mTOR (mammalian target of rapamycin) pathway by enhancing 
expression of REDD1 (regulated in development and DNA damage response)396. The 
mTOR pathway is known to demonstrate aberrant activity in malignant tissue, 
culminating in de-regulation of the cell cycle and cellular proliferation397. 
It would appear that the cytotoxic action of Deferasirox is mediated through a series of 
oncological pathways and not restricted simply to the action of iron deprivation through 
chelation. Considering a potential multi-modal therapeutic action, clinical experience and 
ease of dosing, Deferasirox makes for an attractive chemotherapeutic agent in the 
treatment of cancer. Yet, in-vivo replication of the in-vitro anti-neoplastic action of 
Deferasirox is still to be established. In addition, it is not known if Deferasirox has a 
chemo-sensitising or synergistic effect when combined with standard chemotherapy 
regimens; a pertinent consideration, as the clinical role for Deferasirox would be as an 
adjunct to established combination chemotherapy. 
 
1.17 Promising experimental chelators with anti-neoplastic properties (Dp44mT) 
Although the development of Deferasirox has been a huge leap in improving the 
treatment of patients with iron overload disorders, experimental chelating compounds 
remain a focus for improvement, especially if the anti-neoplastic effects of these agents 
can be enhanced. A series of very promising chelating agents has been identified based 
on a di-2-pyridylketone thiosemicarbazone (DpT) backbone323,398,399.  The most potent of 
this series, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT),  showed 
highly significant cytotoxic in-vitro and in-vivo activity323,399. Extremely low IC50 
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concentrations (0.005-0.4 µM) of Dp44mT were used to inhibit the growth of a panel of 
malignant human cell lines (DMS-53,SK-N-MC and SK-Mel-28) and subsequent murine 
xenografts were massively inhibited by intravenous administration of Dp44mT over a 
seven week period (SK-Mel-28, an aggressive melanoma xenograft, demonstrated just 8% 
growth in the Dp44mT treated mice compared to control)323. Captivatingly, the cytotoxic 
action of Dp44mT was retained when deployed against cell lines known to be highly 
resistant to standard chemotherapeutic agents (Etoposide resistant MCF-7/VP - breast 
cancer; Vinblastine resistant KB-V1; epidermal carcinoma) and in all cases was vastly 
more cytotoxic than equivalent doses of Doxorubicin and DFO323. Furthermore, the action 
of Dp44mT appears to be independent of p53 status323. Dp44mT treatment over four 
weeks induced minimal murine morbidity with retained organ-to-total-body-weight 
ratios323. Over seven weeks a marginal increase in myocardial weight was noted along 
with patchy necrosis of the myocardium and early fibrosis323. Haematological parameters 
were unchanged, apart from a slight increase liver weight secondary to hemosiderin 
deposition, however, intriguingly, myocardial iron concentration was increased and in 
some cases, tumour iron was up or unchanged compared to control323. TfR1 mRNA 
expression was significantly decreased in the livers of Dp44mT treated mice and 
conversely, significantly increased in xenograft tissue. This observation led the authors to 
conjecture that Dp44mT may redistribute iron away from compartments controlling gene 
or TfR1 expression, and may be driven by up-regulating HIF-1 in response to ROS 
generation323. 
The ability of Dp44mT to induce such marked cytotoxicity, without significant systemic or 
specific xenograft iron stripping, may be explained by a dual mechanism of 
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action323,390,398-400. The DpT series mode of action is not solely dependent on iron 
chelation as their iron complexes redox cycle generating ROS323,390,398-400. In the reduced 
ferrous form, these complexes can react with molecular oxygen and the resulting ferric 
complexes may subsequently interact with cellular reductants401-404. This circumstance 
culminates in the catalytic generation of ROS leading to indiscriminate damage to 
essential biomolecules within the cancer cell398. The DpT series analogue, Dp2mT has a 
hypermethylated  and inactive iron binding site which precludes iron chelation and 
therefore eliminates all cytotoxic activity399,405. The DpT series ligands are also strongly 
lipophilic affording permeability across cellular compartments and access to intracellular 
iron pools323,404. 
A further potential anti-neoplastic action of Dp44mT may stem from its ability to up-
regulate the iron-responsive, tumour growth and metastasis suppressor Ndrg1 (N-myc 
downstream regulated gene 1); up regulation suppresses tumour growth and inhibits 
metastatic activity399,405-408. In-vitro exposure of human pancreatic cancer cells to 
Dp44mT demonstrated marked increase in expression and phosphorylation of Ndrg1, 
essential for its anti-cancer activities. In addition, Dp44mT increased the expression of 
the CDK inhibitor p21 and decreased cyclin D1406,408. 
The DpT series has been further developed to include copper complexes. Copper is able 
to form complexes with a number of chelating ligands (thiosemicarbazones, imidazoles 
and phosphines) and has intrinsic anti-neoplastic properties, affected through redox 
activity409-411. Indeed, copper complexes can interact with molecular oxygen, cellular 
oxidants and reductants, allowing copper to redox cycle between its mono and divalent 
oxidative states398,412. As predicted, Cu-Dp44mT exhibited a marked reduction in cellular 
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viability in the SK-N-MC cell line (neuroepithelioma cells) and evoked powerful ROS 
generation in SK-N-MC cells labelled with the fluorescent probe DCF, a method well 
established for assessing intracellular ROS activity in combination with flow 
cytometry398,399,413. There was a pronounced increase in the redox activity of the Dp44mT 
1:1 ligand/Cu complex compared to its 2:1 complex, markedly more than CuCl2 or ligand 
alone400. Co-incubation with copper chelators, tetrathiomolybdate (TM) and 
bathocuproine disulfonate (BCS), caused near complete cessation of all ROS 
generation400. Curiously, Dp44mT and its analogues, exhibit selective cytotoxicity against 
malignant cell lines and spare benign parental lines323,391,399,400,414. The reason for this, 
considering the apparently indiscriminate mode of action, may partly be due to 
differences in how malignant cells metabolise iron and copper ions and the potential for 
divalent complexes of the DpT series to act as lipophilic vehicles, facilitating intracellular 
delivery of the free ligand upon metal dissociation390,410,415. Direct comparison of the 
cytotoxic effect of Dp44mT iron complexes to Dp44mT copper complexes demonstrated 
marked temporal differences in action. Copper complexes exhibit dramatic cytotoxicity 
after just 3 hours, whereas, iron complexes have a slightly more tardy effect with 
maximal activity at 24 hours415. Furthermore, DpT chelators prevent 64Cu mobilisation but 
markedly induce 59Fe efflux415. 64Cu[Dp44mT] accumulates within the 
lysosomal/mitochondrial fraction by the following proposed mechanism: i) the neutral 
ligand enters the lysosome; ii) the ligand becomes protonated and charged at lysosomal 
pH (pH5), preventing passage out of the organelle; iii) the charged ligand binds copper in 
the lysosome; and iv) since the formed copper complex is positively charged it cannot 
escape the lysosome, accounting for 64Cu accumulation in this compartment415. Ensuing 
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ROS generation causes lysosomal disruption, redistributing cathepsin D to the cytosol 
with subsequent cleavage of the pro-apoptotic BH3 protein Bid415. 
Thus, it is likely that the Dp44mT series delivers selective cytotoxic action via a combined 
cytotoxic approach: iron chelation, early lysosomal disruption secondary to Dp44mT 
copper complex induced ROS and late ROS generation via Dp44mT Fe complexes with 
induction of pro-apoptotic pathways.  
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1.18 Hypothesis 
OAC cells are able to capture haem in a manner analogous to inorganic iron acquisition 
and abrogation of LRP1 and HCP1 will reverse haem mediated effects on OAC cell 
phenotype. 
Oesophageal cancer cells are sensitive to iron deprivation and iron chelating agents may 
represent valuable adjuncts in the treatment of oesophageal malignancy. 
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1.19 Aims 
 
1. Characterise the expression of haem import and export proteins in oesophageal 
adenocarcinoma compared to Barrett’s metaplasia and normal oesophageal epithelia 
 
2. Determine the in-vitro and in-vivo effects of abrogating the expression of haem transport 
proteins on OAC phenotype and iron transport protein expression 
 
3. Evaluate the potential anti-neoplastic properties of iron chelating agents using in-vitro 
and in-vivo models of oesophageal cancer 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 General, Cell Culture and Molecular Biology Reagents 
General, cell culture and molecular biology reagents were obtained from the following 
sources: 
Abbott, Global 
Isoflurane 
Abcam, Cambridge UK  
Anti CDC-14A (mouse IgG, clone DCS-291) 
Amersham Pharmacia, Amersham, Buckinghamshire  
ECL reagent; Hybond PVDF, Hyperfilm X-ray film, Peroxidase linked secondary antibodies; 
RPN800 rainbow ladder,  
Antec International, Sudbury, UK 
Virkon 
Applied biosystems, Cheshire  
96-well optical plate; optical adhesive covers; RNAlater; TaqMan ribosomal RNA control 
reagent 
Appleton Woods, Selly Oak, Birmingham  
All disposable plastic ware 
Becton Dickinson (BD), Plymouth UK 
Falcon 5ml round bottom counting tubes; FACS tubes (5ml 12/75mm); BD Matrigel 
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Bioline, Humber Road, London, UK 
Competent cells; SensiMixtm II qRT-PCR probe kit 
Biological Industries, Kibbutz Beit, Haemek, Israel 
DMEM concentrate x2 without L-Glutamine 
Bio-optica, Milano, Italy 
Tris Buffered Saline, W-CAP TEC Buffer© 
Boehringer Mannheim, Lewes, East Sussex  
Ampicillin; Mycoplasma detection Kit 
Cambrex Bio Science Wokingham, Ltd  
ViaLight HS kit (ATP assay)  
Chance Propper, Smethwick, West Midlands  
Glass coverslips 
DAKO UK Ltd, Cambridge, UK 
DAKO Antibody Diluent; DAKO ChemMate substrate buffer; DAKO REAL DAB and 
Chromogen Kit; DAKO Pen 
Difco, West Moseley, Surrey  
Bactoagar; Bacto Tryptone; Yeast Extract 
Dp44mT and 59Fe-Tf: Kind gift of Professor Des Richardson, University of Sydney, 
Australia 
Ecole Polytechnique, Federale De Lausanne 
Lenti Viral packaging plasmids (via Dr Chris Dawson) 
Eurogentec, Seraing, Belgium 
Reverse transcriptase core kit 
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Fisher Scientific, Loughborough, Leicestershire   
BCA protein assay 
Frontier Scientific, Logan, UT, USA  
Zinc protoporphyrin 
Geneflow, Southampton  
Acrylamide 
Genus Pharmaceuticals, Newbury, Berkshire  
Ciprofloxacin 
Invitrogen, Paisley, Renfrewshire (incorporating Gibco BRL)  
Dulbecco's Modified Eagles Medium (DMEM) with Glutamax-1, pyridoxine and 4500mg/L 
glucose; Foetal Calf Serum; Geneticin G418; LTX Reagent; Normal goat serum; Optimem 
medium; Penicillin and Streptomysin solution; PLUS Reagent; PureLink HiPure Plasmid 
Filter Purification Kits – Maxi Prep; Puromycin; RPMI medium with 25mM Hepes buffer 
and L-glutamine; S.O.C media; Trizol reagent; Trypsin EDTA 
Iwaki, Stone, Staffordshire (Subsidiary of Barloworld scientific) 
25, 75 and 150cm2 tissue culture flasks; 96 well culture plates; 12 well culture plates 
Mayne Pharma  
Desferrioxamine mesilate (DFO) 500mg 
Millipore, Watford, UK 
Hexadimethrene Bromide (Polybrene) 
Novartis, UK 
Deferasirox 
Open Biosystems (Thermo Fisher Scientific) Huntsville, Alabama, US 
pGIPZ lenti-viral constructs 
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Pall Corporation, Newquay, Cornwall  
0.2µm filters 
Peptides International, Louisville, Kentucky, USA  
Hepcidin peptide 
Promega, Chilworth Research Centre, Southampton 
Dual-Luciferase Reporter Assay System; Nuclease free water 
Roche Applied Science, Lewes, East Sussex 
BrdU proliferation assay; Proteinase inhibitor cocktail 
Sigma Chemical Company Limited, Poole, Dorset 
Agarose; Ammonium acetate; Ammonium persulphate; Aprotinin; -mercaptoethanol; 
Bromophenol Blue; Calcium chloride; Citric acid (tri-sodium citrate); DAB (3,3’-
diaminobenzidene tetrahydrochloride) tablets; DAPI (4’,6-diaminido-2-phenylindole); 
Deoxynucleotide (dNTP) mix; Dimethyl Formamide; Dimethyl Sulfoxide (DMSO); 
Dithiothreitol (DTT); DNAse I; Ferric chloride; Ferrous cyanate; Ferrous sulphate; 
Ferrozine (3-(2-Pyridyl)-5,6-diphenyl-1,2,4-triazine-4,4-disulfonic acid); Formalin; 
GenElute Mammalian Genomic DNA kit; Glycerol; Glycine; N-[2-Hydroxethyl]piperazine-
n’-[2-ethanesulfonic acid] (HEPES); H2DCF-DA (2,7-dichloro-fluorescein-diacetate); HCl; 
Hydrogen Peroxide 30% w/v; Hydroquinone (1,4-Benzenediol); Immunofluorescence 
Mounting Media; LB Broth EZMix powder; Isopropanol; Lauryl sulphate; Lithium Chloride; 
MgCl2; Mayer’s Haematoxylin 0.1% Solution; Methanol; MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide); NP40; Paraformaldehyde; Polyoxyethylenesorbitan 
monolaurate (Tween 20); Phosphate buffered saline; Potassium Acetate; Potassium 
Chloride; Pronase from Streptomyces Griseus; 1,2-propanediol; Propidium Iodide; RNase 
A; Sodium Acetate; Sodium Ascorbate; Sodium Bicarbonate; Sodium Bisulfite; Sodium 
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Carbonate; Sodium Chloride; Sodium Citrate; Sodium Deoxycholate; Sodium dodecyl 
sulphate (SDS); Sodium Fluoride; Sodium Pyrophosphate; Sucrose; TEMED; 
Trichloroacetic Acid, Trichostatin A; Tris HCl; Trizma base; Urea; Xylene Cyanol 
Sarstedt Limited, Leicester, UK 
Small and Large Culture Dishes 
TPP, Switzerland 
6-well plates for tissue culture 
Turumo, Europe 
Capijet blood tubes 
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2.1.2 Primary antibodies 
Target Antigen Molecular weight Source and clone Antibody class Positive 
control 
Optimum Dilution 
Beta- actin 42kDa 
Abcam 
Ab8226 
Mouse IgG anti-
human 
 WB: 1/1000 
BCRP 72kDa 
Abcam 
Ab3380 
Mouse IgG anti-
human 
Duodenum 
WB: 1/250 
IHC- P: 1/100 
CDC-45L 83kDa Abcam ab56476 
Mouse IgG anti-
human 
Hydroxy-urea 
treatment 
WB: 1/300 
c-Myc 41kDa 
Abcam  
ab32 
Mouse IgG anti-
human 
 WB: 1/500 
FLVCR 35kDa Abcam ab57317 
Mouse IgG anti-
human 
Duodenum  
WB: 1/350 
IHC-P: 1/250 
Ferritin 
40kDa dimer, 
20kDa subunit 
Kind gift of Prof A 
Mckie 
Rabbit IgG anti-
human 
Liver 
WB: 1/500 
IHC-P: 1/200 
Ferroportin 63kDa Abcam Ab85370 
Rabbit IgG anti-
human 
Duodenum  
WB: 1/300 
IHC-P: 1/200 
HCP1 55kDa Abcam ab25134 
Rabbit IgG anti-
human 
Duodenum  
WB: 1/500 
IHC-P: 1/200 
IRP2 105kDa Abcam ab80339 
Rabbit IgG anti-
human 
Duodenum  WB: 1/500 
LRP1 85kDa Abcam ab28320 
Mouse IgG anti-
human 
Liver 
WB: 1/250 
IHC-P: 1/150 
TfR1 
190kDa dimer, 
95kDa subunit 
Invitrogen   13-6800 
Mouse IgG anti-
human 
Liver 
WB : 1/500 
IHC-P: 1/250 
      
Table 2.1 Primary antibodies, origin, class, positive controls and optimum working 
concentrations 
(WB= Western Blotting; IHC-P= paraffin embedded immunohistochemistry) 
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2.1.3 Secondary Antibodies 
Amersham Pharmacia, Amersham, Buckinghamshire  
Peroxidase conjugated anti-mouse IgG (WB: 1:10,000); Peroxidase conjugated anti-rabbit 
IgG (WB: 1:10,000) 
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2.1.4 Oligonucleotides 
The following oligonucleotides were used in qRT-PCR reactions (F=Forward, R=Reverse).  
 Probe (5’FAM 3’TAMRA) Forward Primer, 5’-3’ Reverse Primer, 5’-3’ 
c-MYC CAGCACAACTACGCAGCG
CCTCC 
TCAAGAGGTGCCACGTC
TCC 
TCTTGGCAGCAGGATAGTC
CTT 
Ferritin H  CCAACGAGGTGGCCGAAT
CTTCCTT 
GGAACATGCTGAGAAA
CTGATGAA 
CATCACAGTCTGGTTTCTTG
ATATCC 
Ferroportin AGGATTGACCAGTTAACC
AACATCTTAGCCCC 
AGCAAATATGAATGCCA
CAATACG- 
CAAATGTCATAATCTGGCC
AACAG 
HCP1 ATG GGT TGC TTT TCC 
TGT CAT TAG TCA TCA 
CA 
CTA TCA CGC CTC TCA 
TGT TCA CA 
GGA GAG TTT AGC CCG 
GAT GAC 
IRP-2 TTTGACAAACAGAGGCCT
TACCCC 
AGGAATAGTGCTGCCGC
TAAGT 
TCGAGCTCCGTAAGAGTTG
AATT 
LRP1 TGC CAT TTA CTC AGC 
CCG TTA CGA CG 
TGG ATT GAC GCC GGT 
CAG 
CCC GAA GCA CCT CCA 
TGT 
TfR1 AAA GAC AGC GCT CAA 
AAC TCG GTG ATC ATA G 
CGT GAT CAA CAT TTT 
GTT AAG ATT CA 
CCA CAT AAC CCC CAG 
GAT TCT 
 
Pre-optimised TaqMan® gene expression assays (Applied Biosystems) were utilised for 
BCRP (Hs00184979_ml) and FLVCR (Hs0017953_ml) qrt-PCR reactions. 
Table 2.2 Oligonucleotides 
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2.1.5 Ex-vivo tissue Samples 
The most suitable control tissue for OAC was considered to be adjacent matched BM 
from the same patient. For benign BM samples, matched normal squamous (NS) mucosa 
was used as control tissue. 
2.1.5.1 Fresh Material 
Oesophageal cancer resection specimens: Samples (n=9) of OAC matched with normal NS 
and associated BM (immediately adjacent to the tumour) were collected during surgery, 
snap frozen and stored in liquid nitrogen. 
Biopsy samples: Benign BM samples were obtained as biopsies, taken during endoscopy 
from patients undergoing endoscopic surveillance of benign BM. Written consent was 
given prior to the procedure. Samples of BM (n=9) were confirmed as non-dysplastic on 
histological assessment (PT, Consultant Histopathologist, Queen Elizabeth Hospital 
Birmingham). 
Xenografted human oesophageal cell lines and mouse organs were harvested from 
immunodeficient mice models divided and snap frozen in liquid nitrogen or placed in 
formalin. 
Duodenal and liver biopsies were obtained to act as positive controls as appropriate. 
2.1.5.2 Paraffin Embedded Material  
Paraffin sections of OAC with associated BM and NS present in the same section (n=16) 
and biopsy specimens of benign BM with normal mucosa in the same section (n=26) were 
selected for immunohistochemistry. Material was screened by a consultant pathologist to 
confirm the samples contained the relevant tissue types. Normal liver, small bowel and 
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kidney sections were utilised as appropriate for positive and negative controls during 
immunohistochemistry. 
2.1.5.3 Tissue microarray (paraffin embedded samples) 
78 samples of OAC were used to evaluate the association between haem import and 
export protein expression and tumour stage.  Data was available on: degree of tumour 
differentiation (well, moderate or poor, as assessed by the original reporting consultant 
histopathologist); T stage of the tumour (T1: tumour invades lamina propria or 
submucosa; T2: tumour invades muscularis propria; T3: tumour invades adventia); and 
presence or absence of lymph node metastases (positive or negative). 
To facilitate the screening of multiple tissue blocks from each patient, tissue microarrays 
were prepared containing 3 representative samples of tumour per patient (kind gift of Dr 
J Bury, Sheffield Medical School, Sheffield UK). 
 
2.1.6 Cell lines 
OE33 (JROECL33), OE19 (JROECL19) and OE21 (JROECL21) 
OE33, OE19 and OE21 were derived from primary oesophageal tumours in the late 1990’s 
to establish long-term lines for the investigation of oesophageal malignancy416. Genetic 
analysis indicated aberrant karyotypes; all were grossly aneuploid. HLA-A, B and C were 
expressed constitutively. All three cell lines were shown to have the ability to form 
xenografts in athymic nude mice. 
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OE33 
Human oesophageal adenocarcinoma cell line established from an adenocarcimoma of 
the lower oesophagus (Barrett’s metaplasia) of a 73-year-old female patient. The tumour 
was identified as a pathological stage IIA (UICC) and showed poor differentiation416. 
OE19 
Human adenocarcinoma derived from the gastro-oesophageal junction of a 72-year-old 
male patient. The tumour was identified as a stage III (UICC) and showed moderate 
differentiation416. 
OE21 
Human oesophageal squamous carcinoma derived from the mid oesophagus of a 74-
year-old male patient. The tumour was identified as pathological stage IIa (UICC) and 
showed moderate differentiation416. 
293FT cell line (kind gift of NPC Group – University of Birmingham, UK) 
The 293FT cell line is a fast-growing, highly transfectable, clonal isolate derived from 
human embryonic kidney cells417. The cell line has been commercially transformed with 
the SV40 large T antigen making the 293FT line a particularly suitable host for generating 
lentiviral constructs containing the SV40 origin such as the pGIPZ vectors418. 293FT cells 
stably express the neomycin resistance gene under control of the SV40 
enhancer/promoter and can be maintained in media containing Geneticin® 500µg/ml419. 
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2.2 Methods 
2.2.1 Immunohistochemistry 
Archived tissues (originally fixed in 10% (v/v) neutral buffered formalin prior to 
embedding in paraffin) were sectioned at 5μm intervals and applied to SuperFrost glass 
sides. Sections were softened at 55°C for 30 minutes prior to being submerged in boiling 
W-CAP TEC buffer© (pH 8) (combined solution for wax capture and antigen retrieval) for 
45 minutes. Slides were then rinsed in Tris-buffered saline (TBS) pH 7.6, blotted dry and 
the section outlined by a hydrophobic delineating pen. Sections were blocked with 50-
100μl of 20% (v/v) normal goat serum in antibody diluent (Tris buffer pH 7.2 with 15mM 
sodium azide) for 30 minutes. Sections were incubated for 1 hour with primary antibody 
in antibody diluent. Antibody concentrations were pre-optimised (table 2.1). Following 
three washes, sections were then incubated with EnVision reagent (peroxidase-
conjugated dextran coupled with goat antibodies against rabbit and mouse 
immunoglobulins) for 1 hour. Sections were again washed three times and 
immunoreactivity visualised using DAB+ chromogen (3,3´-diaminobenzidine 
tetrahydrochloride) in DAB substrate buffer (1:50) for 10 minutes. The slides were rinsed 
in TBS, counterstained with 0.1% Mayer’s haematoxylin (v/v) for 30 seconds and washed 
in running tap water for approximately 2 minutes for haematoxylin bluing. Sections were 
then dehydrated in sequential baths of ethanol and xylene before mounting in Depex. 
Positive controls comprising sections of tissue known to express the protein of interest 
were included for each series. In addition, a negative control (omission of primary 
antibody) was used for each tissue type. 
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Images were visualised from paraffin sections using a Nikon Eclipse E600 microscope and 
digital image captured using a Nikon DXM1200F camera (Surrey, UK). Nikon ACT-1 version 
2.62 software was used for image acquisition (Surrey, UK). 
 
2.2.2 Evaluation of immunoreactivity 
Immunoreactivity was scored on a semi-quantitative basis (observers blinded to tissue 
and antibody identity) by three independent observers, (SF, KR and CT). Staining intensity 
was scored as a function of two factors: a scale of 0-3 (0= absent, 3=strong); and 
percentage of positively stained cells within microscopic view (0= no cells, 1= 1-25%, 2= 
26-50%, 3= 51-75% and 4=>76%). The two scores were multiplied to give a total score 0-
12 (after Di Martino et al)420. Slides were further evaluated by a Consultant 
Histopathologist (PT) to confirm specific cellular location of immunoreactivity (nuclear, 
cytoplasmic or membranous). 
 
2.2.3 DAB-enhanced Perls’ Prussian blue staining 
Dilute mineral acid hydrolysis releases ferric ions from protein bound tissue deposits that, 
in the presence of ferrocyanide ions, are precipitated as a deep purple blue water 
insoluble complex (potassium ferric ferrocyanide or Prussian blue). 
Paraffin sections were de-waxed using a succession of xylene and ethanol baths (x3 for 5 
minutes), washed with dH20 and incubated in a 1:1 solution of 4% (v/v) HCl and 4% (w/v) 
ferrous cyanate for 30 minutes. Sections were then washed in PBS for 5 minutes x 3 and 
incubated in DAB Solution 50X (diluent - Dako ChemMate substrate buffer) 1:200 for 15 
minutes. Sections were further incubated for 15 minutes in DAB 1:50 before washing in 
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PBS and counter staining with haematoxylin for 30 seconds. Slides were then dehydrated 
in ethanol before mounting. Images were visualised using a Nikon Eclipse E600 
microscope and digital images taken using a Nikon DXM1200F camera (Surrey, UK). Nikon 
ACT-1 version 2.62 software was used for image acquisition (Surrey, UK). 
 
2.2.4 Electrophoresis and Western Blotting 
2.2.4.1 Sample Preparation 
Samples were derived from in-vitro and in-vivo sources: Human frozen tissue, mouse 
frozen tissue, xenografted human cell lines and in-vitro cultured cells. 
All samples were kept on ice and lysed into RIPA buffer (1% (v/v) NP40, 0.5% (w/v) sodium 
deoxycholate, 0.1% (w/v) SDS) containing a cocktail of proprietary protease inhibitors 
(dissolve 1 tablet of Roche “complete” per 50mls RIPA buffer). Tissue samples were 
homogenised in RIPA buffer with an UltraTurrax homogeniser and cell cultures washed 
with ice-cold PBS prior to lysis. All samples were then subject to probe sonication x2 for 10 
seconds and mixed using a tube rotator for 20 minutes at 4°C. Each sample was then 
centrifuged for 20 minutes at 13000g. 20µl of the supernatant was used for protein 
determination and the remainder added to 3x sample loading buffer (Laemmli loading 
buffer) (0.0625M Tris HCL pH 6.7, 10% (v/v) glycerol, 2% (w/v) sodium dodecyl sulphate 
(SDS), 1% (v/v) β-mercaptoethanol and 0.001% (w/v) bromophenol blue) and heated to 
100oC for 5 minutes. 
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2.2.4.2 Cellular fractionation (nuclear protein extraction) 
Cells were cultured in 6-well plates. Cell were trypsinised, washed with PBS and 
centrifuged to form a pellet at 1000 rpm for 4 minutes. The pellet was re-suspended in 
5ml ice-cold buffer A (hypotonic buffer – 10mls: 100µl 1M HEPES, pH 7.9; 15µl 1M MgCl2; 
40µl 2.5M KCl; 5µl 1M DTT, made up to 10ml with dH2O; protease inhibitor cocktail) and 
kept on ice for 5 minutes. Cells were lysed to release nuclei using a pre-chilled Dounce 
homogeniser. 
Dounced cells were centrifuged at 228g for 5 minutes at 4oC to pellet nuclei and other 
fragments. The supernatant was retained as the cytoplasmic fraction if required. 
The nuclear pellet was then re-suspended in 3ml of S1 (S1 – 0.25M sucrose, 10mM MgCl2; 
20mls: 1.96ml 2.5M sucrose; 200µl 1M MgCl2; made up to 20ml with dH2O; protease 
inhibitor cocktail) layered over a 3ml cushion of S3 (S3 – 0.88M sucrose, 0.5mM MgCl2; 
20mls: 6.9ml 2.5M sucrose; 10µl 1M MgCl2; made up to 20mls with dH2O; protease 
inhibitor cocktail) and centrifuge at 2800g for 10 minutes at 4oC. RIPA buffer was then 
added to the purified nuclear fraction as per protein extraction protocol. 
2.2.4.3 Protein assay technique 
Protein concentration of samples was determined using a bicinchoninic acid (BCA™) 
protein assay and compared with bovine serum albumin at standard concentrations 
between 0 and 20mg/ml. 25μl of each standard, along with 1:10 diluted tissue or cell 
lysates, were aliquoted in triplicate onto a clear flat bottomed 96-well plate. 200μl of 
BCA™ working reagent (reagent B 1:50 in reagent A) was added to each well and 
incubated for 30 minutes at 37°C. Absorbance was then measured at 562nm using a Bio-
Tek ELx800 absorbance microplate reader. The sample protein concentrations were then 
derived from a graph of standard concentrations plotted against optical density at 562nm. 
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2.2.4.5 Protein normalisation 
Results of the BCA protein assay were used to calculate the volume of protein lysate 
required to load 20µg of protein into each sample well. Uniformity of protein loading was 
further normalised by expressing the optical band densities of the protein of interest as a 
ratio of the corresponding β-actin band. β-actin blotting was performed on the same 
PVDF membrane as the probe of interest after antibody stripping (stripping buffer: 
200mM glycine, 3.5mM SDS, 1% Tween 20 (v/v), pH to 2.2). (Membrane stripping 
protocol: cover membrane in stripping buffer for 5 minutes; repeat; wash twice with PBS 
and twice with TBS-T for 5 minutes each time; block with 10% (w/v) skimmed milk 
powder). Band optical densities were derived using a Biorad G800 densitometry reader.  
 
2.2.4.6 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
A BioRad Protean–II mini-gel apparatus was used and the appropriate percentage 
resolving gel poured. The stacking gel was added, combs inserted and wells equilibrated 
with electrophoresis running buffer (0.192 M glycine, 0.01% (w/v) SDS, 25 mM Tris HCl pH 
8.3) prior to use. An aliquot of sample equal to 20µg of protein was loaded into each well. 
One well contained wide range kaleidoscopic pre-stained standards added (5µl) to 
calibrate protein molecular weights. Electrophoresis was carried out at 200V until the dye 
front had descended to the lower border of the gel. 
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Table 2.3 SDS-PAGE gels 
SDS-Polyacrylamide Resolving Gel Composition 
 
  
Constituent Stacking Gel Separating Gel 
4% 8% 10% 12.5% 
Ammonium 
Persulphate 
30mg 30mg 30mg 30mg 
Water 3.7ml 4.8ml 3.5ml 1.9ml 
Buffer  5ml 
0.2% (w/v) SDS; 
0.25M Tris HCl, pH 
6.8 
10ml 
0.2% (w/v) SDS; 
0.75M Tris HCl,  
pH 8.8 
10ml 
0.2% (w/v) SDS; 
0.75M Tris HCl,  
pH 8.8 
10ml 
0.2% (w/v) SDS; 
0.75M Tris HCl, pH 
8.8 
30% 
Acrylamide/ 
8%  
bisacrylamide 
1.3ml 5.2ml 6.5ml 8.1ml 
TEMED 70l 70l 70μl 70l 
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2.2.4.7 Western Blotting: Transfer of SDS-PAGE gels and protein detection 
Proteins separated by SDS-PAGE were wet-transferred directly onto Hybond PVDF 
membranes pre-soaked in methanol for 1 minute. Transfer was performed at 100V for 1 
hour in electrophoresis transfer buffer (48mM Tris HCl; 39mM glycine, 20% (v/v) 
methanol, 0.0375% (w/v) SDS) with constant cooling from an ice pack within the transfer 
apparatus. 
Following transfer, the PVDF membrane was blocked overnight in 10% (w/v) skimmed 
milk powder in tris-buffered saline tween (TBST) (10mM Tris-Cl pH 8.0, 150mM NaCl, 
0.05% tween-20). The PVDF membrane was incubated with the primary antibody for 1 
hour at room temperature. Membranes were then washed in TBST (6 x 5 minutes), 
incubated with secondary peroxidase conjugated antibody for 30 minutes at room 
temperature and then washed again in TBST (6 x 5min). The membrane was exposed to 
ECL reagent, placed on Kodak X-OMAT AR film in a darkroom and developed using an X-
OGRAPH X2 automatic developer. Band optical densities were derived using a Biorad 
G800 densitometry reader. 
 
2.2.5 RNA extraction from frozen tissue and cells  
2.2.5.1 RNA extraction from frozen tissue 
Tissue was thawed on ice and homogenised in 750µl Trizol reagent using a PolyTurrax 
homogeniser. Samples were incubated for 5 minutes at room temperature to allow 
complete dissociation of nucleoprotein complexes. 100µl of chloroform was added and 
vortexed for 15 seconds and then incubated at room temperature for 15 minutes. 
Samples were then centrifuged at 12,000g for 15 minutes at 4oC and the upper aqueous 
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phase harvested. RNA was precipitated by addition of 250µl isopropanol and incubated 
for a further 10 minutes at room temperature. RNA was pelleted by centrifugation at 
12,000g at 4oC for 10 minutes and washed with 75% ethanol. The 75% ethanol was then 
aspirated and the residual volume allowed to evaporate followed by RNA re-suspension in 
10µl of nuclease free water. Optical density of the re-suspended RNA was measured at 
260nm on a spectrophotometer and the concentration of RNA calculated using the 
equation 1 OD unit= 40µg/ml RNA. RNA was stored at -80 oC. 
2.2.5.2 RNA extraction from cells 
 Cells were cultured in 6-well plates as per the experimental protocol. At the end of the 
experiment the cells were washed twice with filter sterilised PBS. 500µl Trizol reagent was 
added to cells and left at room temperature for 10 minutes. The subsequent Trizol cell mix 
was aspirated and processed for RNA extraction.  
2.2.5.3 cDNA Generation 
cDNA was synthesized from RNA using a reverse transcription system (Eurogentec). 0.4μg 
of total RNA was added to nuclease free water to attain a total volume of 8.1μl. 11.9µl of 
reverse transcription mastermix (4μl 25mM MgCl2, 2μl of reverse transcription buffer 
(10x), 4μl 2.5mM dNTP mix, 1µl random nonamer, 0.4µl RNAse inhibitor, 0.5µl EuroScript 
reverse transcriptase) was then added to each RNA sample to achieve a reaction mix 
volume of 20µl. Each sample was then subjected to the reverse transcription thermal 
cycle (BioRad My Cyclertm thermal cycler) consisting of: initial step - 10 minutes at 25°C; 
reverse transcriptase step - 30 minutes at 48°C; inactivation of reverse transcriptase 
enzyme - 5 minutes at 95°C; finally held at 4°C. The synthesized cDNAs were subsequently 
diluted with the addition of 16µl nuclease free water and stored at -20°C until required for 
qRT-PCR. 
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2.2.5.4 TaqMan quantitative real-time polymerase chain reaction (qRT-PCR) 
The technique of qRT-PCR allows quantification of the amplified product; the amount 
detected at a certain point of the run is directly related to the initial amount of target in 
the sample. qRT-PCR is initially an exponential process but eventually reaches a plateau 
phase when one of the reagents becomes limited. Analysis takes the Ct (cycle number) 
value at the point when the signal is detected above the background and the amplification 
is in exponential phase. The more abundant the original template, the quicker this point is 
reached. In conventional PCR the amplified product is quantified at the conclusion of the 
reactions. Primers were designed to allow the amplicon to span an mRNA exon/exon 
boundary for the gene of interest in order to eliminate contamination from genomic DNA. 
Fluorogenic probes incorporating a 5´ reporter dye and a 3´ quencher dye were designed 
to a sequence which lay between the two primer annealing sites, the sequences of these 
and the primers are given in table 2.2. Cleavage of the probe, through a Taq DNA 
polymerase, separates the two dyes and permits reporter dye fluorescence. Further 
probing leads to cleavage with every cycle resulting in an increase in the intensity of the 
fluorescence which is proportional to amount of amplicon produced. 
2.2.5.6 qRT- PCR technique 
1μl of newly synthesised cDNA was loaded in triplicate into an optical 96-well reaction 
plate. 14µl qRT-PCR mastermix (7.5µl 2x PCR reaction buffer ‘SensiMixTM’ (containing 
dNTPS, DNA polymerase, MgCl2, uracil-N-glycosylase, stabilisers and ROX passive 
reference), 1.5μl to 3μl of 1.25pM gene specific fluorogenic probe (optimised for volume - 
listed in table 2.4) 1.5μl of 9pM forward and reverse primers specific for the gene of 
interest, 0.15μl of 18s forward and reverse primers and 0.075µl 18s probe(18s rRNA 
control kit), nuclease free water to adjust final volume to 14μl for each reaction well). The 
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reaction mix for each replicate totalled 15μl. In the case of pre-optimised TaqMan® gene 
expression assays (Applied Biosystems) 1µl of pre-optimised probe was added to the 
reaction mix in place of separate gene specific probe and primers and subsequent 
reaction volume difference made up with nuclease free water. Once complete, the optical 
plate was sealed with an optical adhesive cover and loaded into the Applied Biosystems 
7500 Fast Real-Time PCR detection system. The standard reaction protocol consisted of 10 
minutes at 95°C, 40 cycles of 10 seconds at 95°C and finally 1 minute at 60°C. 
2.2.5.7 Probe optimisation 
Each newly designed and synthesised gene-specific fluorogenic probe required 
optimisation in order to maximize the acquired fluorescent signal. Using 1μl of positive 
control cDNA reactions were set up as described above but with varying volumes of 
1.25pM probe from 0.5μl up to 4μl, the final volume adjusted to 15μl by varying the 
nuclease free water volume. Following the same thermal cycle real-time protocol the 
results were graphically analysed as cycle threshold against volume and the point at which 
the resultant curve levelled off was taken as the optimal volume for subsequent reactions. 
All optimised specific probes are listed by volume for each reaction in table 2.4. 
2.2.5.7 Real-time PCR analysis 
Samples were analysed using SDS software. Each reaction was associated with a 
fluorescence threshold during exponential replication. The fluorescence baseline tool was 
optimally adjusted to reflect a best fit for exponential replication across the sample 
replicates. The cycle number at which fluorescence reached the adjusted baseline 
threshold was termed the cycle threshold (CT). This value was used for analysis: δCT value 
calculated by subtracting the 18s (internal standard) CT number from that of the target 
gene for each replicate; each δCT value subtracted from the average control δCT to give 
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the δδCT; fold change calculated by using the equation 2
-δδCT
; average each sample 
triplicate and divide by control to obtain the normalised fold change value. 
 
 
 
 
 
 
 
 
 
 
 
 
Pre-optimised TaqMan® gene expression assays (Applied Biosystems) were pre-optimised 
to 1µl per reaction (BCRP and FLVCR). 
Table 2.4 Volumes of optimised fluorogenic probe used for TaqMan q-RT-PCR reactions 
  
Gene 
Optimised Reaction 
Volume (μl) 
c-myc 3 
H-ferritin 2.5 
Ferroportin 2.5 
HCP1 2.5 
IRP2 1.5 
LRP1 2 
TfR1 2 
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2.2.6 Cell Culture 
2.2.6.1 Routine cell culture 
All cell culture procedures were performed in a laminar flow tissue culture cabinet using 
aseptic technique. Cells were cultured in an incubator at 37C and 5% CO2 atmosphere. 
Cell lines were grown in Dulbecco's Modified Eagles Medium (DMEM) with Glutamax-1, 
pyridoxine and 4500mg/L glucose supplemented with 10% (v/v) Foetal Calf Serum (FCS), 
50U/ml penicillin and 50µg/ml streptomycin. All cell lines utilised for study grew as an 
adherent monolayer and were passaged at ~90% confluence by aspirating the culture 
medium, washing in media without FCS and incubating with 6 ml of 0.05% (w/v) trypsin 
EDTA until cells had detached. 5 ml of culture media was added and cells were 
disaggregated by trituration and then centrifuged at 250g for 3 minutes. The cell pellet 
was either re-suspended in culture media and reseeded or was re-suspended in 1 ml of 
10% (v/v) dimethyl sulphoxide (DMSO) in FCS and placed in a cryovial for 
cryopreservation. Vials were kept at –70oC for 3 days before transfer to liquid nitrogen 
storage. Frozen cells were resurrected by rapid warming of the cryovial in a 37oC water 
bath and the cells were then washed and suspended in pre-warmed culture media.  Cells 
were then seeded into tissue culture flasks and cultured in the standard manner. 
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2.2.6.2 Iron loading of cells and co-culturing with chelators or chemotherapy agents 
Cells were plated out at 1x105 cells per ml to achieve an initial 50-60% confluence into 6-
well (3ml of media per well) or 96-well plates (100µl per well) depending upon the 
experiment protocol. Cells became adherent to the plastic over a 12 hour period 
whereupon the media was replaced with experimental media as follows: 
2.2.6.2.1 Iron and haem 
Inorganic Iron: FeSO4 was dissolved in sterilised dH20 to achieve a stock solution of 
100mM. Stock solution was then added to fresh culture media to achieve a final 
concentration of 100µM. 
Haem: Haem stock solution (1.5mM) was prepared by dissolving haem in just enough 
0.1M NaOH (typically 0.5ml) to create a solution and then made up to 1.5mM with 
sterilised dH2O. Stock solution was then added to fresh media to achieve a final 
concentration of 50µM. 
2.2.6.2.2 Iron chelators and chemotherapeutic agents 
The IC50 concentrations of iron chelators and chemotherapeutic agents were determined 
by dose titration and cell culture for 48 hours followed by and MTT and BrdU assays for 
viability and proliferation. The IC50 value of each agent was the concentration that 
reduced viability and proliferation by 50% compared to control. IC50 values were used in 
all experiments apart from where a dose response was required. 
Deferrioxamine: A stock solution of 10mM was established by dissolving DFO powder in 
dH2O. Stock solution was added to fresh media to achieve the IC50 concentration of 
10µM. 
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Deferasirox: A stock solution of 10mM was achieved by dissolving Deferasirox powder in 
just enough 0.1M NaOH to create a solution and slowly titrating in media (serum free) to 
avoid precipitation. A final working concentration at an IC50 value of 20 µM was made by 
adding the appropriate volume for stock solution to fresh media. 
Dp44mT: A 10mM stock solution was made up in DMSO and kept frozen at -20 C until 
required. A final IC50 concentration of 1µM was achieved by adding the appropriate 
amount of stock solution to fresh media. Dp2mT (made up as per Dp44mT) was used as 
the negative control for Dp44mT. 
Chemotherapy agents: Concentrated vials of chemotherapy agents for clinical 
intravenous use were used as stock solutions and added to fresh media to attain the 
following IC50 concentrations: Cisplatin 8µM, 5-FU 8µM and Epirubicin 1µM. 
 
2.2.7 MTT cell viability assay 
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay is used to 
quantify cellular viability following a period of tissue culture421. Metabolically active cells 
cleave the tetrazolium rings of pale yellow MTT, by the action of mitochondrial 
dehydrogenase, to form dark blue formazan crystals. Upon subsequent cellular lysis the 
accumulated formazan crystals are solubilised and the colour proportional to the number 
of viable cells. 
1x106 cells/ml were plated and cultured in clear, flat-bottomed 96-well plates under the 
desired experimental conditions, such that a cellular confluence of approximately 70% 
was achieved at MTT assay. 
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MTT was freshly dissolved into sterile x1 PBS at 5mg/ml and further filter sterilised to 
remove any insoluble particles. 10μl of MTT solution was added to each 100µl of culture 
media per well of the 96-well plate. The plates were then returned to the incubator for a 
further 3 hours, after which the media was aspirated and replaced with 100μl of DMSO to 
dissolve the accumulated formazan crystals. After 30 minutes at room temperature, the 
plates were placed into a Bio-Tek ELx800 absorbance microplate reader and absorbance 
read at 490nM. The resulting optical densities were used to calculate percentage viability 
with respect to control. 
 
2.2.8 BrdU proliferation assay 
The pyrimidine analogue 5-bromo-2'-deoxyuridine (BrdU) is incorporated into cellular 
DNA in place of thymidine during replication and can therefore be used to quantify 
cellular proliferation422. Incorporated BrdU can be detected by the use of a peroxidase 
conjugated anti-BrdU antibody followed by a colorimetric reaction involving tetramethyl-
benzidene (TMB).  
Cells were plated and cultured in clear, flat-bottomed 96-well plates under the desired 
experimental conditions, such that a cellular confluence of approximately 70% was 
achieved to coincide with the BrdU assay. 10μl of BrdU labelling reagent was added to 
each well (1:100 dilution of the original 10mM stock with culture medium) including a 
standard-well containing culture medium alone.  Plates were then returned to the 
incubator for a further 4 hours to allow BrdU incorporation. The media/BrdU solution was 
gently aspirated and 200μl per well of DNA denaturing solution (FixDenat) added to each 
well and the plate incubated at room temperature for 30 minutes. The FixDenat solution 
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denatures DNA and increases access to incorporated BrdU. Aspiration of this solution was 
then followed by the addition of 100μl per well of anti-BrdU-peroxidase antibody and 
incubated at room temperature for 90 minutes. This solution was then removed and cells 
gently washed x3 with 200μl of washing solution provided with the assay kit. The washing 
solution was finally aspirated and replaced with 100μl per well of substrate solution 
(TMB) and the plate incubated at room temperature for a further 5-30 minutes. The 
absorbance of each well was determined at 370nM in a Bio-Tek ELx800 absorbance 
microplate reader and corrected using blank wells (no cells). The resulting optical 
densities were used to calculate percentage proliferation with respect to control. 
 
2.2.9 Ferrozine assay 
The ferrozine assay has been established for decades to quantify intracellular iron levels. 
Ferrozine forms a stable, water soluble, magenta complex with divalent iron that is 
suitable for colorimetric quantification423. 
Cells were cultured in 6-well plates with appropriate media. After a pre-determined 
incubation period the monolayer was washed three times with 1 ml x1 PBS. The cells 
were then trypsinised and the cell slurry transferred to Eppendorfs and centrifuged for 5 
minutes at 1200 RPM. The supernatant was aspirated and the cell pellet re-suspended in 
100µl HEPES saline (10mM HEPES in 0.9% (w/v) sodium chloride at pH 7.4). 90µl of this 
suspension was removed and added to 200µl 20% (w/v) trichloroacetic acid in 4% (w/v) 
sodium pyrophosphate (TCA) (5µl of the remainder was added to 95µl RIPA solution and 
used for protein quantification. This was boiled for 5 minutes then re-centrifuged for a 
further 5 minutes at 12000 RPM. 200µl of the supernatant was aspirated and added to 
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100μl of 0.23M sodium ascorbate, 80μl of 10mM ferrozine and 420μl of 2M sodium 
acetate. This solution was thoroughly mixed and 200μl aliquots placed in triplicate in a 
flat-bottomed clear 96-well plate. A blank (HEPES + TCA + reaction mix) and a standard 
(the same mix with 1µl 10mM FeCl3 added to make a 12.5µM FeCl3 solution) were 
included. The colorimetric change in each sample was measured using a Bio-Tek ELx800 
plate reader at 550nm. The absorbance in the blank was used to correct each sample. 
The concentration of iron in each sample was calculated by multiplying the corrected 
absorbance of the sample by 12.5 and dividing the product by the corrected absorbance 
of the standard. The protein concentration (analogous to overall cell number) in each 
sample was determined, as described in section 2.2.4.3, allowing the iron content of each 
sample to be expressed as a function of protein content. 
 
2.2.10 Anchorage Independent Growth Assay (colony forming assay) 
A malignant cell phenotype is typically capable of growth which is independent of 
external signals that may restrain or stimulate division. The anchorage independent 
growth assay measures independent proliferation of an isolated cell in semi-solid culture 
media; an in vitro assay analogous to the ability to form a metastasis in vivo424. 
To make the base gel, 1% (w/v) agar was autoclaved and then kept in a water bath at 
40°C. In a tissue culture hood, an equal volume of solution containing 2xDMEM with 20% 
FCS was warmed to 37°C. The solutions were mixed to give final concentrations of 0.5% 
agar, 1xDMEM and 10% FCS. 2ml of base agar was pipetted into 6-well plates, using 3 
wells per experimental line. Care was taken to avoid air bubble inclusions. Plates were 
allowed to cool and kept refrigerated at 4°C until adding the superficial agar. 
 91 
 
The superficial gel solution was prepared as described above (substituting 0.7% for 1% 
agar, giving a final concentration of 0.35%) and kept warm in a water bath at 37°C. 
Appropriate supplementary reagents were added. 
Trypsinised cells were passed through a 50µm cell sieve to prevent clumping and then 
added to the superficial gel solution at a density of 0.5x104/ml. 0.5ml of superficial gel 
solution was then gently pipetted onto the base gel, ensuring even distribution. 
Each well was then imaged at random locations using a Zeiss Axiovert 40 CFL microscope 
and camera with Axiovision Rel. 4.6 imaging software (N=6 for each well). The 6-well 
plates were then kept in a humidified incubator at 37°C for 14 days after which imaging 
was repeated to count the total surface area of the colonies within the captured field of 
view. 
 
2.2.11 Wound healing assay 
The scratch or wound healing assay was designed to study cell migration in vitro425. The 
assay involves observing the cellular migration into a wound that is created in a cell 
monolayer. Migration of cells under these circumstances is regulated by intercellular 
interactions and is assessed by capturing images of the wound at the beginning and at 
regular intervals during cell migration, until closure of the wound425. 
Cells are cultured in 6-well plates until 100% confluent. Once confluent, the growing 
medium was aspirated and a wound created in the cell monolayer with a fine pipette tip 
at 45o to the base. An indelible ink line was drawn on the underside of the plate at 90o to 
the direction of the wound, for orientation and precise positioning during serial 
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measurements. The cells were then washed with sterile PBS and control or experimental 
media added. The wound was then imaged using Zeiss Axiovert 40 CFL microscope at 20x 
magnification and digital images recorded (N=12, two images per wound over 6 wells) 
with Axiovision Rel. 4.6 imaging software. The total wound surface was measured as a 
baseline. Plates were replaced in the incubator and at 12 hourly intervals the wounds 
were photographed, guided by the ink markers to ensure regional consistency of the 
wound to be imaged. Measurement continued until the wound had healed. 
 
2.2.12 Fluorescence-activated cell sorting (FACS) with propidium iodide labelling for cell 
cycle analysis 
Propidium iodide (PI) is an intercalating agent that can be used to stain cellular DNA. The 
quantifiable fluorescent properties of PI can be correlated with the relative amount of 
cellular DNA and thus, assessment of cell cycle in a given population of cells 
(fluorescence-activated cell sorting).  
1x106 cells per ml were seeded into T25 flasks such that a confluence of 70% would be 
achieved at time of FACS. Cells were cultured with media appropriate to the planned 
experimental conditions (N=3 for each condition including a control cultured in plain 
media). At a predetermined time point, the cells were trypsinised and centrifuged at 
1500g for 5 minutes. The cell pellet, following media aspiration, was washed by re-
suspension in PBS containing 1% FCS (v/v) and then centrifuged at 8000g for 5 minutes. 
Upon re-suspension, cells were adjusted to 1x106 cells per 1ml PBS. 1ml of PBS containing 
cells was then vortexed whilst 1ml of ice cold 95% ethanol (v/v) was added drop wise to 
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fix the cells. Cell suspensions were then stored at -20ºC for at least 30 minutes and up to 
2 weeks. 
Before preparing the cells for analysis, the following solutions were made up: 
10x PI stock solution (0.5mg/ml) – 0.5mg PI dissolved in 0.038M sodium citrate (pH 7.0), 
covered and stored at 4 ºC. 10 ml PI working solution (50μg/ml) - 1ml PI stock solution, 
100µl 1M TRIS (pH 7.5), 50µl 1M MgCl2, 20µl RNase A (20mg/ml), 8.9ml DEPC H2O, 
covered and stored at 4 ºC. 
For analysis, cells were centrifuged at 2000g for 5 minutes and the supernatant aspirated. 
The pellet was washed in PBS and centrifuged at 2000g and the supernatant aspirated for 
the final time. The pellet was then re-suspended in 500μl PI working solution, transferred 
to FACS tubes and incubated at 37 ºC for 30 minutes in the dark. Cells were then gently 
vortexed immediately prior to being analysed on a Coulter™ EPICS XL™ analyser and 
Multicycler for Windows. 
 
2.2.13 Intracellular reactive oxygen species assay - 2,7-dichloro-fluorescein-diacetate 
(H2DCF-DA) 
Intracellular reactive oxygen species (ROS) generation can be assessed using 2, 7-
dichloro-fluorescein-diacetate (H2DCF-DA)398,413. H2DCF-DA diffuses into cells and is 
hydrolysed to the non-fluorescent derivative H2DCF, which becomes trapped within the 
cell. H2DCF becomes highly fluorescent when oxidised by O2-, H2O2 or HO·. Cellular 
fluorescence intensity is directly proportional to intracellular ROS. 
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Cells were seeded at 7.5x104 per ml to achieve 30% confluence (2mls in small culture 
dishes 35x10mm) in triplicate for each experimental condition and incubated for 12 
hours. 
Standard media were removed and replaced with 2mls of media containing 30nM H2DCF-
DA (stock solution 10µM in DMSO). Care was taken to minimise light contamination. The 
cells were incubated for a further 30 minutes. A background control (no H2DCF-DA) was 
incubated with standard media alone. 
The H2DCF-DA media was aspirated and the cells washed three times with warm PBS. 
2mls of standard media containing differing concentrations of iron chelators was added 
and the cells incubated for a pre-optimised period of time (30 minutes–24 hours). A 
negative control (H2DCF-DA exposed cells and no chelator) and a positive control (pre-
optimised concentrations of H2O2 – usually 25-100µM) were utilised. 
The media was removed and transferred to 15ml Falcon tubes and kept on ice. Cells were 
detached with 2mls 0.05% (w/v) trypsin and added to the corresponding Falcon tube. The 
tubes were centrifuged at 8000g for 4 minutes and the supernatant aspirated and 
discarded. The cell pellet was re-suspended in 350µl plain culture media (FCS free) and 
moved to FACS tubes (5ml 12/75mm) kept on ice. Light contamination was kept to a 
minimum throughout the experiment. FACS analysis for oxidised H2DCF was performed 
with a BD FACSCantoTM Flow Cytometer and the data analysed using FLOJO software. 
Background fluorescence was subtracted from all data and results expressed as a 
percentage of control. 
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2.2.14 59Fe extraction (efflux) with 59Fe-Tf 
Cells were plated at 70% confluence in small culture dishes (35x10mm) n=3. After 12 
hours, culture media was removed and replaced with 1ml of media spiked with 59Fe-Tf 
(kind gift of Professor Richardson, University of Sydney, Australia) (stock solution 36.7 
mg/ml) at 60µg/ml. Dishes were then incubated at 37°C for 3 hours. The media was 
removed and disposed of as per safety protocol and the cellular monolayer washed on ice 
with ice cold PBS three times. 
1ml of chelator spiked media was added and incubated at 37°C for a further 3 hours. The 
culture dishes were placed on ice and media removed and transferred to 5ml counting 
tubes. 1ml ice cold PBS was added and the monolayer scraped off and transferred with 
the PBS to empty counting tubes. 
Gamma counts were then measured using a Perkin Elmer 2480 automated gamma 
counter for 5 minutes per tube. Three blank tubes were inserted for background counts. 
The averaged background counts were subtracted from the media and cellular fraction 
counts and the results expressed by the culture media fraction as a percentage of the 
combined culture media and cellular fractions  (i.e. total 59Fe taken up). 
2.2.15 Cellular 59Fe up-take blocking 
Cells were seeded to achieve 70% confluence in small culture dishes and cultured for 12 
hours (n=3). Growing media was aspirated and replaced with 0.06 µg/ml 59Fe-Tf media 
spiked with differing concentrations of iron chelators.  Media with 59Fe-Tf alone was 
included as a control. Cells were incubated for a further 3 hours. Radiolabelled media was 
then aspirated and the cells washed with ice cold PBS three times. Ice-cold Pronase 
(1mg/ml in plain culture media) was added and cells incubated on ice for a further 30 
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minutes to ensure removal of membrane bound 59Fe-Tf. The remaining cell monolayer 
was then scraped from the dish in 1ml PBS and transferred to 5ml counting tubes.  
Gamma counts were then measured using a Perkin Elmer 2480 automated gamma 
counter for 5 minutes per tube. Three blank tubes were inserted for background count 
estimation and subtracted from the average experimental counts. Results were 
expressed as a percentage of the control up-take. 
 
 
2.2.16 Stable silencing (knock-down) of LRP1 and HCP1 protein expression by pGIPZ 
construct bearing lenti-viral preparations 
2.2.16.1 RNA interference 
RNA interference (RNAi) inhibits the translation of target mRNA426,427. Short hairpin RNA 
(shRNA) is a method of RNAi that utilises cellular defence mechanisms against viral double 
stranded (dsRNA) to ultimately cause silencing of a protein of interest by cleavage of its 
corresponding mRNA to prevent translation426,427. shRNAs are transcribed products of 
plasmid DNA delivered to the cell via the lenti-virus system as part of a pGIPZ construct. 
The transcribed shRNA nucleotide sequence is specifically created as the antisense 
sequence to a segment of target mRNA and due to construct design creates a hair-pin 
looped dsRNA428. The RNA endonuclease, Dicer, recognises the dsRNA of shRNA as viral 
and cleaves it into short interfering RNA (siRNA)426,427,429. These siRNA fragments are 
bound by the RNA induced silencing complex (RISC) where the antisense siRNA strand is 
used to recognise and bind the corresponding mRNA sequence430. Once bound, the mRNA 
is cleaved by RNase activation preventing translation and protein formation430. The pGIPZ 
construct contains promoters to ensure that shRNA is constitutively expressed to create a 
 97 
 
stable knock-down which is passed on to daughter cells. The gene for green fluorescent 
protein (GFP) is included at the beginning of the pGIPZ construct to allow visual 
confirmation of gene silencing and antibiotic resistance genes are incorporated to provide 
a facility to actively select cell lines that have been infected by the lenti-viral vector. As a 
safety feature, the incorporated viral DNA has been modified to prevent replication of 
viable lenti-viruses. 
 
 
CMV Promoter RNA Polymerase II promoter 
cPPT 
Central Polypurine tract  
helps translocation into the nucleus of non-dividing cells  
WRE Enhances the stability and translation of transcripts 
turbo GFP Marker to track shRNAmir expression 
Puror Mammalian selectable marker 
AMPr Ampicillin bacterial selectable marker 
5'LTR 5' long terminal repeat 
pUC ori High copy replication and maintenance in e.coli 
SIN-LTR 3' Self inactivating long terminal repeat 
RRE Rev response element 
ZEOr Bacterial selectable marker 
 
Figure 2.1 pGIPZ Construct Design 
Reproduced from Open Biosystems product website 
The pGIPZ constructs were delivered to the oesophageal cancer cell lines via a competent 
lenti-virus. Lenti-viruses were manufactured by 293FT cells following transfection of the 
specifically designed pGIPZ constructs and viral packaging plasmids. 
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2.2.16.2 Lenti-virus production 
All work was carried out in a level II tissue culture hood with full safety clothing. All 
equipment and waste media were sterilised in 1% Virkon in the tissue culture hood for at 
least 12 hours and then autoclaved as standard. 
2.2.16.3 Transfecting 293FT cells for lenti-virus production 
Transfection was performed using lipofectamine LTX and PLUS reagents, a liposomal 
delivery system (Invitrogen, UK). The optimum number of cells seeded and ratios of 
plasmid DNA, lipofectamine LTX and PLUS reagents for the highest transfection 
efficiencies had been previously ascertained by a member of a collaborating group in the 
laboratory (J O’Neil, personal communication). 
293FT cells were cultured in standard media with the addition of Genaticin G418 
antibiotic (10µg/ml media). The cells were briefly trypsinised, centrifuged for 5 minutes at 
5000g and then washed in PBS. After further centrifugation cells were re-suspended in 
standard media and 1x106 cells seeded into each 10cm culture dish (4 dishes per viral 
preparation). Cellular confluence of approximately 80% was required to proceed to 
transfection. 
All dishes were re-fed with 5mls standard media at least 1 hour before starting 
transfection. For each viral preparation (4 x 10cm culture dishes) the following were 
combined and incubated for 15 minutes at room temperature: 16µl (µg) lenti-viral 
plasmids encoding gene/shRNA of interest (pGIPZ), 16µl (µg) psPAX2, 16µl (µg) pMD2.G, 
12ml Optimem, 48µl PLUS reagent. 
After 15 minutes, 152µl of LTX reagent was added, gently mixed and further incubated 
for 30 minutes at room temperature. 
 99 
 
The standard culture media was aspirated from the culture dishes and 3062µl of the 
above reaction mix added in a drop wise fashion to the surface of each culture dish. The 
reaction mix was gently equilibrated over the cellular monolayer by slowly tilting the 
culture dish from side to side. Each dish was incubated at 37°C overnight. 
The reaction mix was aspirated and replaced with 5mls of standard media, except the 
added FCS had been heat inactivated (heated to 55°C for 25 minutes) to destroy the 
complement system that may neutralise any virus produced. Dishes were further 
incubated for 48 hours for virus production. 
2.2.16.4 Concentration of lenti-viral preparations 
The lenti-virus containing media was removed from all 4 dishes and combined. Cellular 
debris was removed by centrifugation at 12000g for 5 minutes and the supernatant 
filtered through a 0.45µm acrodisk filter. 
The media was then loaded into 12ml Beckman tubes and topped up to the lip of the 
tube with heat-inactivated media if required. The tubes were then ultra-centrifuged in a 
Beckman SW40T rotor at 30,000 RPM for 2 hours at 4°C (the centrifuge carrousel must be 
balanced accurately). 
The supernatant was then aspirated and 50µl heat inactivated media added to the viral 
pellet and re-suspended on an orbital shaker at 4°C for 24 hours. The concentrated viral 
media was stored at 4°C in a Nunc tube for a maximum of 4 weeks. 
2.2.16.5 Infecting OE33, OE19 and OE21 cells with concentrated lenti-virus 
Cells to be infected were cultured in 24 well plates until approximately 30% confluent on 
the day of infection. 
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The optimal concentration of virus to infect the cells was determined by serial dilutions of 
the concentrated virus in heat-inactivated media (0.1 - 5 µl of virus in 250µl). The 
percentage of cells infected with lenti-virus was increased by approximately 10% with the 
addition of hexadimethrene bromide (Polybrene™) 10µg/ml. 
Standard media was aspirated from each well and replaced with viral spiked media. The 
plates were incubated at 37°C for 12 hours with gentle mixing of the virus by tilting the 
plates every hour for the first 4 hours. 
Viral media was then aspirated and replaced with standard media and the cells 
monitored for expression of GFP for 24, 48 and 72 hours post-infection (infected cells 
fluoresce green during microscopy under a blue light) . A puromycin resistance gene was 
incorporated into the lenti-virus to allow for selection of virus infected cells. Selection of 
infected cells was undertaken at 72 hours with 10µg/ml of puromycin added to the 
culture media for 12 hours. 
Successful silencing of the protein of interest was further confirmed by Western blotting. 
2.2.16.6 Preparation of shRNA encoding plasmids 
Plasmids were supplied in transformed E.coli bacteria which were amplified by initial 
culture on agar with 100µg/ml ampicillin (plasmids encoded ampicillin resistance). After 
overnight culture at 37°C one colony of each plasmid was transferred to 3ml of Luria-
Bertani (LB) broth (1% (w/v) Tryptone Peptone, 0.5% (w/v) Yeast Extract, 1% (w/v) NaCl) 
supplemented with ampicillin (50µg/ml)) for 5 hours of pre-culture at 37°C before transfer 
to 500ml LB broth for a further 12 hours of incubation in a rotating incubator. 1ml of each 
culture was aspirated and added to 400µl of glycerol and frozen at -80oC for storage. 
Having amplified the E.coli, plasmids were extracted and purified using PureLink HiPure 
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Plasmid Filter Purification Kit – Maxi Prep (Invitrogen, UK) as per manufacturer’s 
instructions and using supplied solutions. Briefly, cultures in LB broth were spun at 4000g 
for 10 minutes, the supernatant discarded, the pellet re-suspended in 20ml of re-
suspension buffer and transferred to a 50ml centrifuge tube. 20ml of lysis buffer was 
added and cells mixed and incubated at room temperature for 5 minutes. 20ml 
precipitation buffer was then added and mixed by inversion. The solution was passed 
through a maxi column with filtration cartridge and allowed to flow through by gravity. 
Columns were then rinsed with 10ml wash buffer and the filtration cartridge was removed 
and discarded. The column was then washed with 60ml wash buffer and all flow through 
solution was discarded. 15ml elution buffer was added to the columns and effluent, 
containing purified plasmids, collected. 10.5ml isopropanol was added and mixed by 
inversion. Tubes were centrifuged at 15000g for 30 minutes and the supernatant 
discarded. The pellet was re-suspended in 70% ethanol before being re-spun at 15000g 
for 5 minutes, supernatant discarded and the pellet air dried at room temperature for 20 
minutes.  The plasmid DNA pellet was then re-suspended in 500µl TE Buffer (0.1mM EDTA 
in 10mM Tris-HCl, pH 8) and stored at -20oC. 
2.2.16.7 LRP1 and HCP1 shRNA encoding pGIPZ plasmids 
Stable LRP1 and HCP1 knockdowns were created in OE33, OE19 and OE21 cell lines by 
pGIPZ constructs containing specifically designed shRNA sequences for LRP1 and HCP1. In 
each case two clones were sourced targeting different mRNA regions. The clone that 
produced the greatest degree of post-transcriptional mRNA destruction and therefore 
protein suppression on Western blotting, was chosen for experimentation. A non-
silencing shRNA was used as a control and a double LRP1 and HCP1 knock down was 
created by combining the viral vectors. 
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pGIPZ plasmids were obtained from (Open Biosystems, UK) and packaging plasmids were 
received as a kind gift of Dr Chris Dawson, University of Birmingham. 
 
 
 
 Sequence  
Catalogue 
number and 
clone 
Function Sense Anti-sense Loop 
RHS4346 Non-
silencing 
Not disclosed but verified to produce siRNA with no match in 
mammalian genome 
RHS4531 
V2LHS-7406 
LRP1 
silencing 
ACCCGCGAGGACTACA
TTGAAT 
ATTCAATGTAGTC
CTCGCGGGC 
TAGTGAAGCCACA
GATGTA 
RHS4531 
V2LHS-134038 
LRP1 
silencing 
AGGCCTGACTGTGTTT
GAGAAT 
ATTCTCAAACACA
GTCAGGCCG 
TAGTGAAGCCACA
GATGTA 
RHS4531 
V2LHS-70748 
HCP1 
silencing 
ACGATCCATTGTCCAG
CTCTAT 
ATAGAGCTGGAC
AATGGATCGG 
TAGTGAAGCCACA
GATGTA 
RHS4531 
V2LHS_249843 
HCP1 
silencing 
ACCTCTGTCTAGGATC
TAGAAT 
ATTCTAGATCCTA
GACAGAGGC 
TAGTGAAGCCACA
GATGTA 
 
Table 2.5 Sense, anti-sense and loop sequences for shRNA control, LRP1 and HCP1 
knockdown 
 103 
 
2.2.17 Murine studies 
All murine work was undertaken at the University of Sydney, Australia, under the 
guidance of the Animal Ethics Committee, University of Sydney – AEC K20/4-10/3/5299 
and the Biomedical Services Unit, University of Birmingham, UK. 
Balb/C nu/nu (nude/athymic – T-cell deficient) 6-weeks-old female mice were utilised 
initially, however xenografts were slow to establish and spontaneously involuted. Mice 
were then substituted for NOD-SCID (non-obese diabetic-severe combined 
immunodeficiency – T and B cell deficient, no functioning natural killer cells and lack of 
complement) murine models which yielded near 100% rate of well established xenografts 
with OE33, OE19 and OE21 cell lines.  The mice were housed under quarantine 
conditions: air filtered with Techniplast Italy, HEPA-ULPA internal filter; gloves, gown and 
foot coverings were mandatory. All procedures were performed in a Gelaine biology 
safety hood. Mice were fed with Riverina rat and mice cubes (an irradiated and balanced 
composite).  
2.2.17.1 Xenograft formation 
The mice were examined to confirm a healthy status before commencing the procedure. 
Cells were harvested at 70% confluence with 0.05% (w/v) trypsin, washed and re-
suspended in plain media for counting. The number of cells required for each xenograft 
was pre-optimised to 1x106. After counting, the cells were centrifuged at 8,000g and re-
suspended in 50µl plain media per xenograft and kept on ice. Just before injection, the 
cell slurry was mixed 50/50 (v/v) with freshly thawed Matrigel (extracellular matrix 
substitute secreted by Engelbreth-Holm-Swarm mouse sarcoma cells431), using ice cold 
syringes, to form a total volume of 100µl per xenograft and kept on ice. 
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The mice were anesthetised in turn (with isoflurane) in an auto-regulated anesthetising 
chamber. The thoroughly mixed cell/Matrigel composite was injected in the 
subcutaneous tissue plane on the left flank of each mouse and allowed to form a solid 
bleb before the mouse was recovered and returned to the cage. 
After receiving xenografts, mice were ear tagged for identification. The health of the mice 
and size of the xenograft were closely monitored through observation of behaviour, 
mouse weight and calliper measurements. Established xenografts were seen 2 weeks 
post injection. 
2.2.17.2 Gavarging, culling and tissue collection 
Mice were sorted into treatment groups such that the mean mouse weight and xenograft 
dimensions were equal in each group. 
Mice were gavarged on alternate days using a gavarging needle and luer lock 1ml syringe. 
A chelator suspension was formed for gavarge in 30% 1,2-propanediol and 70% sterile 
0.9% (v/v) sodium chloride solution. Cisplatin was freshly diluted in sterilised dH2O for 
intraperitoneal (IP) injection with a fine bore needle. Control treatment (vehicle alone) 
consisted of 30% (v/v) 1,2-propanediol and 70% (v/v) sterile 0.9% (w/v) sodium chloride 
solution for gavarge and sterile dH20 for IP injection. 
Weight and xenograft dimensions were recorded on non-gavarging days to minimise 
distress. 
After the allotted treatment period the mice were culled under humane conditions. Blood 
samples were obtained by direct cardiac puncture for full blood count (FBC) and 
biochemical analysis (blood aliquoted into Capiject® blood tubes - lavender, dipotassium 
EDTA for FBC and cherry red serum gel/clot activator tubes for biochemistry). The 
biochemistry tube was allowed to clot and spun at 12000g for 10mins; serum aspirated, 
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transferred to analysis tubes and dispatched to the Veterinary School for analysis of (full 
blood count, urea, creatinine, ALT, AST, albumin, total bilirubin, serum iron, and total iron 
binding capacity). 
The xenograft, liver, heart and spleen were removed and weighed before being divided 
and snap frozen in liquid nitrogen or placed in formalin. 
 
2.2.18 Statistical Analysis 
Analyses of data were performed using SPSS version 10.0 (SPSS Inc, USA) and Microsoft 
Excel Professional 2009. Normally distributed data was analysed using paired and 
independent T-tests and non-parametric data, or where a normal distribution could not 
be assumed, were analysed using the Mann-Whitney U test. Comparison between 
categorical variables was made using χ2 and formal correlation assessed with Pearson’s 
correlation co-efficient. Significance was accepted at α-level of 5% (p=≤0.05) and all data 
means presented with ± 2 standard error of the mean (SEM). 
To assess the performance of two drugs, an iron chelator (Dp44mT, Deferasirox and DFO) 
and a chemotherapeutic agent (Cisplatin, 5-FU and Epirubicin) in combination, two series 
of cell counts were observed, one at various concentrations of the iron chelator alone and 
another in combination with the chemotherapy agent given at IC50 concentration. The 
additional effect of the iron chelator was estimated from the difference between the two 
series of counts and significance was assessed using a Wilcoxon signed rank test. Any 
enhancement of effect from using the two drugs (iron chelator and chemotherapy agent) 
in combination above that to be expected from observing their performance separately 
was then estimated by first subtracting the zero concentration cell counts from each 
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series, and then computing the difference between these two adjusted series (analysis 
kindly performed by Dr Roger Holder, University of Birmingham, UK). 
 
2.2.19 Ethical approval 
This work has been carried out in accordance with the declaration of Helsinki (2008) of 
the World Medical Association. Ethical approval for this study was approved by the 
Solihull Local Research Ethics Committee (LREC 06/Q2706/65). All patients providing 
tissue samples gave informed written consent. Murine studies were performed under the 
departmental licences of the Department of Pathology, University of Sydney, Australia 
and the Biomedical Services Unit, University of Birmingham, UK. 
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CHAPTER 3: CHARACTERISATION OF HAEM TRANSPORT PROTEINS 
IN THE PROGRESSION OF BARRETT’S METAPLASIA TO 
OESOPHAGEAL ADENOCARCINOMA 
 
3.1 Introduction 
The weight of epidemiological and experimental evidence associating iron with the 
incidence and progression of cancer is mounting. Iron is essential for cellular metabolism 
and is intrinsic to cell growth and replication186. It has long been known that iron plays a 
crucial role in the conversion of ribonucleotides to deoxyribonucleotides, a rate limiting 
step in DNA synthesis, catalysed by RNR187,188. Iron depletion classically arrests the cell 
cycle at G1/S
193,194. It follows that a selective advantage is conferred upon cancer cells 
that are able to acquire iron in greater quantities, to drive the cell cycle and enhance 
proliferation. 
Recent studies of ex-vivo BM associated OAC resection specimens, have shown that 
progression to invasive OAC is associated with increased expression of the inorganic iron 
import proteins, TfR1, DMT1 and DcytB along with the iron storage protein H-ferritin171. 
mRNA and protein expression of the iron efflux protein FPN was paradoxically increased 
in OAC, however FPN localisation was cytoplasmic, representing functional loss of iron 
export171. Such findings are entirely compatible with previous observations of deranged 
iron regulation in colorectal carcinogenesis175. Alterations in the expression of inorganic 
iron transport proteins were not just evident in the latter stages of OAC but apparent in 
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early stages of the dysplastic transformation of BM171. DMT1 expression was found to be 
significantly associated with a more aggressive phenotype and correlated with metastatic 
potential171. The authors postulated that over expression of iron transport proteins was 
unlikely to culminate in increased luminal iron uptake, rather the acquisition of systemic 
inorganic iron, through TfR1 mediated endocytosis171. Gross OAC iron content was 
significantly raised (200% increase in mean iron content) compared to adjacent dysplastic 
BM, supporting a paradoxical over expression of TfR1 and DMT1171. Furthermore, in-vitro 
culture of OAC cell lines with supplementary iron prompted avid proliferation and 
significant gross intracellular iron loading compared to control171. TfR1 mRNA expression 
was significantly suppressed and H-ferritin protein levels increased on iron loading, in 
keeping with an IRE-IRP mediated response171. 
The omnivorous human diet contains large quantities of organic iron, principally in the 
form of haem that is far more readily bio-available than inorganic iron201. In addition, 
there exists a large systemic circulating pool of haem iron bound to haemopexin290. 
Recent identification of haem importing proteins LRP1298 and HCP1274 raises the 
hypothesis that OAC cells express these proteins and acquire systemic haem in a manner 
analogous to TfR1 mediated endocytosis of transferrin bound inorganic iron. In addition, 
haem export proteins FLVCR and BCRP are thought to have a role in preventing cellular 
toxicity from haem and other dietary derived carcinogens273,279. Whether haem export 
protein expression is abrogated in OAC, to mirror the functional loss of inorganic iron 
efflux, is unknown. 
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3.2 Aims 
 
1. Characterise the expression of haem import proteins LRP1 and HCP1 in the progression of 
BM to OAC 
 
2. Characterise the expression of haem export proteins BCRP and FLVCR in the progression 
of BM to OAC 
 
3. Examine the relationship between haem transport protein expression and OAC 
pathological stage 
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3.3 Results 
3.3.1 mRNA expression of the haem import proteins LRP1 and HCP1 and haem export 
proteins BCRP and FLVCR in the malignant progression of BM to OAC 
Fresh OAC resection specimens (n=9) matched with adjacent dysplastic BM and benign 
non-dysplastic BM (n=9) matched with normal squamous oesophageal mucosa (NS), were 
obtained from surgical resection specimens and surveillance endoscopy. Histological 
identities of the samples were confirmed and specifically, benign BM tissue was certified 
to be columnar epithelium with no evidence of dysplasia or OAC. Samples were snap 
frozen in liquid nitrogen and subsequently processed for mRNA expression utilising qRT-
PCR. Mean fold change in LRP1, HCP1, BCRP and FLVCR mRNA expression were compared 
between matched samples: benign BM versus NS; and dysplastic BM versus OAC. 
3.3.1.1 mRNA expression for the haem import proteins LRP1 and HCP1 in the malignant 
progression of OAC 
The expression of LRP1 and HCP1 mRNA in benign BM compared to NS was variable with 
no statistical difference in fold change observed (p=0.3 and p=0.1 for LRP1 and HCP1) 
(figure 3.1). However, a degree of concordance was noted, at the level of each matched 
sample as LRP1 and HCP1 mRNA expression appeared to be either raised or decreased in 
tandem. 
In contrast, a marked increase in LRP1 and HCP1 mRNA expression was evident between 
dysplastic BM and OAC (figure 3.2) (p=0.049 and p=0.018 for LRP1 and HCP1). LRP1 and 
HCP1 mRNA expression was raised in 8 out of 9 matched samples. 
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3.3.1.2 mRNA expression for the haem export proteins BCRP and FLVCR in the 
malignant progression of OAC 
No significant differences in haem export protein mRNA expression was seen in the 
pathological change of NS to benign BM (p=0.27 and p=0.7 for BCRP and FLVCR) (figure 
3.1). BRCP and FLVCR mRNA expression was raised in the same samples that exhibited an 
increase in LRP1 and HCP1. 
Overall, a significant increase in BCRP and FLVCR mRNA expression was observed in the 
progression of dysplastic BM to invasive OAC (p=0.05 and p=0.042 for BCRP and FLVCR)  
(figure 3.2). A degree of variation between matched dysplastic BM and OAC was noted 
with BCRP mRNA raised in 6 of 9 and FLVCR mRNA raised in 7 of 9 samples. In the 
majority of cases, BCRP and FLVCR mRNA expression were raised in the same samples. 
One matched set of samples (T7) did not exhibit a change in either haem import or export 
protein mRNA expression. 
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Figure 3.1 mRNA expression for the haem transport proteins is not significantly altered 
in the metaplastic transformation of NS to BM 
Matched endoscopic biopsy samples of NS and benign BM (n=9) were processed for LRP1, 
HCP1, BCRP and FLVCR mRNA expression by qRT-PCR. Results are displayed as a fold 
change in mRNA expression by benign BM sample compared to average NS control. No 
significant change in average mRNA fold change was observed in the metaplastic 
transformation of NS to benign BM for LRP1, HCP1, BCRP or FLVCR. Error bars denote ± 
SEM. 
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Figure 3.2 mRNA expression for the haem transport proteins is significantly up-
regulated in the malignant progression of dysplastic BM to invasive OAC 
Matched surgical resection samples of dysplastic BM and OAC (n=9) were processed for 
LRP1, HCP1, BCRP and FLVCR mRNA expression by qRT-PCR. Results are displayed as a 
fold change in mRNA expression by OAC sample compared to average dysplastic BM 
control. Statistically significant changes in average mRNA fold change were observed in 
the malignant progression of dysplastic BM to invasive OAC for LRP1, HCP1, BCRP or 
FLVCR (p=0.049, p=0.018, p=0.05 and p=0.042 respectively). Error bars denote ± SEM. 
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3.3.2 Protein expression of the haem import proteins LRP1 and HCP1 and export 
proteins BCRP and FLVCR in the malignant progression of BM to OAC 
Fresh OAC resection specimens (n=9) matched with adjacent dysplastic BM and benign 
non-dysplastic BM (n=9) matched with NS, were obtained from surgical resection 
specimens and surveillance endoscopy. Protein expression was determined by Western 
blotting and densitometric scanning of the observed protein normalised to β-actin. Mean 
fold changes in LRP1, HCP1, BCRP and FLVCR protein expression were compared between 
matched samples: benign BM versus NS; and dysplastic BM versus OAC. 
3.3.2.1 Protein expression for the haem import proteins LRP1 and HCP1 in the 
malignant progression of OAC 
Haem import protein expression was analogous to observed changes in mRNA 
expression. LRP1 and HCP1 protein expression was not significantly different between 
benign BM and matched NS, although HCP1 tended towards up-regulation in benign BM, 
this failed to reach statistical significance (p=0.94 and p=0.084 for LRP1 and HCP1) (figure 
3.3). Haem import protein expression was strongly up-regulated in OAC compared to 
matched dysplastic BM (p=0.001 and p=0.03 for LRP1 and HCP1 respectively) (figure 3.3). 
3.3.2.2 Protein expression for the haem export proteins BCRP and FLVCR in the 
malignant progression of OAC 
In accordance with mRNA, no change in BCRP or FLVCR protein expression was apparent 
when comparing benign BM to NS (p=0.71 and p=0.8 for BCRP and FLVCR) (figure 3.3). 
The observed increase in BCRP and FLVCR mRNA expression, on progression of dysplastic 
BM to invasive OAC, was supported by a corresponding significant overexpression at the 
translational level. Fold change in protein expression for BCRP and FLVCR was 
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significantly raised for OAC compared to dysplastic BM (p=0.001 and p=0.001 for BCRP 
and FLVCR) (figure 3.3). 
  
 116 
 
 
Figure 3.3 The expression of proteins capable of haem transport is up-regulated in the 
malignant progression of dysplastic BM to invasive OAC 
Matched biopsy samples of NS (squamous) and benign BM (BM-ve) and resection 
specimens of dysplastic BM (BM+ve) and OAC were processed for LRP1, HCP1, BCRP and 
FLVCR protein expression by Western blotting. Results were standardised to β-actin and 
expressed as an average fold change compared to control. No significant change in 
expression was observed in the metaplastic replacement of NS with benign BM. However, 
both import and export protein expression was significantly up-regulated in the 
malignant progression of dysplastic BM to OAC (p=0.001, p=0.03, p=0.001 and p-0.001 for 
LRP1, HCP1, BCRP and FLVCR). 
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3.3.3 Immunolocalisation of the haem import proteins LRP1 and HCP1 and haem export 
proteins BCRP and FLVCR in the malignant progression of BM to OAC 
Semiquantitative immunohistochemistry was utilised to elucidate the cellular localisation 
and approximate expression levels of the haem import and export proteins in paraffin 
sections. Selected sections were biopsy specimens of benign BM with adjacent NS (n=26) 
and surgical resection specimens of OAC with associated dysplastic BM and NS (n=16). All 
material was screened by a consultant pathologist (PT) to confirm the samples contained 
the relevant tissue types. Normal liver and small bowel were utilised for positive and 
negative control. 
3.3.3.1 Semiquantitative immunolocalisation of haem import proteins LRP1 and HCP1 
in the malignant progression of OAC 
LRP1 (figure 3.4): No immunoreactivity for LRP1 was observed in NS mucosa. Benign BM 
similarly demonstrated minimal immunoreactivity for LRP1 with no observed difference 
on semi-quantitative analysis (p=0.23). Dysplastic BM associated with invasive OAC 
demonstrated moderate immunoreactivity, principally on the apical border with slight 
enhancement towards the crypts. Strong immunoreactivity for LRP1 was observed in OAC 
with marked pan-membranous activity. The difference in immunoreactivity between OAC 
and associated dysplastic BM was strongly significant (p=0.003). Normal liver was used as 
a positive control where pan-membranous and cytosolic immunoreactivity was observed. 
HCP1 (figure 3.5): HCP1 immunoreactivity within NS was very weak. No significant 
difference in immunoreactivity was noted between NS and benign BM (p=0.3) where 
immunoreactivity remained weak and mainly apical. A significant difference in 
immunoreactive intensity was observed between OAC and associated dysplastic BM 
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(p=0.001). OAC associated dysplastic BM still maintained apical membrane 
immunoreactivity which contrasted with more generalised membranous 
immunoreactivity for OAC. Normal small bowel was used as a positive control and 
demonstrated strong HCP1 immunoreactivity evenly along the villous apical membrane. 
3.3.3.2 Semiquantitative immunolocalisation of haem export proteins BCRP and FLVCR 
in the malignant progression of OAC 
BCRP (figure 3.6): Moderate BCRP immunoreactivity was noted in NS mucosa, more 
evident towards the basal cell layer. No significant difference was observed in the 
intensity of immunoreactivity between NS and benign BM (p=0.4). In benign BM, 
immunoreactivity remained weak but was more clearly localised to the apical membrane. 
In OAC, very intense apical immunoreactivity was observed. OAC associated dysplastic 
BM was significantly less immunoreactive (p=0.001) but still demonstrated apical activity. 
Normal liver was employed as a positive control with strong immunoreactivity in the 
cytoplasm and membrane. No evidence of nuclear BCRP immunoreactivity was observed. 
FLVCR (figure 3.7): The most striking observation was that FLVCR immunoreactivity was 
exclusively nuclear in all tissue types. No statistical difference in activity was noted 
between NS and benign BM (p=0.24), although the former appeared to be graduated 
with more intense immunoreactivity towards the basal cell-layer of the oesophagus. 
Nuclear immunoreactivity was markedly more pronounced in OAC compared to 
associated dysplastic BM (p=0.001) and again was specifically nuclear. Small bowel was 
used as a positive control where again exclusively strong nuclear staining was observed. 
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Protein 
immunoreactivity 
NS 
 
(n=26;mean±SE) 
Benign BM  
 
(n=26;mean±SE) 
BM associated 
with OAC 
(n=16;mean±SE) 
OAC  
 
(n=16;mean±SE) 
LRP1 0.6 ± 0.1 0.91 ± 0.31 2.45 ± 0.52 7.45 ± 1.2 * 
HCP1 1.8 ± 0.3 2.62 ± 0.7 4.13 ± 0.85 7.04 ± 0.9 * 
FLVCR 1.88 ± 0.1 2.33 ± 1.66 5.27 ± 0.43 8.4 ± 0.83 * 
BCRP 0.3 ± 0.21 0.5 ± 0.16 2.35 ± 0.46 6.52 ± 0.7 * 
 
Table 3.1 Immunoreactivity score for organic iron transport proteins in the progression 
of NS to invasive OAC 
Immunoreactivity of the haem import (LRP1 and HCP1) and export proteins (BCRP and 
FLVCR) was evaluated using paraffin embedded immunohistochemistry. Selected 
sections: biopsy specimens of benign BM with adjacent NS (n=26) and surgical resection 
specimens of OAC with associated dysplastic BM and NS (n=16). Immunoreactivity was 
scored on a semi-quantitative basis (observers blinded to tissue and antibody identity) by 
three independent observers. Staining intensity was scored as a function of two factors: a 
scale of 0-3 (0= absent, 3=strong); and percentage of positively stained cells within 
microscopic view (0= no cells, 1= 1-25%, 2= 26-50%, 3= 51-75% and 4=>76%). The two 
scores were multiplied to give a total score 0-12 (*p-value <0.05 benign BM compared to 
BM and OAC compared to OAC associated BM). 
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Figure 3.4 LRP1 immunoreactivity 
Paraffin sections of NS, benign BM, BM and OAC. Liver used as a positive and negative control. 
Magnification x20 and boxed area extrapolated to x60. Dotted lines: Ai squamo-submucosal border; Bi 
squamo-submucosal border and extent of OAC invasion; Ci border between squamous mucosa and BM. 
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Figure 3.5 HCP1 immunoreactivity 
Paraffin sections of NS, benign BM, BM and OAC. Small bowel used as a positive and negative control.  
Magnification x20 and boxed area extrapolated to x60. 
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Figure 3.6 BCRP Immunoreactivity 
Paraffin sections of NS, benign BM, BM and OAC. Liver used as a positive and negative control. 
Magnification x20 and boxed area extrapolated to x60. Dotted lines: Di border between BM and ADC; Ei 
border between BM and squamous mucosa; Fi border between squamous mucosa and OAC. 
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Figure 3.7 FLVCR immunoreactivity 
Paraffin sections of NS, benign BM, BM and OAC. Small bowel used as a positive and negative control.  
Magnification x20 and boxed area extrapolated to x60. Dotted lines: Di extent of OAC invasion into NS. 
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3.3.4 Haem transport protein immunoreactivity stratified by tumour stage 
An OAC tissue microarray derived from surgical resection specimens (n=78) (kind gift of 
Dr J Bury, University of Sheffield) with known pathological staging was processed for 
LRP1, HCP1, BCRP and FLVCR immunohistochemistry (figure 3.8). Semiquantitative 
analysis was performed by three observers blinded to the targeted immunoreactivity and 
OAC staging (SF, CT, KR). Results were stratified by staging criteria (local infiltration T-
stage 1-3, tumour differentiation and presence of nodal metastases). Despite the 
observed up-regulation of haem import and export proteins in the malignant progression 
of BM to invasive OAC, none of the import or export proteins demonstrated a significant 
change in immunoreactivity score with T-stage, tumour differentiation or presence of 
nodal metastases. 
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Figure 3.8 Semi-quantitative immunohistochemistry analysis of haem transport 
proteins by tumour stage 
OAC tissue microarray (n=78) stratified by tumour infiltration (T-stage), differentiation 
and presence of nodal disease. No significant difference in immunoreactivity was 
observed for haem import or export proteins.  
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3.4 Conclusions 
Haem transport proteins are hereby shown to be expressed in OAC and associated 
dysplastic BM for the first time. This novel finding is highly suggestive that haem 
acquisition has a significant role in contributing to the increased intracellular iron pool 
previously demonstrated in the malignant progression from BM to invasive OAC171. 
Indeed, haem import protein expression appears to be nonexistent in NS, negligible in 
benign BM and significantly up-regulated at both the transcription and translation levels 
upon malignant transformation of dysplastic BM to invasive OAC. Haem, once acquired 
by the cell, is metabolised and incorporated into inorganic iron processing pathways276. 
Iron loading of cancer cells serves as a means to drive the cell cycle, facilitate DNA 
synthesis, diminish cell-cell adhesion and increase the potential for further DNA 
aberrations through ROS generation178. 
LRP1 and HCP1 mRNA transcripts and protein expression were significantly up-regulated 
in the malignant transition from dysplastic BM to invasive OAC. LRP1 immunoreactivity 
was absent in NS and benign BM but present in dysplastic BM suggesting that LRP1 over 
expression is likely to be an early event in the evolution of BM associated dysplasia. 
Direct comparison of the expression of the haem transport proteins between benign BM 
and dysplastic BM was not performed as it was not possible to match samples derived 
from the same patient. HCP1 immunoreactivity was also weak in NS and benign BM but 
much more pronounced in dysplastic BM. LRP1 and HCP1 were immunolocalised to the 
apical border in dysplastic BM, however on progression to OAC, cellular polarity was lost 
with abundant LRP1 and HCP1 immunoreactivity evident in pan-membranous locations. 
Localisation to the cancer cell membrane is highly suggestive of a metabolically active 
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role for LRP1 and HCP1 supporting the hypothesis that OAC cells can acquire systemic 
haem either bound to haemopexin via LRP1 mediated endocytosis or free haem actively 
transported by HCP1. The disorganised interstitium of the tumour is likely to contain a 
relative abundance of haem secondary to the friable nature of tumour 
neovascularisation, central necrosis, ulceration and direct vessel invasion. The 
membranous location of HCP1 in particular is notable as the protein is post-
transcriptionally regulated to the cytoplasm in iron replete states274; further evidence of 
the errant iron metabolism seen in OAC cells. HCP1 is also up-regulated in hypoxic 
conditions such as those potentially encountered within the tumour substance. The 
normal physiological role of HCP1 is not solely to import haem but is also strongly 
associated with folate transport296 and as such, caution must be given when considering 
the exact role of HCP1 in the malignant progression of OAC. In a similar fashion, LRP1 is 
putatively regarded as a haem import protein as part of a larger scavenging and signalling 
role298, although its role in carcinogenesis is yet to be fully explored. The non-specific 
membranous immunolocalisation of LRP1 observed in OAC is analogous to that observed 
in hepatocytes for the endocytosis of haemopexin bound haem300. Although it is likely 
that LRP1 is actively importing haem iron, given its ubiquitous nature, it may have 
another, as yet, unidentified function in carcinogenesis. 
Although evident in the progression of dysplastic BM to OAC, LRP1 and HCP1 were not 
significantly associated with advanced OAC staging on semi-quantitative 
immunohistochemistry suggesting that further up-regulation in an established tumour is 
not essential to propagation of the malignant phenotype. 
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The up-regulation of FLVCR mRNA and protein expression in OAC and associated 
dysplastic BM was an unexpected observation based on the evidence that FLVCR is able 
to efflux haem and therefore potentially diminish the intracellular iron pool. However, 
the immunolocalisation of FLVCR is exclusively nuclear and therefore unlikely to be 
facilitating haem export from the cancer cell. FLVCR was first identified in erythrocyte 
precursors as an apically located membrane haem exporter keeping cytosolic haem 
concentrations below critical toxicity and plays a similar role in macrophages, post-
phagocytosis of senescent erythrocytes, to prevent cell death when the ability of HO1 to 
detoxify haem is overwhelmed305.  Similarly, in the face of increased haem import from 
overexpression of LRP1 and HCP1, the activity of HO1 to detoxify haem within a 
potentially hypoxic cancer cell may not be sufficient to prevent critical toxicity, promoting 
the protective expression of haem efflux proteins. However, this does not explain the 
apparent localisation of FLVCR to the nucleus unless to facilitate haem efflux and prevent 
toxicity within the nucleus. FLVCR has significant receptor homology with members of the 
Major Facilitator Superfamily305 and could have a role other than haem iron transport in 
the nucleus.  It may be possible that the FLVCR monoclonal antibody has significant cross-
reactivity with members of the Major Facilitator Superfamily erroneously identifying 
FLVCR as a nuclear protein in OAC. This is the first time that FLVCR has been characterised 
in cancer genesis; it may be that other cancers exhibit similar nuclear immunolocalisation. 
The observed up-regulation of BCRP mRNA, protein expression and immunolocalisation 
does not aid preservation of intracellular iron. However, the findings are consistent with 
observations in breast cancer where overexpression of the ATP-binding cassette 
transport system protects cells from cytotoxic agents due to drug efflux and is a major 
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mechanism mediating multi-drug resistance310. All of the analysed OAC and associated 
dysplastic BM was taken from resection specimens pre-exposed to neoadjuvant 
chemotherapy. These tumours may be subject to a selection bias, as those tumours with 
the ability to efflux chemotherapeutic agents would potentially be less likely to be 
obliterated at the time of resection and therefore more prevalent for research. There are 
very few studies on the expression pattern of BCRP in native tumour tissues and 
therefore the clinical relevance of BRCP in the pathophysiology of cancer is still unknown. 
Increased expression of BCRP from dysplastic BM to OAC could represent preserved 
negative feed-back in the presence of elevated intracellular haem concentrations driven 
by up-regulated haem import. In this capacity, it may be advantageous to the cancer cell 
to regulate cytosolic haem concentration to avoid haem toxicity, especially during 
hypoxic stress which is regularly encountered in rapidly expanding tumours. Indeed BCRP 
has a hypoxia responsive element, increasing expression and translocation to the cell 
membrane317. 
Up-regulation of the haem import proteins appears to be an early event in the evolution 
of OAC and supports the hypothesis that OAC cells are able to acquire systemic organic 
iron in a manner analogous to that of inorganic iron. The apparent increase in expression 
of the haem export proteins in OAC is likely to be multi-factorial; however it may be that 
these proteins maintain a crucial detoxifying role especially during hypoxic stress. 
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CHAPTER 4: THE IN-VITRO AND IN-VIVO EFFECTS OF HAEM AND 
ABROGATION OF HAEM TRANSPORT PROTEINS ON 
OESOPHAGEAL CANCER CELLS 
4.1 Introduction 
Whole body iron stores slowly accumulate with age, as intake gradually exceeds loss165. 
Cohort studies have correlated a replete iron state with increased risk of cancer mortality 
and the genetic iron loading disorder, haemochromatosis, is strongly associated with a 
variety of gastrointestinal malignancies151,152,154,155,166. Excessive red meat consumption is 
associated with OAC and oesophageal SCC development independent of preservation and 
cooking methods148,149. Furthermore, animal models receiving supplementary iron 
demonstrate progressive epithelial proliferation, hyperplasia, inflammation and iron 
deposition culminating in OAC150,170. 
Inorganic iron has been strongly implicated in the development of BM and progression to 
invasive OAC171. A sequential up-regulation of inorganic iron import proteins, together 
with functional loss of iron export and subsequent iron loading has been established on 
progression through the BM-dysplasia-OAC sequence171. In-vitro culture of OAC cells with 
supplementary iron prompts avid proliferation and gross cellular iron loading171. The 
mechanistic consequence of up-regulating iron import proteins is the ability of OAC cells 
to acquire systemic iron via TfR1 mediated endocytosis171. The iron loaded OAC cell is 
then able to proliferate unencumbered by the finite constraints of iron dependent 
processes controlling the cell cycle186-188. 
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Dietary haem, principally derived from red meat, is readily bio-available and actively 
transported across the enterocytes brush border by HCP1271,274. Iron is then liberated 
from haem by HO1 within the enterocytes and enters the inorganic iron metabolic 
pathways270,276. In addition, there exists a large systemic pool of haemopexin bound 
haem, predominantly derived from the turn-over of senescent erythrocytes by the 
reticulo-endothelial system270,274,285. The recent identification of a systemic haemopexin 
receptor, LRP1, led to the hypothesis that OAC cells could also acquire systemic organic 
iron by endocytosis of haemopexin bound haem292. In chapter 3, ex-vivo oesophageal 
tissue was utilised to establish for the first time that haem import proteins LRP1 and 
HCP1 are both up-regulated in the progression of BM to invasive OAC. The extent to 
which LRP1 and HCP1 contribute to the malignant phenotype of OAC cells and the 
potential to abrogate these proteins as therapeutic targets is unknown. 
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4.2 Aims 
 
1. Characterise the influence of LRP1 and HCP1 protein abrogation on cellular iron loading 
and iron transport protein expression in-vitro 
 
2. Determine the impact of LRP1 and HCP1 silencing on cell phenotype 
 
3. Examine the impact of LRP1 and HCP1 silencing on cell cycle 
 
4. Investigate the impact of LRP1 and HCP1 abrogation on tumour burden in a murine 
model 
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4.3 Results 
 
4.3.1 Abrogation of LRP1 and HCP1 protein expression (LRP1 and HCP1 knock-downs) 
Stable LRP1 and HCP1 knock-downs (KD) were created in OE33, OE19 and OE21 cell lines 
by introducing pGIPZ constructs, using a lenti-virus vector, containing specifically 
designed shRNA sequences for LRP1 and HCP1. A non-silencing shRNA was used as a 
control and a double LRP1 and HCP1 KD was created by combining the viral vectors. 
Successfully knocked-down cells, containing an antibiotic resistance cassette as part of 
the pGIPZ construct, were selected by culture with Puromycin. Successful infection and 
expression of the pGIPZ construct was also visually confirmed by expression of GFP under 
blue light excitation (figure 4.1). Interference of LRP1 and HCP1 mRNA by siRNA and 
subsequent protein knock-down was confirmed by Western blotting (figure 4.2). 
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Figure 4.1 OE33 cell line expressing GFP after successful infection with lenti-virus vector 
containing pGIPZ constructs and culture with Puromycin 
OE33 cell line was co-cultured with lenti-virus vector containing pGIPZ constructs 
specifically designed to abrogate LRP1 and HCP1 protein expression via RNAi. Each pGIPZ 
construct contains shRNA to LRP1, HCP1 or non-silencing control along with green 
fluorescent protein (GFP) expression and Puromycin resistance cassette. x60 
magnification. 
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Figure 4.2 Confirmation of successful silencing of LRP1 and HCP1 protein expression in 
OE33, OE19 and OE21 cell line knock-downs 
OE33, OE19 and OE21 cell line knock-downs (KD) were co-cultured with lenti-virus vector 
containing pGIPZ constructs specifically designed to abrogate LRP1 and HCP1 protein 
expression via RNAi. Successful silencing of LRP1 and HCP1 protein expression was 
confirmed by Western blotting. β-actin used as an internal protein loading control. 
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4.3.2 Characterisation of the influence of LRP1 and HCP1 protein abrogation on cellular 
iron loading and iron transport protein expression in-vitro 
 
4.3.2.1 LRP1 and HCP1 knock-down suppresses cellular ability to acquire haem to 
augment the intracellular iron pool compared to control 
To determine if the abrogation of haem importing proteins, LRP1 and HCP1, has an effect 
on intracellular iron concentration, OE33, OE19 and OE21 cell line knock-downs (non-
silencing control, LRP1, HCP1 and LRP1/HCP1 knock-downs) were cultured in control or 
haem loaded media (20µM) for 48 hours prior to ferrozine assay (figure 4.3). 
After 48 hours of culture in plain media, there was no significant difference in cellular iron 
concentration between non-silenced control and LRP1, HCP1 and combined knock-downs 
in any cell line. A significant difference was seen between non-silenced controls cultured 
in control media and haem loaded media (p=0.001 for all cell lines). This significance was 
lost when LRP1, HCP1 and LRP1/HCP1 knock-downs, across all cell lines, were cultured in 
haem loaded media. 
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Figure 4.3 LRP1 and HCP1 knock-down suppresses cellular ability to acquire haem to 
augment the intracellular iron pool compared to control 
OE33, OE19 and OE21 cell line knock-downs were cultured with or without 20µM haem 
for 48 hours and processed for a ferrozine assay. No significant difference in intracellular 
iron was seen between non-silenced control and knock-downs when cultured in media 
alone. Non-silenced control cells, across all three lines, demonstrated a significant 
increase in intracellular iron (*p=0.001) when cultured with haem. However, knock-down 
of LRP1 and HCP1 suppressed cellular ability to acquire haem, even in the presence of 
haem loaded media, there was no significant difference in intracellular iron concentration 
when compared to non-silenced controls grown in media alone. Control: non-silenced 
control; HL: haem loaded; KD: knock-down. N=3 for each regime. Error bars denote ± 
SEM. 
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4.3.2.2 Knock-down of LRP1 and HCP1 proteins in oesophageal cancer cells influences 
mRNA of iron transport proteins 
OE33, OE19 and OE21 cell line knock-downs were cultured with or without 20µM haem 
for 48 hours. Cells were then harvested and mRNA expression for TfR1, FPN and ferritin 
determined using qRT-PCR (figure 4.4). 
TfR1 mRNA expression was significantly increased, compared to control, in LRP1 and 
HCP1 knock-down cells cultured with or without supplementary haem. Up-regulation of 
TfR1 mRNA was preserved across all three cell lines (all p=<0.05). No difference in TfR1 
mRNA expression was seen between non-silenced cells cultured with or without haem. 
Overall, FPN mRNA expression in knock-down cells trended towards a decrease in fold 
change in the presence or absence of supplementary haem, reaching significance in a 
number of cases: OE33 LRP1/HCP1 KD haem loaded 0.75±0.05 p=0.05; OE21 HCP1 KD 
0.69±0.13 p=0.048; OE21 LRP1 KD and HCP1 KD haem loaded 0.5±0.12, 0.43±0.02 p=0.04 
and 0.01 respectively. 
Ferritin mRNA expression was significantly repressed in the majority of knock-downs 
compared to non-silenced control in the presence or absence of haem loading. Fold 
change in ferritin mRNA was most marked in the OE19 cell line (all p-values =<0.05 except 
LRP1 KD which showed no change in ferritin mRNA expression). Again, no change in 
mRNA expression was noted when non-silenced controls were cultured with 
supplementary haem. 
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Figure 4.4 Knock-down of LRP1 or HCP1 proteins alters TfR1, FPN and ferritin mRNA 
expression 
Figure A: OE33, Figure B: OE19 and Figure C: OE21 knock-downs were cultured with or 
without 20µM haem for 48 hours. Control: non-silenced control; KD: knock-down; HL: 
haem loaded. (*p=<0.05 compared to non-silenced control cultured in plain media). Error 
bars denote ± SEM. 
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4.3.2.3 Knock-down of LRP1 and HCP1 proteins in oesophageal cancer cells influences 
iron transport protein expression 
OE33, OE19 and OE21 cell line knock-downs were cultured with or without 20µM haem 
for 48 hours. Cells were then harvested and protein expression for TfR1, FPN and ferritin 
determined by Western blotting (figure 4.5: OE33, figure 4.6: OE19 and figure 4.7: OE21). 
TfR1 protein expression was significantly elevated in LRP1 and HCP1 knock-downs 
compared to non-silenced control across all three cell lines with changes most marked in 
the SCC OE21 cell line (all p=<0.05). No change in TfR1 protein expression was seen when 
non-silenced control cells were cultured in plain or haem loaded media. 
FPN protein expression varied across the cell lines. OE33 LPR1 and HCP1 knock-downs 
demonstrated significant decreases in FPN protein expression when cultured in either 
plain or haem loaded media, broadly in keeping with changes seen at the mRNA level (all 
p-values <0.05). OE19 and OE21 cell line knock-downs showed no significant change or 
slight elevation in FPN protein expression when cultured with haem loaded media. No 
change in FPN protein expression was demonstrated between non-silenced controls 
cultured in plain or haem loaded media in any cell line. 
Ferritin protein expression was suppressed in OE33 and OE19 LRP1 and HCP1 knock-
downs cultured in plain media compared to non-silenced controls. When cultured with 
haem loaded media, ferritin expression in the OE19 and OE21 cell line knock-downs 
tended towards a marginal elevation reaching significance in a minority. In all knock-
downs demonstrating increased ferritin protein expression, none were higher than their 
respective haem loaded non-silenced controls. OE19 and OE21 cell lines demonstrated 
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significant increases in ferritin protein expression in non-silenced haem loaded controls 
compared to non-silenced controls cultured in plain media (OE19: 1.43±0.24 p=0.01 and 
OE21: 1.96±0.34 p=0.02). 
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Figure 4.5 Knock-down of LRP1 and HCP1 proteins in the OE33 cell line alters TfR1, FPN 
and ferritin protein expression 
OE33 cell line knock-downs cultured with or without 20µM haem for 48 hours. Control: 
non-silenced control; KD: knock-down; HL: haem loaded. (*p=<0.05 fold change in 
protein expression compared to non-silenced control cultured in plain media). Error bars 
denote ± SEM. 
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Figure 4.6 Knock-down of LRP1 and HCP1 proteins in the OE19 cell line alters TfR1, FPN 
and ferritin protein expression 
OE19 cell line knock-downs cultured with or without 20µM haem for 48 hours. Control: 
non-silenced control; KD: knock-down; HL: haem loaded. (*p=<0.05 fold change in 
protein expression compared to non-silenced control cultured in plain media). Error bars 
denote ± SEM. 
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Figure 4.7 Knock-down of LRP1 and HCP1 proteins in the OE21 cell line alters TfR1, FPN 
and ferritin protein expression 
OE21 cell line knock-downs cultured with or without 20µM haem for 48 hours. Control: 
non-silenced control; KD: knock-down; HL: haem loaded. (*p=<0.05 fold change in 
protein expression compared to non-silenced control cultured in plain media). Error bars 
denote ± SEM. 
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4.3.2.4 Knock-down of LRP1 and HCP1 proteins in oesophageal cancer cells alters mRNA 
expression of haem transporting proteins 
OE33, OE19 and OE21 cell line knock-downs were cultured with or without 20µM haem 
for 48 hours. Cells were then harvested and mRNA expression for LRP1, HCP1, BCRP and 
FLVCR determined using qRT-PCR (figure 4.8 A: OE33, B: OE19 and C: OE21). 
Haem importing proteins LRP1 and HCP1 were targets for RNAi. Loss of LRP1 protein 
expression did not influence HCP1 mRNA expression. This observation held true across all 
cell lines; in the presence or absence of haem loading. Conversely the loss of HCP1 
protein expression showed a significant increase in LRP1 mRNA expression in the OE21 
cell line but no change in the OAC lines, OE33 and OE19 (1.58±0.24, p=0.024 and 
1.36±0.31, p=0.048 for OE21 HCP1 KD plain media and haem loaded media respectively). 
mRNA expression for the haem effluxing proteins BRCP and FLVCR generally 
demonstrated a significant decrease in the presence of LRP1 and HCP1 knock-downs. 
However, this observation was not consistent across the panel of cell lines. Both BCRP 
and FLVCR mRNA expression was suppressed in OE33 knock-downs cultured in plain but 
not haem loaded media. BCRP mRNA expression was significantly reduced in OE19 knock-
downs cultured in plain media and both BCRP and FLVCR mRNA expression was 
suppressed with the presence of haem loading. OE21 knock-downs exhibited significantly 
repressed BCRP mRNA expression in plain media but little difference compared to non-
silenced control with the addition of haem loading. Conversely, OE21 knock-downs 
showed a significant decrease in FLVCR mRNA expression in haem loaded media but no 
change in expression compared to non-silenced control in plain media. Interestingly, no 
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significant difference in either BCRP or FLVCR mRNA expression was noted between non-
silenced controls cultured in plain or haem loaded media across the three cell lines. 
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Figure 4.8 Knock-down of LRP1 or HCP1 proteins alters mRNA expression of haem 
transport proteins 
Figure A: OE33, figure B: OE19 and figure C: OE21. OE33, OE19 and OE21 LRP1, HCP1 and 
combined knock-downs were cultured with or without 20µM haem for 48 hours. Control: 
non-silenced control; KD: knock-down; HL: haem loaded. (*p=<0.05 compared to non-
silenced control cultured in plain media). Error bars denote ± SEM. 
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4.3.2.5 Knock-down of LRP1 and HCP1 proteins in oesophageal cancer cells influences 
haem transport protein expression 
OE33, OE19 and OE21 cell line knock-downs were cultured with or without 20µM haem 
for 48 hours. Cells were then harvested and protein expression for LRP1, HCP1, BCRP and 
FLVCR determined by Western blotting (figure 4.9: OE33, figure 4.10: OE19 and figure 
4.11: OE21). 
LRP1 and HCP1 proteins were successfully knocked-down with negligible protein 
expression seen on Western blotting. As previously noted with mRNA expression, there 
was very little interplay between expression of the haem import proteins with no 
compensatory increase in HCP1 protein expression on knock-down of LRP1 and vice-
versa, no up-regulation of LRP1 in the absence of HCP1 protein expression. One exception 
was the OE21 LRP1 knock-down cultured in haem loaded media that demonstrated a 
significant increase in HCP1 protein expression (1.57±0.35, p=0.001). 
Expression of the haem efflux protein BCRP was significantly reduced in all knock-downs 
of the OE33 and OE21 cell lines but did not alter those of OE19 cell line origin. 
FLVCR expression was affected to a much lesser degree with suppression seen in the 
OE19 cell line knock-downs cultured in plain media only (OE19 fold changes: 0.66±0.03, 
0.57±0.04 and 0.63±0.02 for LRP1 KD, HCP1 KD and LRP1/HCP1 KD respectively). On 
comparison of the non-silenced controls, OE19 controls alone exhibited a significant 
increase in BRCP expression when cultured in haem loaded media. No change was 
observed for FLVCR expression across the cell panel. 
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Figure 4.9 Confirmation of knock-down of LRP1 and HCP1 proteins in OE33 cell line and 
altered expression of haem transporting proteins 
OE33 cell line knock-downs cultured with or without 20µM haem for 48 hours. Control: 
non-silenced control; KD: knock-down; HL: haem loaded. (*p=<0.05 fold change in 
protein expression compared to non-silenced control cultured in plain media). Error bars 
denote ± SEM. 
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Figure 4.10 Confirmation of knock-down of LRP1 and HCP1 proteins in OE19 cell line 
and altered expression of haem transporting proteins 
OE19 cell line knock-downs cultured with or without 20µM haem for 48 hours. Control: 
non-silenced control; KD: knock-down; HL: haem loaded. (*p=<0.05 fold change in 
protein expression compared to non-silenced control cultured in plain media). Error bars 
denote ± SEM. 
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Figure 4.11 Confirmation of knock-down of LRP1 and HCP1 proteins in OE21 cell line 
and altered expression of haem transporting proteins 
OE21 cell line knock-downs cultured with or without 20µM haem for 48 hours. Control: 
non-silenced control; KD: knock-down; HL: haem loaded. (*p=<0.05 fold change in 
protein expression compared to non-silenced control cultured in plain media). Error bars 
denote ± SEM. 
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4.3.3 Determination of the impact of LRP1 and HCP1 silencing on cell viability, 
proliferation and phenotype 
An increase in intracellular iron increases cellular viability, proliferation and creates a 
more aggressive phenotype. Up-regulation of the haem importing proteins LRP1 and 
HCP1 in ex-vivo OAC samples suggests that OAC cells are able to acquire circulating haem 
by scavenging free haem or capturing haemopexin bound haem to augment the 
intracellular iron pool. Abrogation of the active haem import proteins should therefore 
have an impact on cellular viability, proliferation and phenotype. 
4.3.3.1 LRP1 and HCP1 knock-down reduces oesophageal cancer cell viability and 
proliferation and neutralises the stimulatory effect of supplementary haem 
OE33, OE19 and OE21 cell line LRP1 and HCP1 knock-downs were cultured with or 
without supplementary haem (20µM) for 48 hours. Cells were then assessed for 
differences in cellular viability and proliferation with MTT and BrdU assays respectively 
(Figure 4.12). 
When cultured with plain media, LRP1 and HCP1 knock-downs derived from the OAC line 
OE33 did not demonstrate any change in either viability or proliferation. However, when 
cultured in the presence of supplementary haem, the viability and proliferation of the 
non-silenced control was significantly enhanced (p=0.007 and p=0.0039) compared to 
culture in plain media alone. The increase in viability and proliferation induced by 
supplementary haem was lost in the LRP1 and HCP1 knock-downs. This observation was 
consistent across all three cell lines. OE19 knock-downs, cultured in plain media, 
demonstrated significantly reduced viability compared to non-silenced control in both 
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LRP1 and HCP1 knock-downs but the double LRP1/HCP1 knock-down missed significance 
(p=0.0052, p=0.034 and p=0.14 respectively). OE19 knock-down proliferation was not 
significantly different from control in plain media. Supplementary haem enhanced 
viability and proliferation in the non-silenced OE19 control (p=0.05 and p=0.02) which 
was again lost in the LRP1 and HCP1 knock-downs that were no different to plain media 
control. The most marked changes in viability and proliferation were determined in the 
oesophageal SCC cell line OE21. HCP1 and the double LRP1/HCP1 knock-down both 
demonstrated significantly reduced viability compared to non-silenced control (p=0.006 
and p=0.016). Proliferation was reduced in all three OE21 knock downs cultured in plain 
media (p=0.0046, p=0.012 and p=0.0005 for HCP1, LRP1 and LRP1/HCP1 KDs 
respectively). OE21 non-silenced controls cultured with supplementary haem exhibited 
an expected increase in viability and proliferation (p=0.012, p=0.05) compared to plain 
media alone. OE21 knock-downs continued the observed trend in lacking any enhanced 
viability in the presence of supplementary haem and actually showed a decrease in 
proliferation compared to non-silenced plain media control (p=0.01, p=0.6 and p=0.05 for 
HCP1, LRP1 and LRP1/HCP1 KD respectively). 
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Figure 4.12 LRP1 and HCP1 knock-down reduces oesophageal cancer cell viability and 
proliferation and neutralises the stimulatory effect of supplementary haem 
OE33, OE19 and OE21 cell line knock-downs cultured in plain media (figure A) or 20µM 
haem (figure B) for 48 hours. Control: non-silenced control; KD: knock-down; HL: haem 
loaded. (*p=<0.05 fold change in viability or proliferation compared to non-silenced 
control cultured in plain media). 
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4.3.3.2 LRP1 and HCP1 knock-down prevents the stimulatory effect of supplementary 
haem on oesophageal cancer cell migration 
OE33, OE19 and OE21 cell line LRP1 and HCP1 knock-downs were cultured until 100 
percent confluent. The cellular monolayer was then scratched to create a “wound” and 
media substituted for either fresh plain media (control) or media supplemented with 
20µM haem. Cellular migration across the wound was visually recorded at 12 hourly 
intervals and expressed as a percentage of wound remaining (figures 4.13 and 4.14: 
OE33, figures 4.15 and 4.16: OE19 and figures 4.17 and 4.18: OE21). After 60 hours of 
observation the majority of scratch wounds had healed. No significant difference was 
noted in cell migration rate between non-silenced controls and LRP1 or HCP1 knock-
downs cultured in plain media.  OE19 and OE21 double LRP1/HCP1 knock-downs cultured 
in plain media did show a significant reduction in overall wound healing compared to 
control (p=0.032 and p=0.001 for OE19 and OE21 LRP1/HCP1 KD). In all three cell lines 
the addition of supplementary haem to the culture media of non-silenced controls led to 
a significant increase in the rate of overall wound closure (non-silenced control plain 
media vs. non-silenced control haem supplemented media p=0.001, p=0.04 and p=0.05 
for OE33, OE19 and OE21 respectively). The stimulatory effect of supplementary haem on 
non-silenced control was lost upon knock-down of either LRP1 or HCP1 in all three cell 
lines with no significant difference in cell migration compared to plain media control. 
Again, the double LRP1/HCP1 knock-downs of OE19 and OE21 demonstrated reduced 
cellular migration with significantly inhibited overall wound closure rates compared to 
plain media control (p=0.02 and p=0.0001 for OE19 and OE21). OE33 double LRP1/HCP1 
knock-down it not show a significant reduction in migratory ability compared to non-
silenced control cultured in plain or haem supplemented media. 
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Figure 4.13 LRP1 and HCP1 knock-down prevents the stimulatory effect of 
supplementary haem on OE33 cell line migration 
OE33 cell line knock-downs cultured in plain media or 20µM haem loaded media (n=9). 
Figure A: non-silenced control vs. LRP1 KD, figure B: non-silenced control plain and HL 
media vs. LRP1 KD HL, figure C: non-silenced control vs. HCP1 KD, figure D: non-silenced 
control plain and HL media vs. HCP1 KD HL, figure E: non-silenced control vs. double 
LRP1/HCP1 KD and figure F: non-silenced control plain and HL media vs. double 
LRP1/HCP1 KD HL. Control: non-silenced control; KD: knock-down; HL: haem loaded. Error 
bars denote ± SEM. 
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Figure 4.14 LRP1 and HCP1 knock-down prevents the stimulatory effect of 
supplementary haem on OE33 cell line migration 
Representative images of OE33 cell line knock-downs cultured in plain and 20µM haem 
supplemented media over 60 hours. Scrambled: non-silenced control; KD: knock-down; 
HL: haem loaded. 
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Figure 4.15 LRP1 and HCP1 knock-down prevents the stimulatory effect of 
supplementary haem on OE19 cell line migration 
OE19 cell line knock-downs cultured in plain media or 20µM haem loaded media (n=9). 
Figure A: non-silenced control vs. LRP1 KD, figure B: non-silenced control plain and HL 
media vs. LRP1 KD HL, figure C: non-silenced control vs. HCP1 KD, figure D: non-silenced 
control plain and HL media vs. HCP1 KD HL, figure E: non-silenced control vs. double 
LRP1/HCP1 KD and figure F: non-silenced control plain and HL media vs. double 
LRP1/HCP1 KD HL. Control: non-silenced control; KD: knock-down; HL: haem loaded. Error 
bars denote ± SEM. 
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Figure 4.16 LRP1 and HCP1 knock-down prevents the stimulatory effect of 
supplementary haem on OE19 cell line migration 
Representative images of OE19 cell line knock-downs cultured in plain and 20µM haem 
supplemented media over 60 hours. Scrambled: non-silenced control; KD: knock-down; 
HL: haem loaded. 
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Figure 4.17 LRP1 and HCP1 knock-down prevents the stimulatory effect of 
supplementary haem on OE21 cell line migration 
OE21 cell line knock-downs cultured in plain media or 20µM haem loaded media (n=9). 
Figure A: non-silenced control vs. LRP1 KD, figure B: non-silenced control plain and HL 
media vs. LRP1 KD HL, figure C: non-silenced control vs. HCP1 KD, figure D: non-silenced 
control plain and HL media vs. HCP1 KD HL, figure E: non-silenced control vs. double 
LRP1/HCP1 KD and figure F: non-silenced control plain and HL media vs. double 
LRP1/HCP1 KD HL. Control: non-silenced control; KD: knock-down; HL: haem loaded. Error 
bars denote ± SEM. 
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Figure 4.18 LRP1 and HCP1 knock-down prevents the stimulatory effect of 
supplementary haem on OE21 cell line migration 
Representative images of OE21 cell line knock-downs cultured in plain and 20µM haem 
supplemented media over 60 hours. Scrambled: non-silenced control; KD: knock-down; 
HL: haem loaded. 
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4.3.3.3 LRP1 and HCP1 knock-down suppresses independent colony formation with or 
without supplementary haem 
OE33, OE19 and OE21 cell line knock-downs were seeded as a single cell suspension in 
agar containing plain media or spiked with 20µM haem. After two weeks of incubation, 
the average colony size was calculated in pixels2 (figure 4.19: OE33, figure 4.20: OE19 and 
figure 4.21: OE21). 
All cell line knock-downs formed colonies. Similar observations in the range of average 
colony size were made from OE33, OE19 and OE21 cell line knock-downs. Compared to 
non-silenced controls, abrogation of LRP1 and HCP1 protein expression significantly 
impaired average colony size (OE33: p=0.01, p=0.05 and p=0.001; OE19: p=0.05, p=0.04 
and p=0.001; OE21: p=0.022, p=0.02 and p=0.001 for LPR1, HCP1 and LRP1/HCP1 knock-
downs respectively). Non-silenced control colonies, incubated in agar spiked with haem, 
demonstrated significantly larger average colony sizes compared to non-silenced 
controls, grown in agar containing plain media. This observation was identified in all cell 
lines (p=0.001, p=0.01 and p=0.048 for OE33, OE19 and OE21 lines). In a similar fashion to 
changes seen with viability, proliferation and migration, the stimulatory effect of 
additional haem on colony formation was entirely lost with the silencing of LRP1 and 
HCP1 proteins. In fact, even when incubated in supplementary haem, knock-downs from 
each cell line still demonstrated reduced average colony size compared to non-silenced 
controls grown in agar containing plain media alone (OE33: p=0.05, p=0.04 and p=0.02; 
OE19: p=0.05, p=0.04 and p=0.001; OE21: p=0.01, p=0.008 and p=0.0001 for LPR1, HCP1 
and LRP1/HCP1 knock-downs respectively). 
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Figure 4.19 LRP1 and HCP1 knock-down suppresses independent colony formation with 
or without supplementary haem in OE33 cell line 
OE33 cell line LRP1 and HCP1 knock-downs were seeded as a single cell suspension in 
agar containing plain or media spiked with 20µM haem. After two weeks of incubation, 
the average colony size was calculated in pixels2. Figure A: images of initial seeding (T0) 
and at 14 days. Figure B: average colony sizes at 14 days. Control: non-silenced control; 
KD: knock-down; HL: haem loaded. (*p=<0.05 significant change in average colony size 
compared to non-silenced control cultured in plain media, n=9).  
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Figure 4.20 LRP1 and HCP1 knock-down suppresses independent colony formation with 
or without supplementary haem in OE19 cell line 
OE19 cell line LRP1 and HCP1 knock-downs were seeded as a single cell suspension in 
agar containing plain or media spiked with 20µM haem. After two weeks of incubation, 
the average colony size was calculated in pixels2. Figure A: images of initial seeding (T0) 
and at 14 days. Figure B: average colony sizes at 14 days. Control: non-silenced control; 
KD: knock-down; HL: haem loaded. (*p=<0.05 significant change in average colony size 
compared to non-silenced control cultured in plain media, n=9).  
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Figure 4.21 LRP1 and HCP1 knock-down suppresses independent colony formation with 
or without supplementary haem in OE21 cell line 
OE21 cell line LRP1 and HCP1 knock-downs were seeded as a single cell suspension in 
agar containing plain or media spiked with 20µM haem. After two weeks of incubation, 
the average colony size was calculated in pixels2. Figure A: images of initial seeding (T0) 
and at 14 days. Figure B: average colony sizes at 14 days. Control: non-silenced control; 
KD: knock-down; HL: haem loaded. (*p=<0.05 significant change in average colony size 
compared to non-silenced control cultured in plain media, n=9).  
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4.3.4 The impact of LRP1 and HCP1 silencing on OE33, OE19 and OE21 cell cycle in-vitro 
To assess the impact of LRP1 and HCP1 silencing on cell cycle, OE33, OE19 and OE21 cell 
line knock-downs were cultured in plain or haem loaded media (20µM haem) for 48 
hours. Cells were then harvested and processed for propidium iodide FACS analysis of the 
cell cycle (figure 4.22). 
4.3.4.1 LRP1 and HCP1 protein knock-down neutralises the stimulatory effect of 
supplementary haem on the cycle cell 
Cell cycle was assessed using propidium iodide FACS analysis and represented as the 
average percentage of cells in G0/G1, S or G2/M phases of the cycle. The distribution of 
cells in the cycle was not significantly different between non-silenced controls and LRP1 
and HCP1 knock-downs cultured in plain media. A predicted stimulatory effect of 
supplementary haem was demonstrated by a significant decrease in the percentage of 
cells in the G0/G1 phase, and a significant increase in S-phase and G2/M phases in non-
silenced haem loaded controls, compared to those cultured in plain media (OE33: G0/G1 
p=0.01, S p=0.001 and G2/M p=0.09; OE19: G0/G1 p=0.01, S p=0.001 and G2/M p=0.05; 
OE21: G0/G1 p=0.012, S p=0.001 and G2/M p=0.044). Abrogation of LRP1 and HCP1 
removed the stimulatory effect of haem in knock-down cells cultured with haem showing 
no change in the distribution of cells in any phase of the cell cycle. These observations 
were constant across the three cell lines. 
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Figure 4.22 LRP1 and HCP1 protein knock-down neutralises the stimulatory effect of 
supplementary haem on the cycle cell 
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OE33, OE19 and OE21 cell line knock-downs were cultured in plain or haem loaded media 
(20µM) for 48 hours. Cells were then harvested and processed for propidium iodide FACS 
analysis of the cell cycle presented as the average percentage of cells in G0/G1, S or G2/M 
phases. Figure A: percentage of cells in each phase of the cell cycle for OE33, OE19 and 
OE21 cell line knock-downs. Figure B: graphical representation of OE33 cell line knock-
downs by DNA content (x-axis) and number of cells (y-axis), first peak: G0/G1, second 
plateau peak: S-phase and final peak: G2/M. Control: non-silenced control; KD: knock-
down; HL: haem loaded. (*p=<0.05 significant change in percentage distribution within 
the cell cycle compared to non-silenced control cultured in plain media, n=9). 
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4.3.5 In-vivo effects of LRP1 and HCP1 protein silencing 
Silencing of the haem import proteins, LRP1 and HCP1 is detrimental to oesophageal 
cancer cell viability, proliferation, migration and independent colony forming. In addition, 
loss of LRP1 and HCP1 alters expression of iron transport proteins, cell cycle and 
eliminates the stimulatory effects of supplementary haem on cell phenotype. To see if 
these in-vitro observations would influence tumour burden in-vivo, OE33 cell line knock-
downs were xenografted into a NOD-SCID mouse model and allowed to establish. After a 
period of 24 days the mice were culled and xenografts harvested, weighed and processed 
for immunohistochemistry and mRNA analysis. 
4.3.5.1 Silencing of LRP1 and HCP1 in the OE33 cell line significantly reduces xenograft 
tumour burden in NOD-SCID mice 
OE33 cell line knock-downs (1x106cells) were injected in the left flank, subcutaneous 
tissue plane of NOD-SCID mice (n=5). After 24 days xenografts had established and 
developed in 100 percent of mouse models. Mice were culled and the xenografts 
harvested and weighed. Significant differences in average xenograft weight (mg) were 
recorded between LRP1 and HCP1 knock-downs and non-silenced control (figure 4.23). 
The most dramatic difference was observed in the LRP1 knock-down with a 70% 
reduction in tumour burden (LRP1 KD 29.9±5.5 vs. control 100.9±23.1, p=0.014). Loss of 
HCP1 also resulted in a significant decrease in tumour burden of 58% (HCP1 KD 
42.0±10.5, p=0.043). The combined knock-down of LRP1 and HCP1 had the least, but still 
significant effect on tumour burden with a reduction of 51% (LRP1/HCP1 KD 49.1±3.31, 
p=0.05). 
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Figure 4.23 Silencing of LRP1 and HCP1 in OE33 cell line xenografts significantly reduced 
tumour burden in a murine model 
OE33 cell line LRP1 and HCP1 knock-downs were xenografted into a NOD-SCID mouse 
model and allowed to develop for 24 days. Mice were then culled and average xenograft 
weight (mg) recorded and compared to non-silenced control (LRP1 KD 70% reduction in 
tumour burden, p=0.014; HCP1 KD 58% reduction, p=0.043; LRP1/HCP1 KD 51% 
reduction, p=0.05). Control: non-silenced control; KD: knock-down. (*p=<0.05 significant 
change in mean xenograft weight compared to non-silenced control, n=5). Error bars 
denote ± SEM. 
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4.3.5.2 Silencing of LRP1 and HCP1 in OE33 cell line xenografts significantly alters mRNA 
expression of iron and haem transport proteins 
OE33 LRP1 and HCP1 knock-down xenografts were harvested after 24 days of growth in a 
NOD-SCID mouse model. A representative fragment of xenograft tissue was snap frozen 
and processed for mRNA expression (figure 4.24). 
IRE-IRP regulated mRNA expression was significantly altered; most notably, a marked 
increase in TfR1 expression in LRP1 and HCP1 knock-downs compared to control (fold 
change in TfR1 mRNA: LRP1 KD 2.42±0.44, p=0.05; HCP1 KD 2.41±0.48, p=0.035; 
LRP1/HCP1 KD 7.94±2.01, p=0.001). FPN mRNA expression was significantly repressed in 
the HCP1 and combined LRP1 and HCP1 knock-downs compared to non-silenced control 
(fold change in FPN mRNA expression: HCP1 KD 0.53±0.08, p=0.005; LRP1/HCP1 KD 
0.57±0.08, p=0.022). LRP1 knock-down demonstrated reduced FPN mRNA expression but 
this narrowly missed statistical significance 0.83±0.17, p=0.082. Similarly a marked 
reduction in ferritin mRNA expression was observed in all knock-down xenografts 
compared to non-silenced control (fold change in ferritin mRNA expression: LRP1 KD 
0.53±0.04, p=0.0001; HCP1 KD 0.42±0.08, p=0.0001; LRP1/HCP1 KD 0.65±0.024, p=0.01). 
Very little difference in mRNA expression of the haem transporting proteins was 
demonstrated in xenografted knock-downs compared to control. There was no apparent 
change in HCP1 expression in LRP1 knockdowns and conversely no interplay between 
silencing of HCP1 and LRP1 mRNA expression. In contrast to the in-vitro behaviour of 
haem effluxing protein mRNA expression, where suppression was seen, no fold change in 
BCRP or FLVCR mRNA expression was noted, with the exception of BCRP in the combined 
LRP1/HCP1 knock-down (0.52±0.09, p=0.022). 
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Figure 4.24 Silencing of LRP1 and HCP1 in OE33 cell line xenografts significantly alters 
mRNA expression of iron transport proteins but has little impact on haem transport 
mRNA expression 
Figure A: mRNA expression for the iron transport proteins and figure B: mRNA for haem 
transport proteins in OE33 cell line LRP1 and HCP1 knock-down xenografts. Control: non-
silenced control; KD: knock-down; (*p=<0.05 significant change in mRNA expression fold 
change compared to non-silenced control, n=5). 
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4.3.5.3 Silencing of LRP1 and HCP1 in OE33 cell line xenografts is maintained and 
confirmed by immunohistochemistry 
OE33 LRP1 and HCP1 knock-down xenografts were harvested after 24 days of growth in 
the NOD-SCID mouse model. Xenografts were fixed in formalin, blocked in paraffin and 
mounted on slides. Slides were then subjected to immunohistochemistry and 
immunoreactivity scored as described in section 2.2.2. 
LRP1 and HCP1 silencing was maintained with minimal immunoreactivity in the 
corresponding xenograft tissue (figure 2.25) (LRP1: LRP1 KD p=0.001; HCP1 KD p=0.6; 
LRP1/HCP1 KD p=0.001) (HCP1: LRP1 KD p=0.56; HCP1 KD p=0.0006; LRP1/HCP1 KD 
p=0.001). 
As previously noted, there was no compensatory increase in the intensity of 
immunoreactivity for either HCP1 or LRP1 on silencing of LRP1 or HCP1, respectively. 
LRP1 immunoreactivity was intense and principally membranous with weak cytoplasmic 
staining evident in the non-silenced control and HCP1 knock-down. Near complete 
absence of LRP1 immunoreactivity was observed in the LRP1 and double LRP1/HCP1 
knock-downs (figure 4.26). 
HCP1 immunoreactivity was also intense and strongly membranous in the non-silenced 
control and LRP1 knock-down. HCP1 reactivity was absent in the HCP1 and combined 
LPR1/HCP1 knock-downs. Normal human small bowel was used as a positive control for 
HCP1 where specific apical immunoreactivity was clearly evident (figure 4.26). 
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4.3.5.4 Silencing of LRP1 and HCP1 in OE33 cell line xenografts significantly increases 
TfR1 and decreases ferritin immunoreactivity 
Silencing of LRP1 and HCP1 significantly increases the expression of TfR1 as evidenced by 
the marked increase in TfR1 immunoreactivity in LRP1 and HCP1 knock-downs compared 
to non-silenced control (immunoreactivity scoring for TfR1: LRP1 KD 8.5±0.5, p=0.0004; 
HCP1 KD 8.33±0.49, p=0.0005; LRP1/HCP1 KD 8.33±0.49, p=0.0005; non-silenced control 
5±0.44) (figure 4.25). 
TfR1 immunoreactivity was mainly membranous with some weak cytosolic reactivity. The 
increase in TfR1 immunoreactivity seen on silencing of LRP1 and HCP1 was intense and 
predominantly membranous (figure 4.27). 
In contrast to the increase in TfR1 immunoreactivity, silencing of LRP1 and HCP1 caused a 
significant suppression of ferritin reactivity compared to non-silenced control 
(immunoreactivity scoring for ferritin: LRP1 KD 4±0.44, p=0.0015; HCP1 KD 5.33±0.42, 
p=0.021; LRP1/HCP1 KD 3.8±0.4, p=0.0012; non-silenced control 7.5±0.67) (figure 4.25). 
Ferritin immunoreactivity was cytosolic in all cases, although as reflected in the 
immunoreactivity scoring, intensity was markedly decreased on silencing of the haem 
importing proteins LRP1 and HCP1 (figure 4.27). 
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Figure 4.25 Semi-quantitative immunoreactivity scoring - silencing of LRP1 and HCP1 in 
OE33 cell line xenografts is maintained and significantly increases TfR1 and decreases 
ferritin immunoreactivity 
OE33 cell line knock-down xenograft tissue was processed for immunohistochemistry and 
scored for immunoreactivity as described in section 2.2.2. Error bars denote ± SEM. 
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Figure 4.26 Representative immunolocalisation of LRP1 and HCP1 for OE33 LRP1 and HCP1 knock-down xenografts 
Controls: Liver for LRP1 and small bowel for HCP1. Antibody omitted for negative control. Magnification x20 and x60. 
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Figure 4.27 Representative immunolocalisation of TfR1 and ferritin for OE33 LRP1 and HCP1 knock-down xenografts 
Controls: Liver for TfR and kidney for ferritin. Antibody omitted for negative control. Magnification x20 and x60. 
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4.4 Conclusions 
Abrogation of LRP1 and HCP1 was successful in all three cell lines, confirmed by Western 
blotting, GFP expression and immunohistochemistry. 
Loss of LRP1 and HCP1 functionality in the presence of plain media had little effect on 
gross cell iron content suggesting that with no exogenous haem supplementation, active 
haem import has little overall contribution to cell iron status or that the cell can 
adequately compensate for lack of haem import by increasing inorganic iron acquisition. 
In the presence of supplementary haem, gross iron concentration was significantly 
increased in non-silenced controls, in-keeping with the hypothesis that oesophageal 
cancer cells are able to acquire haem iron when physiologically available. Culture with 
supplementary haem did not significantly alter gross cell iron content in the absence of 
LRP1 and HCP1, indicating that these import proteins are necessary for active haem 
import and that iron loading, in the presence of supplementary haem, cannot simply be 
explained by passive diffusion. 
The effect of LRP1 and HCP1 abrogation on expression of the IRE-IRP responsive iron 
transport proteins (TfR1, ferritin and FPN) was consistent across OE33, OE19 and OE21 
cell lines. Changes in mRNA expression generally tallied with those of protein expression, 
in keeping with IRE-IRP regulation at the level of transcription. Changes in TfR1 mRNA and 
protein expression were most striking with significant increases in fold change seen in 
LRP1 and HCP1 knock-downs in the presence or absence of supplementary haem. 
Increased TfR1 expression, in the absence of active haem import, is likely to be 
compensatory in order to boost inorganic iron endocytosis and maintain cellular iron 
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homeostasis under the influence of the IRE-IRP system. Compensatory increases in TfR1 
expression explains the retained uniformity of cellular iron content observed in the 
background loss of active haem import. No difference in TfR1 expression was 
demonstrated between non-silenced controls cultured in plain or haem loaded media; 
such an observation was unexpected as cell iron loading, through haem supplementation, 
may be expected to decrease TfR1 expression by the IRE-IRP system. However, cultured 
oesophageal cancer cells may have depleted basal levels of intracellular iron, precluding 
suppression of TfR1 expression, even in the presence of relative haem abundance. An 
alternative explanation may be that experimental cell lines have acquired an aberrant 
IRE-IRP system, akin to that observed in colorectal adenocarcinoma cells lines, exhibiting 
paradoxical TfR1 overexpression in the face of intracellular iron loading175,176. Indeed, 
TfR1 overexpression and relative intracellular iron loading, is associated sequentially with 
progression of the BM-dysplasia-OAC paradigm171. Changes in FPN and ferritin expression 
largely conformed to those predicted by IRE-IRP regulation: decreased expression of the 
iron efflux protein FPN and decreased ferritin mediated iron storage capacity248. 
However, these changes were not uniformly seen across all three cell lines and only 
reached significance in the OE33 OAC line. 
Very little interplay between the expression of LRP1 and HCP1 was noted on silencing 
suggesting that the expression of LRP1 has little bearing on the expression of HCP1 or 
vice-versa. This is not an unexpected observation as HCP1 is post-translationally 
mediated by redistribution between the cytosolic compartment and cell membrane 
depending on iron status; expression is insensitive to intracellular iron concentration but 
is hypoxia mediated274,285,295. The control of LRP1 expression has not yet been elucidated; 
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however it appears that gross intracellular iron concentration and free haem are not 
potent regulators. 
Loss of active haem import had a heterogeneous effect on mRNA and protein expression 
of the haem export proteins. BCRP expression demonstrated the most consistent 
response across all three cell lines with significant suppression at the transcription level 
with corresponding reduction of protein synthesis in LRP1 and HCP1 knock-downs. It 
would follow that in the absence of haem import the detoxifying action of BCRP is less 
crucial to cellular protection from ROS formation, however no significant difference in 
BCRP expression was noted between control cells in plain or haem loaded media, 
implying that even in the presence of supplementary haem, cell lines in-vitro do not 
acquire enough haem to overwhelm HO1 levels and induce cellular toxicity. FLVCR mRNA 
and protein expression were not significantly altered by loss of haem import, drawing a 
potential explanation that the expression of proteins capable of exporting cellular haem 
are more likely to be regulated by cellular hypoxia, possibly potentiated by intracellular 
haem concentration. The significantly elevated expression of BCRP and FLVCR seen in ex-
vivo OAC samples, presented in chapter three, adds credence to this observation. 
Non-silenced controls cultured with supplementary haem exhibited significantly 
enhanced viability and proliferation across all three cell lines. This is the first time that 
haem has been demonstrated to have a stimulatory effect on oesophageal cancer cell 
phenotype and adds further to the hypothesis that cancer cells are able to acquire haem 
to affect cellular iron loading in a manner akin to that demonstrated with inorganic iron 
in oesophageal and colorectal adenocarcinomas171,175. Further evidence of the 
contribution of haem to oesophageal cancer cell viability and proliferation is highlighted 
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by a significant reduction in these parameters when LRP1 and HCP1 are abrogated, even 
with the compensatory increase in inorganic iron acquisition inferred by up-regulation of 
TfR1 when active haem import is lost. The stimulatory effect of supplementary haem was 
attenuated in the LRP1 and HCP1 knock-downs compared to non-silenced controls, again 
demonstrating that the acquisition of available haem lends a survival advantage to 
oesophageal cancer cells. 
Analysis of the surrogate indicators of migratory capacity and ability to form viable 
metastatic tumours (wound healing and independent colony forming assays) affords 
further evaluation of the effect of haem on oesophageal cancer cell phenotype. 
Supplementary haem significantly enhanced the ability of oesophageal cancer cells to 
migrate and form independent colonies, whereas abrogation of active haem import 
attenuated this response. Such an observation is entirely consistent with previous reports 
detailing the positive effects of inorganic iron supplementation on OAC cell phenotype in-
vitro; potentially mediated through the iron dependent down-regulation of the cell-cell 
adhesion molecule E-cadherin128,171. 
Control of the cell cycle is regulated by many factors, not least the iron dependent 
protein RNR187,188. The mitogenic effect of supplementary haem on the cell cycle was 
apparent with a significant reduction in the percentage of cells resting in G0/G1 and 
subsequent significant increase in cells entering S phase through to G2/M. This 
observation was consistently observed in both OAC and SCC lines. The stimulatory effect 
of supplementary haem on the cell cycle was reduced with the abrogation of active haem 
import, strongly implicating haem derived cell iron loading as the driving mechanism. 
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The effect of impeding active haem import in the OE33 cell line was assessed in-vivo, 
utilising a murine xenograft model. A dramatic effect on tumour burden was recorded 
with reductions in mean xenograft weight of seventy percent for LRP1 knock-down and 
fifty-eight percent for HCP1. The combined knock-down of LRP1 and HCP1 did not 
demonstrate an additive or synergistic effect on xenograft weight. These striking results 
implicate systemic haem as a major source of intracellular iron loading in OAC especially 
as knock-down xenografted cells still have access to transferrin bound inorganic iron. 
Haem, both free and bound to haemopexin, is likely to be relatively abundant in the 
substance of the xenograft due to implantation trauma, low grade immunogenic reaction, 
friable neovascularisation, direct vessel invasion and ulceration; a situation comparable 
to that encountered within the substance of in-vivo native oesophageal cancers. In a 
similar manner to observations in-vitro, proteins regulated by the IRE-IRP system 
demonstrated significant changes in mRNA expression to suggest compensatory 
acquisition of inorganic iron in the LRP1 and HCP1 knock-down xenografts; TfR1 was 
significantly up-regulated and ferritin and FPN down-regulated. Semi-quantitative 
immunohistochemistry was again strongly suggestive of the up-regulation of inorganic 
iron acquisition through TfR1 mediated endocytosis in LRP1 and HCP1 knock-down 
xenografts. TfR1 immunoreactivity was apparent on the cell membrane suggesting 
biological activity. In addition, ferritin immunoreactivity was significantly lower in the 
knock-down xenografts inferring reduced requirement for cellular iron storage. The 
immunoreactivity of LRP1 and HCP1 in their respective xenografts was negligible, 
confirming continued successful abrogation of haem import. It must be stressed, 
however, that despite the circumstantial evidence of alterations in cellular iron biology to 
indicate relative iron depletion, in the face of loss of active haem import, LRP1 and HCP1 
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are not solely haem importers. The ubiquitously expressed LRP1 protein interacts with 
extracellular metalloproteinases, potentially limiting the ability of the xenograft to 
expand and invade the extracellular matrix when function of LPR1 is lost298,304,432. HCP1 is 
also a folate transporter and could in theory limit tumourigenic activity due to relative 
folate deficiency within the xenograft296. Unfortunately, the volume of xenografted 
material was not sufficient to allow for accurate assessment of gross iron content and 
therefore a more complete argument in favour of relative iron deprivation as the major 
factor responsible for the observed differences in tumour burden. 
This chapter has demonstrated that oesophageal cancer cells can acquire both organic 
and inorganic iron by the action of several transport proteins which helps explain why 
targeting TfR1 alone with monoclonal antibodies fails to produce a robust anti-neoplastic 
effect in a variety of malignant lineages208. LRP1 and HCP1 could be considered as novel 
targets for therapeutic monoclonal antibodies in the treatment of oesophageal 
malignancy; however the simultaneous functional blockade of multiple targets is not 
practical and likely to be prohibitively expensive and unpredictable. An alternative would 
be to deprive the cancer cell of iron by use of a chelating agent. The effect of iron 
chelators as a potential therapeutic modality has not been explored in oesophageal 
cancer and is the subject of chapter five of this thesis. 
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CHAPTER 5: THE IN-VITRO AND IN-VIVO ANTI-NEOPLASTIC 
ACTIVITY OF IRON CHELATORS IN OESOPHAGEAL CANCER 
 
5.1 Introduction 
The incidence of oesophageal adenocarcinoma has dramatically increased over the last 
25 years and is now rising faster than any other malignant disease in Western 
nations8,9,24. Oesophageal cancer is a devastating condition associated with an extremely 
poor overall five-year survival of just 10%2. Surgical resection is the only curative 
treatment for OAC, however, the majority of patients present with advanced disease or 
are unsuitable for radical intervention3. Of the minority that undergo surgery, the outlook 
remains bleak with only 20-30% surviving two years3. Locally advanced disease and 
undiagnosed metastatic spread greatly contribute to failure of treatment with curative 
intent3. High rates of loco-regional and distant recurrence has led to much interest in pre-
operative (neoadjuvant) combination chemotherapy with response rates of up to 30-
40%3,7. Cisplatin, 5-FU and Epirubicin based chemotherapy, combined with surgery, 
increases overall survival by 6% at five years, compared to surgery alone7. Despite the 
addition of neoadjuvant chemotherapy and refinement of surgical technique, the vast 
majority of patients still die from overwhelming malignant disease progression. It would 
appear that further advances in treatment will be governed by understanding of the 
molecular events involved in oesophageal cancer evolution and the development of novel 
therapeutic strategies where side effects, complications and mortality associated with 
existing forms of treatment can be minimised. 
 187 
 
The transition from BM to invasive OAC is associated with progressive overexpression of 
proteins involved in cellular iron acquisition, coupled with loss of iron efflux171. Chapter 
four of this thesis established the potential for oesophageal cancer cells to actively 
acquire haem, in addition to transferrin bound inorganic iron. Deregulation of iron 
metabolism explains the increase in cellular iron deposition observed in oesophageal 
cancer tissue that is likely to be driving a multitude of iron dependent cellular processes, 
including oxidative phosphorylation, DNA synthesis and the cell cycle171,191,319,433. Rapidly 
proliferating cancer cells are particularly susceptible to iron deprivation, mainly due to 
the expression of the iron dependent enzymes such as RNR, promoting iron chelation as 
an attractive potential anti-neoplastic strategy191,319,433. However, considering the 
number and complexity of cellular iron dependent processes and structural variations in 
iron chelating compounds, differences in the mode of action are highly likely to be 
observed. 
A series of experimental iron chelators, most notably Dp44mT, have been developed that 
exhibit potent anti-neoplastic properties323,415. Dp44mT aggressively suppresses tumour 
growth in a range of murine xenograft models and is able to overcome chemo-resistance 
in an array of malignant cells in-vitro323. The major obstacle to clinical application of such 
agents is the associated systemic toxicity, manifested by myocardial fibrosis in murine 
models323. Encouragingly, systemic stripping of iron is not apparent and in-vitro data 
consistently supports cancer specific targeting of cytotoxicity323,325,328. 
However, a number of iron chelators with excellent post-licensing safety records and 
side-effect profiles are regularly used in clinical practice in patients with iron overload 
disorders. The archetypal iron chelator for clinical use is DFO, which despite its 
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disadvantage of poor lipid solubility, has been shown to induce cytotoxicity in a number 
of in-vitro studies and appears to have at least some potential in the treatment of 
neuroblastoma325,328,359,360,362. The relatively new iron chelator Deferasirox is easily 
administered as an oral preparation and has high lipid solubility374,375. A limited number 
of case reports serendipitously noted that commencing Deferasirox treatment for iron 
overload was associated with remission in some patients with haematological 
malignancies383-385. Recently a number of in-vitro studies have demonstrated the 
cytotoxic potential of Deferasirox against leukaemia and hepatoma cell lines, surpassing 
the action of more traditional experimental chelators385-387. 
To date, the potential anti-neoplastic action of iron chelators on gastrointestinal cancers 
is unknown. The hypothesis that iron chelation therapy could be of benefit in the 
treatment of oesophageal cancer is particularly appealing considering the potential for an 
iron mediated malignant phenotype and the dire need to improve survival outcomes. 
  
 189 
 
5.2 Aims 
1. Determine the ability of iron chelators to block iron up-take and mobilise iron from 
oesophageal cancer cells 
 
2. Characterise the in-vitro effect of iron chelation on iron and haem transport protein 
expression 
 
3. Determine the in-vitro effect of iron chelation on oesophageal cancer cell phenotype and 
cell cycle 
 
4. Establish the influence of iron chelators on tumour burden and cellular iron metabolism 
in a murine xenograft model and calibrate potential systemic side effects and toxicity 
 
5. Characterise the in-vivo effects of iron chelation on xenograft iron content and describe 
alterations in iron transport proteins 
 
6. Explore the anti-neoplastic potential of iron chelators in combination with standard 
chemotherapeutic agents for oesophageal cancer treatment and possible action on 
chemoresistant cell lines 
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5.3 Results 
 
5.3.1 Cell lines and iron chelators 
Cell lines OE33, OE19 and OE21 were utilised for in-vitro experimentation and in-vivo 
xenograft murine models. Cell lines were cultured using standard media and were co-
cultured with iron chelators at predetermined IC50 concentrations, unless specified 
otherwise. Two clinically established iron chelators, DFO and Deferasirox, were routinely 
studied for potential anti-neoplastic action.  The experimental iron chelator, Dp44mT, 
was included in the majority of investigations for academic interest. 
5.3.2 Generation of IC50 values 
Iron chelator IC50 values (half-maximal inhibitory concentration) were derived by plotting 
a dose-response curve for each chelator. Dose response curves were drawn for both 
cellular viability (MTT assay) and proliferation (BrdU assay) for all three cell lines (data not 
shown). Very little variability in IC50 values was noted between lineages and the 
following values were used for all cell lines to avoid unnecessarily complicating 
experiments for the sake of minute variations in exact IC50 values. IC50 values: 
Deferasirox 20µM, DFO 10µM and Dp44mT 1µM. 
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5.3.3 Determine the ability of iron chelators to block iron up-take and extract iron from 
oesophageal cancer cells 
To determine the ability of each iron chelator to prevent the up-take of iron from culture 
media and extract intracellular iron from oesophageal cancer cell lines, gamma emitting 
59Fe bound to transferrin was utilised (Kind gift of Professor Des Richardson, Sydney, 
Australia), as previously described323. 
5.3.3.1 Iron chelators can block the up-take of 59Fe-Tf by oesophageal cancer cells in-
vitro 
OE33, OE19 and OE21 cell lines were cultured in media spiked with 59Fe-Tf and increasing 
concentrations of iron chelators. 59Fe-Tf spiked media alone was used as a control. After 
three hours, the amount of 59Fe-Tf taken up by the cells was measured using a gamma 
counter and expressed as a percentage of control up-take (figure 5.1). 
Dp44mT was consistently the most effective agent at blocking iron up-take across the 
three cell lines; reaching a plateau blocking effect at its IC50 value (1µM) of 
approximately 80%. Higher concentrations of Dp44mT did not further increase the 
amount of iron up-take blocked by the agent. Deferasirox was the next most effective 
agent at blocking iron-uptake. In contrast to Dp44mT, a steady increase in the ability of 
Deferasirox to block iron up-take was observed with increasing concentration, although 
the relationship between concentration and blocking effect was not linear. The majority 
of the blocking effect was achieved at a concentration of 1µM (50% up-take blocked) and 
then it increased in a steady fashion to its IC50 concentration (20µM, at the top end of 
the concentration range assessed) to achieve up-take blocking of 58%, 75% and 77% on 
OE33, OE19 and OE21 cell lines respectively. DFO was the least effective agent at blocking 
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up-take with the relationship between concentration and up-take blocking similar to that 
of Deferasirox (IC50 10µM blocked 20%, 32% and 30% of iron up-take for OE33, OE19 and 
OE21 cell lines respectively). 
5.3.3.2 Iron chelators can extract (efflux) 59Fe-Tf from oesophageal cancer cells in-vitro 
Cell lines OE33, OE19 and OE21 were cultured in media spiked with 59Fe-Tf. After 3 hours, 
59Fe-Tf media was replaced with media containing increasing concentrations of iron 
chelators, DFO, Deferasirox and Dp44mT. After a further 3 hours of incubation, cellular 
and media fractions were subject to gamma counting and results expressed by the media 
fraction as a percentage of the combined media and cellular fractions (i.e. total 59Fe taken 
up) (figure 5.2). 
Dp44mT was the most effective agent at mobilising intracellular 59Fe, extracting 74%, 63% 
and 68% of internalised 59Fe at its IC50 value of 1µM for OE33, OE19 and OE21 lines 
respectively. Any further increase in Dp44mT concentration did not translate to improved 
59Fe extraction. Deferasirox and DFO had similar profiles of extraction ability, exhibiting a 
gradual increase in the amount of 59Fe mobilised with increasing chelator concentration. 
At IC50 values, Deferasirox effluxed 65%, 48% and 54% for OE33, OE19 and OE21 cell 
lines respectively and DFO extracted 41%, 42% and 38% of internalised 59Fe. 
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Figure 5.1 Iron chelators DFO, Deferasirox and Dp44mT can block the up-take of 59Fe-Tf 
by oesophageal cancer cells in-vitro 
Cell lines OE33, OE19 and OE21 cultured in media spiked with 59Fe-Tf and various iron 
chelators for three hours. Up-take of 59Fe-Tf assessed using a gamma counter and 
expressed as a percentage of 59Fe-Tf up-take alone. Error bars denote ± SEM. 
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Figure 5.2 Iron chelators DFO, Deferasirox and Dp44mT can efflux iron from 
oesophageal cancer cells in-vitro 
Cell lines OE33, OE19 and OE21 cultured in media spiked with 59Fe-Tf for 3 hours and 
then substituted for media containing iron chelators DFO, Deferasirox or Dp44mT for a 
further 3 hours. Results expressed by the media fraction gamma count as a percentage of 
the combined media and cellular fractions. Error bars denote ± SEM. 
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5.3.4 The in-vitro effects of iron chelation on iron and haem transport protein 
expression in oesophageal cancer cells 
To determine the effect of iron chelation on the expression of iron and haem transport 
proteins OE33, OE19 and OE21 cell lines were cultured for 48 hours with DFO or 
Deferasirox at IC50 value concentrations (10 and 20µM respectively). The cellular 
monolayer was then harvested and processed for mRNA and protein expression. 
5.3.4.1 Iron chelators influence mRNA expression of the iron transport proteins in-vitro 
OE33, OE19 and OE21 cell lines were cultured with DFO or Deferasirox for 48 hours. Cells 
were then harvested and processed for TfR1, FPN and ferritin mRNA expression and 
presented as a fold change relative to control media alone (figure 5.3). 
Culture with either Deferasirox or DFO induced a dramatic fold change in TfR1 mRNA 
expression in all cell lines. TfR1 mRNA induction was especially marked in the OE33 OAC 
line and the magnitude of change was similar for both chelators (p=0.0094, p=0.01 and 
p=0.005 for Deferasirox OE33, OE19 and OE21 lines respectively, and p=0.033, p=0.02 
and p=0.0001 for DFO) (figure 5.3A). 
The changes in ferritin mRNA expression were less pronounced than TfR1 with borderline 
significant reductions in mRNA fold change in the OE33 and OE21 cell lines cultured with 
DFO (p=0.05 and p=0.02). No significant mRNA changes were induced within the OE19 
cell line and Deferasirox tended to slightly increase ferritin mRNA expression, although no 
changes were statistically significant (figure 5.3B). 
Overall, culture with Deferasirox or DFO reduced FPN mRNA expression, although this 
was not consistently statistically significant. No statistically significant changes were 
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observed in the OE33 cell line (p=0.27 and p=0.91 for Deferasirox and DFO respectively). 
Deferasirox induced a significant reduction in FPN mRNA fold change in OE19 cells 
(p=0.05) and DFO produced a more pronounced reduction in the squamous OE21 cell line 
(p=0.0025) (figure 5.3C). 
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Figure 5.3 Culture with iron chelators Deferasirox and DFO alters mRNA expression of 
iron transport proteins in-vitro 
Figure A: TfR1, figure B: ferritin and figure C: FPN mRNA expression for cell lines OE33, 
OE19, and OE21 after 48 hours culture with iron chelators Deferasirox or DFO. (*p=<0.05 
fold change in mRNA expression compared to plain media control and normalised to 1). 
Error bars denote ± SEM. 
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5.3.4.2 Iron chelators influence iron transport protein expression in-vitro 
OE33, OE19 and OE21 cell lines were cultured with DFO or Deferasirox for 48 hours. Cells 
were then harvested and protein lysates subjected to Western blotting for TfR1, FPN and 
ferritin protein expression. Subsequent optical densities were normalised to β-actin and 
presented as a fold change relative to control media alone (figure 5.4). 
Changes in TfR protein expression mirrored those of mRNA with significant induction 
across all three cell lines. The iron chelating action of Deferasirox and DFO induced 
changes of a similar magnitude (1.92±0.14 p=0.0015, 1.42±0.08 p=0.0024 and 2.03±0.06 
p=0.0001 for Deferasirox OE33, OE19 and OE21 lines respectively and 1.89±0.07 
p=0.0001, 1.33±0.12 p=0.01 and 1.57±0.1 p=0.0007 for DFO) (figure 5.4A). 
Ferritin protein expression was significantly reduced in the OE33 cell line (0.53±0.04 
p=0.0009 and 0.51±0.03 p=0.0009 for Deferasirox and DFO respectively). Neither the 
junctional adenocarcinoma cell line OE19 or squamous carcinoma OE21 line 
demonstrated any significant change in ferritin protein expression with either chelator 
(figure 5.4B). 
FPN protein expression was consistently down in response to iron chelator exposure. No 
difference in degree of reduction was noted between chelators (0.63±0.03 p=0.0006, 
0.62±0.05 p=0.0001 and 0.84±0.05 p=0.0029 for Deferasirox OE33, OE19 and OE21 lines 
respectively and 0.69±0.05 p=0.0022, 0.55±0.06 p=0.0001 and 0.73±0.08 p=0.0001 for 
DFO) (figure 5.4C). 
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Figure 5.4 Culture with iron chelators Deferasirox and DFO alters iron transport protein 
expression in-vitro 
Figure A: TfR1, figure B: ferritin and figure C: FPN protein expression for cell lines OE33, 
OE19, and OE21 after 48 hours culture with iron chelators Deferasirox or DFO. Figure D: 
Western blots for TfR1, ferritin and FPN protein expression. (*p=<0.05 fold change in 
protein expression compared to plain media control and normalised to 1). 
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5.3.4.3 Iron chelators influence the mRNA expression of haem transport proteins in-
vitro 
OE33, OE19 and OE21 cell lines were cultured with DFO or Deferasirox for 48 hours. Cells 
were then harvested and processed for LRP1, HCP1, BCRP and FLVCR mRNA expression 
and presented as a fold change relative to control media alone (figure 5.5). 
LRP1 mRNA expression was elevated across all cell lines in response to Deferasirox and 
DFO exposure. However, only the OE21 cell line cultured with Deferasirox exhibited a 
statistically significant increase in expression (2.54±0.54 p=0.049) (figure 5.5A). 
mRNA expression for the haem import protein HCP1, in a similar fashion to LRP1, was 
raised but did not reach statistical significance. The OE19 cell line showed no change in 
HCP1 mRNA expression after culture with chelators compared to control (figure 5.5B). 
BCRP mRNA expression in the OE33 cell line remained unchanged after culture with 
either chelator (1.26±0.15 p=0.19 and 1.07±0.03 p=0.41 for Deferasirox and DFO 
respectively). However, in contrast, both the OE19 and OE21 cell lines exhibited marked 
repression in BCRP mRNA expression compared to control (0.1±0.018 p=0.003, 0.26±0.03 
p=0.05 for Deferasirox exposed OE19 and OE21 lines respectively and 0.1±0.03 p=0.0082, 
0.39±0.1 p=0.15 for DFO) (figure 5.5C). 
Changes in the haem effluxing protein FLVCR mRNA expression were very similar to BCRP. 
Culture with Deferasirox or DFO failed to elicit an expression change in OE33 cells 
(0.73±0.17 p=0.2 and 1.17±0.06 p=0.12 for Deferasirox and DFO respectively). Both OE19 
and OE21 cell lines responded to iron chelation by suppressing FLVCR mRNA expression 
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(0.22±0.02 p=0.015, 0.17±0.04 p=0.02 for Deferasirox exposed OE19 and OE21 cell lines 
respectively and 0.28±0.04 p=0.0026, 0.46±0.04 p=0.05 for DFO) (figure 5.5D). 
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Figure 5.5 Culture with iron chelators Deferasirox and DFO influences mRNA expression 
of haem transport proteins in-vitro 
Figure A: LRP1, figure B: HCP1, figure C: BCRP and figure D: FLVCR mRNA expression for 
cell lines OE33, OE19, and OE21 after 48 hours culture with iron chelators Deferasirox or 
DFO. (*p=<0.05 fold change in mRNA expression compared to plain media control and 
normalised to 1). Error bars denote ± SEM. 
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5.3.4.4 Iron chelators influence haem transport protein expression in-vitro 
OE33, OE19 and OE21 cell lines were cultured with DFO or Deferasirox for 48 hours. Cells 
were then harvested and protein lysates utilised for Western blotting for LRP1, HCP1, 
BCRP and FLVCR protein expression. Subsequent optical densities were normalised to β-
actin and presented as a fold change relative to control media alone (figure 5.6). 
LRP1 protein expression was significantly raised in response to culture with Deferasirox or 
DFO in OE33 and OE21 cell lines (2.08±0.09 p=0.0004, 1.69±0.08 p=0.0001 for OE33 and 
OE21 cell lines cultured with Deferasirox respectively and 1.47±0.07 p=0.0019, 1.4±0.06 
p=0.0005 for DFO. OE19 cells exhibited minor elevation in LRP1 protein expression which 
narrowly missed statistical significance (1.11±0.05 p=0.091 and 1.19±0.04 p=0.056 for 
Deferasirox and DFO respectively) (figure 5.6A). 
HCP1 protein expression, in response to culture with iron chelators, was near identical to 
mRNA observations. OE33 cells exhibited an increase in expression without reaching 
statistical significance (1.32±0.06 p=0.062, 1.13±0.09 p=0.12 for Deferasirox and DFO 
respectively), OE19 cells offered no change (0.99±0.06 p=0.67, 1.01±0.1 p=0.66 for 
Deferasirox and DFO respectively) and OE21 determined a significant rise in HCP1 protein 
expression compared to control (1.73±0.08 p=0.0002, 1.45±0.07 p=0.0003 for Deferasirox 
and DFO respectively) (figure 5.6B). 
The suppression in BCRP mRNA expression reflected a marked reduction in protein 
expression in OE19 and OE21 cell lines for both Deferasirox and DFO (0.47±0.11 
p=0.0001, 0.67±0.05 p=0.0001 for OE19 and OE21 cultured with Deferasirox and 
0.46±0.06 p=0.0001, 0.60±0.09 p=0.0001 for DFO). OE33 cells did not demonstrate a 
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difference in BCRP protein fold change compared to control (0.9±0.1 p=0.3, 0.97±0.13 
p=0.63 for Deferasirox and DFO respectively) (figure 5.6C). 
In accordance with suppressed mRNA expression, the OE19 cell line exhibited reduced 
FLVCR protein production in response to both chelators (0.62±0.11 p=0.0001, 0.53±0.1 
p=0.0001 for Deferasirox and DFO respectively). Iron chelators induced no change in 
FLVCR protein fold change in OE33 cells (0.84±0.07 p=0.12, 0.9±0.08 p=0.22) or the OE21 
cell line, despite the latter demonstrating a significant suppression of FLVCR mRNA 
(1.06±0.07 p=0.86, 0.9±0.08 p=0.2) (figure 5.6D). 
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Figure 5.6 Culture with iron chelators Deferasirox and DFO influences haem transport 
protein expression in-vitro 
Figure A: LRP1, figure B: HCP1, figure C: BCRP and figure D: FLVCR protein expression for 
cell lines OE33, OE19, and OE21 after 48 hours culture with iron chelators Deferasirox or 
DFO. Figure E: Western blots for LRP1, HCP1, BCRP and FLVCR protein expression. 
(*p=<0.05 fold change in protein expression compared to plain media control and 
normalised to 1). 
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5.3.5 The in-vitro effect of iron chelation on oesophageal cancer cell phenotype 
OE33, OE19 and OE21 cell lines were utilised to assess the effect of iron chelation on 
cellular phenotype in-vitro. Iron chelators were used at IC50 values (Deferasirox 20 µM, 
DFO 10 µM and Dp44mT 1 µM). Iron 100µM and plain media alone were used as positive 
and negative controls respectively. Changes in cellular phenotype were assessed with 
MTT assay (viability), BrdU assay (proliferation), colony forming assay (ability to form 
independent colonies) and scratch assay (migration). 
5.3.5.1 Iron chelators Deferasirox and DFO inhibit oesophageal cancer cell viability and 
proliferation in-vitro 
OE33, OE19 and OE21 cell lines were cultured in the presence of Deferasirox or DFO +/- 
iron or haem (Deferasirox 20µM, DFO 10µM, iron 100µM and haem 50µM). After 48 
hours of culture, cells were assessed for viability and proliferation relative to control 
media (figures 5.7 and 5.8). 
Observations were consistent between OE33 and OE19 OAC lines and the SCC line, OE21. 
Supplementary iron and haem induced significant increases in viability and proliferation, 
compared to control media alone. Deferasirox and DFO reduced viability and proliferation 
by approximately 50%, in line with observations expected with both agents used at IC50 
concentrations. Supplementary iron or haem co-cultured with Deferasirox or DFO failed 
to completely rescue the cells from the inhibitory effect of chelation.  Deferasirox and 
haem appeared to decrease viability and proliferation compared to Deferasirox alone, 
whereas additional haem partially reversed the effects of DFO. 
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Figure 5.7 Iron chelators Deferasirox and DFO inhibit oesophageal cancer cell viability  
OE33, OE19 and OE21 cell lines cultured for 48 hours in the presence of Deferasirox or 
DFO +/- iron (figure A) or haem (figure B) (Deferasirox 20µM, DFO 10µM, iron 100µM 
haem 50µM). Viability presented relative to plain control media and normalised to 1. 
Associated p-values given in table beneath figures. (*p=<0.05 fold change in viability or 
proliferation compared to control and normalised to 1). Error bars denote ± SEM. 
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Figure 5.8 Iron chelators Deferasirox and DFO inhibit oesophageal cancer cell 
proliferation 
OE33, OE19 and OE21 cell lines cultured for 48 hours in the presence of Deferasirox or 
DFO +/- iron (figure A) or haem (figure B) (Deferasirox 20µM, DFO 10µM, iron 100µM 
haem 50µM). Proliferation presented relative to plain control media and normalised to 1. 
Associated p-values given in table beneath figures. (*p=<0.05 fold change in viability or 
proliferation compared to control and normalised to 1). Error bars denote ± SEM. 
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5.3.5.2 Dp44mT inhibits oesophageal cancer cell viability and proliferation in-vitro 
OE33, OE19 and OE21 cell lines were cultured in the presence of Dp44mT 1µM or Dp2mT 
1µM (negative control) with or without Fe (100µM) (positive control). After 48 hours of 
culture cells were assessed for viability and proliferation relative to plain control media 
and normalised to 1 (figure 5.9). 
Results were again consistent across all three cell lines with iron in combination with 
Dp2mT inducing significant increases in viability and proliferation compared to Dp2mT 
alone. Dp44mT significantly reduced viability and proliferation by approximately 50% in 
line with use at the predetermined IC50 value of 1µM. The addition of iron to Dp44mT 
containing media did not rescue the exposed cell lines from the effects Dp44mT with 
viability and proliferation remaining at values seen with Dp44mT alone. 
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Figure 5.9 Dp44mT inhibits oesophageal cancer cell viability and proliferation in-vitro 
OE33, OE19 and OE21 cell lines were cultured in the presence of Dp44mT 1µM or Dp2mT 
1µM (negative control) with or without Fe 100µM (positive control). After 48 hours of 
culture cells were assessed for viability (figure A) and proliferation (figure B) relative to 
plain control media and normalised to 1. (*p=<0.05 fold change in viability or 
proliferation compared to control and normalised to 1). Error bars denote ± SEM. 
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5.3.5.3 Iron chelators inhibit oesophageal cancer cell anchorage independent growth 
OE33, OE19 and OE21 cell lines were seeded as a single cell suspension in agar containing 
plain media or media with iron chelators at IC50 concentrations (Deferasirox 20µM, DFO 
10µM and Dp44mT 1µM). Iron (100µM) was used as a positive control or in combination 
with iron chelators. After two weeks of incubation, the average colony size was calculated 
in pixels2 (figures 5.10: OE33, 5.11: OE19 and 5.12: OE21). 
Observations were consistent across all three cell lines. The addition of iron to agar 
growing media significantly enhanced the average colony size (p=0.01, p=0.038 and 
p=0.032 for OE33, OE19 and OE21 cell lines respectively). In the absence of 
supplementary iron, Deferasirox and DFO significantly retarded colony size with the 
former agent exhibiting a slightly superior inhibitory effect (p=0.0054, p=0.0019 and 
p=0.005 for OE33, OE19 and OE21 cell lines exposed to Deferasirox and p=0.017, 
p=0.0036 and p=0.0019 for DFO). The addition of supplementary iron to growing media 
containing Deferasirox or DFO neutralised the inhibitory effect of the iron chelators. 
In the presence of Dp44mT (compared to growing media containing Dp2mT as a non-iron 
chelating control) no viable colonies formed in any cell line (p=<0.0001 for all lines). The 
addition of iron to Dp2mT control media invoked a significantly increased colony size 
(p=0.0002, p=0.001 and p=0.001 for OE33, OE19 and OE21 cell lines respectively). In 
marked contrast to Deferasirox and DFO, the addition of supplementary iron to Dp44mT 
containing growth media failed to reverse the inhibitory effect of Dp44mT alone (figures 
5.13: OE33, 5.14: OE19 and 5.15: OE21). 
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Figure 5.10 Iron chelators inhibit OE33 cell line anchorage independent growth 
Figure A: OE33 OAC cell line seeded as a single cell suspension in agar containing plain 
media or media with iron chelators at IC50 concentrations (Deferasirox 20µM and DFO 
10µM) (n=9). Iron 100µM was used as a positive control or in combination with iron 
chelators. Figure B: after 14 days of incubation, the average colony size was calculated in 
pixels2. (*p=<0.05 significant change in average colony size compared to plain media 
control). Error bars denote ± SEM. 
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Figure 5.11 Iron chelators inhibit OE19 cell line anchorage independent growth 
Figure A: OE19 junctional OAC cell line seeded as a single cell suspension in agar 
containing plain media or media with iron chelators at IC50 concentrations (Deferasirox 
20µM and DFO 10µM) (n=9). Iron 100µM was used as a positive control or in combination 
with iron chelators. Figure B: after 14 days of incubation, the average colony size was 
calculated in pixels2. (*p=<0.05 significant change in average colony size compared to 
plain media control). Error bars denote ± SEM. 
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Figure 5.12 Iron chelators inhibit OE21 cell line anchorage independent growth 
Figure A: OE21 oesophageal SCC line seeded as a single cell suspension in agar containing 
plain media or media with iron chelators at IC50 concentrations (Deferasirox 20µM and 
DFO 10µM) (n=9). Iron 100µM was used as a positive control or in combination with iron 
chelators. Figure B: after 14 days of incubation, the average colony size was calculated in 
pixels2. (*p=<0.05 significant change in average colony size compared to plain media 
control). Error bars denote ± SEM. 
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Figure 5.13 Iron chelator Dp44mT inhibits OE33 cell line anchorage independent growth 
Figure A: OE33 cell line seeded as a single cell suspension in agar containing control 
media (1µM Dp2mT) or Dp44mT 1µM (n=9). Fe 100µM used as a positive control (with 
Dp2mT) or in combination with Dp44mT. Figure B: after 14 days of incubation, the 
average colony size was calculated in pixels2. (*p=<0.05 significant change in average 
colony size compared to plain media control). Error bars denote ± SEM. 
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Figure 5.14 Iron chelator Dp44mT inhibits OE19 cell line anchorage independent growth 
Figure A: OE19 cell line seeded as a single cell suspension in agar containing control 
media (1µM Dp2mT) or Dp44mT 1µM (n=9). Fe 100µM used as a positive control (with 
Dp2mT) or in combination with Dp44mT. Figure B: after 14 days of incubation, the 
average colony size was calculated in pixels2 (Fig B). (*p=<0.05 significant change in 
average colony size compared to plain media control). Error bars denote ± SEM. 
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Figure 5.15 Iron chelator Dp44mT inhibits OE21 cell line anchorage independent growth 
Figure A: OE21 cell line seeded as a single cell suspension in agar containing control 
media (1µM Dp2mT) or Dp44mT 1µM (n=9). Fe 100µM used as a positive control (with 
Dp2mT) or in combination with Dp44mT. Figure B after 14 days of incubation, the 
average colony size was calculated in pixels2. (*p=<0.05 significant change in average 
colony size compared to plain media control). Error bars denote ± SEM. 
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5.3.5.4 Iron chelators inhibit oesophageal cancer cell migration in-vitro 
OE33, OE19 and OE21 cell lines were cultured in plain media and allowed to form a 
monolayer. The cell monolayer was then scratched (wounded) and plain media 
substituted for media spiked with iron chelators at IC50 concentrations (Deferasirox 
20µM, DFO 10µM and Dp44mT 1µM). Iron 100µM was used as a positive control or in 
combination with iron chelators. The degree to which the wound healed was described as 
a percentage of wound remaining as a function of time and compared to control media 
alone (figures 5.16 and 5.17 for Deferasirox; figure 5.18 for DFO and figures 5.19 and 5.20 
for Dp44mT). 
Observations were consistent across the three cell lineages. Addition of iron to the 
culture media was associated with significantly more rapid wound closure compared to 
control. In the presence of Deferasirox, DFO or Dp44mT wound closure was significantly 
retarded compared to control. Deferasirox and DFO demonstrated similar inhibitory 
effects with Dp44mT exhibiting a very potent anti-migratory action. In contrast to 
previous observations, where the addition of supplementary iron reverses the inhibitory 
effects of Deferasirox and DFO, additional iron did not prevent the chelators impeding 
cellular migration. Dp44mT retained its potent inhibition of migration with 
supplementary iron, in accordance with previous observations of colony forming, viability 
and proliferation. 
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Figure 5.16 Deferasirox inhibits oesophageal cancer cell migration in-vitro 
Figure A: OE33, figure B: OE19 and figure C: OE21 cell lines were cultured in plain media 
and allowed to form a monolayer. The cell monolayer was then scratched (wounded) and 
plain media substituted for media spiked with Deferasirox 20µM. Iron 100µM was used 
as a positive control or in combination with Deferasirox. The degree to which the wound 
healed was described as a percentage of wound remaining as a function of time and 
compared to control media alone. Error bars denote ± SEM. 
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Figure 5.17 Deferasirox inhibits oesophageal cancer cell migration in-vitro 
Figure A: OE33, figure B: OE19 and figure C: OE21 cell lines were cultured in plain media 
and allowed to form a monolayer (n=9). The cell monolayer was then scratched 
(wounded) and plain media substituted for media spiked with Deferasirox 20µM. Fe 
100µM was used as a positive control alone or a combination of Deferasirox. 
Representative images of wound closure over 48 hours; 20 x magnification. 
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Figure 5.18 DFO inhibits oesophageal cancer cell migration in-vitro 
Figure A: OE33, figure B: OE19 and figure C: OE21 cell lines were cultured in plain media 
and allowed to form a monolayer (n=9). The cell monolayer was then scratched 
(wounded) and plain media substituted for media spiked with DFO 10µM. Fe 100µM was 
used as a positive control alone or a combination of DFO. The degree to which the wound 
healed was described as a percentage of wound remaining as a function of time and 
compared to control media alone. Error bars denote ± SEM. 
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Figure 5.19 Dp44mT inhibits oesophageal cancer cell migration in-vitro 
Figure A: OE33, figure B: OE19 and figure C: OE21 cell lines were cultured in plain media 
and allowed to form a monolayer (n=9). The cell monolayer was then scratched 
(wounded) and plain media substituted for media spiked with Dp44mT 1µM (Dp2mT 1 
µM as negative control). Fe 100µM was used as a positive control alone or in combination 
with Dp44mT or Dp2mT. The degree to which the wound healed was described as a 
percentage of wound remaining as a function of time and compared to control media 
alone. Error bars denote ± SEM. 
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Figure 5.20 Dp44mT inhibits oesophageal cancer cell migration in-vitro  
Figure A: OE33, figure B: OE19 and figure C: OE21 cell lines were cultured in plain media 
and allowed to form a monolayer (n=9). The cell monolayer was then scratched 
(wounded) and plain media substituted for media spiked with Dp44mT 1µM (Dp2mT 1 
µM as negative control). Fe 100µM was used as a positive control alone or in combination 
with Dp44mT or Dp2mT. Representative images of wound closure over 60 hours; 20 x 
magnification. 
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5.3.6 Characterisation of the in-vitro effect of iron chelation on oesophageal cancer cell 
cycle 
Culture of oesophageal cancer cells with supplementary iron and haem stimulates 
proliferation compared to standard media alone. The addition of an iron chelator 
attenuates the stimulatory effect of supplementary iron. The effect of iron chelation on 
the cell cycle of oesophageal cancer cells was determined using FACS with propidium 
iodide labelling. OE33, OE19 and OE21 cell lines were cultured with or without 
Deferasirox, DFO and Dp44mT +/- supplementary iron or haem for 48 hours before 
propidium iodide staining and FACS analysis. Results were expressed as a percentage of 
cells in G0/G1, S or G2/M phases of the cell cycle and compared to control media alone 
(figure 5.21A: OE33, 5.21B: OE19 and 5.21C: OE21). 
5.3.6.1 Iron chelation significantly inhibits oesophageal cancer cell cycle 
Culture with supplementary iron significantly altered the percentage of cells in each 
phase of the cell cycle implying an increase in proliferation. OE33, OE19 and OE21 cell 
lines all decreased the percentage of cells in G0/G1 (p=0.05, p=0.0055 and p=0.007 for 
OE33, OE19 and OE21 respectively) and significantly increased percentage in S phase 
(p=0.05, p=0.0008 and p=0.005) which followed into a significant increase in G2/M 
(p=0.092, p=0.05 and p=0.015). Similar but less pronounced changes were observed with 
supplementary haem with a trend towards a decreased percentage of cells in G0/G1 and 
an increase in S and G2/M phases, but changes reached statistical significance in the OE19 
cell line only (p=0.003, p=0.0011 and p=0.0071 for G0/G1, S and G2/M). The most dramatic 
change in cell cycle compostion was seen in the presence of Deferasirox. Deferasirox  
dramatically increased the percentage of cells in S phase (all p= <0.001 for G0/G1, S and 
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G2/M) at the expense of the proportion of cells in G0/G1, across all three cell lines (all 
p=0.001). The expectionally large percentage of cells in S phase was not seen to be 
translated into an increase in G2/M (p=0.77, p=0.9 and p=0.045), suggesting that 
Deferasirox had arrested oesophageal cancer cells in S phase. Culture with DFO failed to 
demonstrate a discernable change in cell cycle composition in any cell line. The addition 
of Deferasirox to culture media containing supplementary iron returned the distribution 
of cells in each phase of the cycle to those of control media alone, eliminating the 
sitmulatory effect of iron and the inhibitory changes seen with Deferasirox alone. The 
addition of Deferasirox to media supplemented with haem had a similar effect, with the 
loss of accummulation of cells in S phase, except in the OE21  line where some features of 
Deferasirox inhibition persisted. Changes in cell cycle composition were inconsistant 
when DFO was added to media spiked with supplementary iron or haem. The stimulatory 
effect of iron or haem was only partially reversed by the addition of DFO in the OE33 and 
OE19 cell lines and similar to control in the OE21 line. 
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Figure 5.21 Iron chelation significantly inhibits the oesophageal cancer cell cycle 
Propidium iodide FACS analysis of oesophageal cancer cell lines. Figure A: OE33, figure B: 
OE19 and figure C: OE21 after 48 hours culture with or without Deferasirox and DFO at 
IC50 concentrations +/- supplementary 100µM iron or haem 20µM. Deferasirox arrests 
oesophageal cancer cells in S phase and prevents the stimulatory effect of supplementary 
iron and haem. (*p=<0.05 significant change in percentage of cells in given cell cycle 
phase compared to plain media control). Error bars denote ± SEM. 
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5.3.6.2 Deferasirox increases expression of the cell cycle related nuclear protein CDC45L 
in oesophageal cancer cells 
Deferasirox appears to arrest the cell cycle of oesophageal cancer cells in S phase when 
the iron dependent, cell cycle regulatory protein RNR is normally active. Inactivation of 
RNR activity, secondary iron chelation, may account for cell arrest in S phase. To add 
credence to this argument, a proxy marker of S phase suspension, CDC45L accumulation 
was utilised434,435. Cell lines OE33, OE19 and OE21 were cultured with or without 
Deferasirox 20µM +/- iron 100µM. Hydroxyurea (HU) 2mM, a potent inhibitor of RNR, 
and plain media were included as positive and negative controls respectively. After 48 
hours cells were harvested and the nuclear fraction isolated and processed for CDC45L 
Western blotting. Protein loading was standardised to the highly expressed nuclear 
protein SP-1 (figure 5.22). 
In all three cell lines, HU exposure induced a highly significant rise in CDC45L protein 
expression (all p=<0.0001). Media spiked with Deferasirox demonstrated a similar but 
slightly less pronounced induction of CDC45L. Deferasirox induced CDC45L expression 
was statistically significant in all, but most evident in, the OE21 cell line (fold change 
1.64±0.07 p=0.001, 2.46±0.25 p=0.002 and 2.62±0.21 p=0.0001 for OE33, OE19 and OE21 
respectively). The addition of supplementary iron to Deferasirox containing media 
nullified the increase in CDC45L expression to levels consistent with control media alone 
(0.95±0.06 p=0.9, 1.12±0.09 p=0.42 and 1.21±0.06 p=0.14 for OE33, OE19 and OE21 
respectively). Supplementary iron alone increased CDC45L protein expression in all cell 
lines, reaching statistical significance in OE19 and OE21 cells (1.36±0.07 p=0.012, 
1.53±0.15 p=0.05 and 2.1±0.16 p=0.012 for OE33, OE19 and OE21 cell lines). 
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Figure 5.22 Deferasirox increases expression of the cell cycle related nuclear protein 
CDC45L in oesophageal cancer cells 
Cell lines OE33, OE19 and OE21 were cultured with or without Deferasirox 20µM +/- iron 
100µM. Hydroxyurea (HU) 2mM, a potent inhibitor of RNR, and plain media were 
included as positive and negative controls respectively. After 48 hours cells were 
harvested and the nuclear fraction isolated and processed for CDC45L Western blotting. 
Protein loading was standardised to the highly expressed nuclear protein SP-1. (*p=<0.05 
significant change in CDC45L protein expression relative to control and normalised to 1). 
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5.3.7 The in-vivo activity of oral Deferasirox on tumour burden in murine xenograft 
models of oesophageal cancer and quantification of systemic toxicity 
OE33, OE19 and OE21 cell lines, mixed 50/50 v/v with freshly thawed Matrigel, were 
injected into the subcutaneous plane of NOD-SCID mice (1x106) and allowed to establish 
mature xenografts. The mice were then gavaged with Deferasirox (20mg/Kg) or vehicle 
alone on alternate days for 3 weeks. The mice were culled and xenografts, organs and 
blood harvested for analysis (xenograft weight, haematological and biochemical 
parameters, gross xenograft iron content, xenograft tissue for qRT-PCR and 
immunohistochemistry). 
5.3.7.1 Oral Deferasirox significantly reduces xenograft tumour burden in murine 
models of oesophageal cancer 
OE33, OE19 and OE21 cell xenografts were harvested after a 21 day period of orally 
gavaged Deferasirox. Oral Deferasirox significantly reduced average xenograft weight in 
the OAC and SCC xenografts compared to control vehicle alone (OE33: control n=14, 
409±52mg; Deferasirox n= 12, 232±17.9mg, p=0.061; OE19: control n=8, 344±45mg; 
Deferasirox n=5, 199±40mg, p=0.05; OE21: control n=5, 426±70mg; Deferasirox n=5, 
217±29mg, p=0.025). Deferasirox reduced overall tumour burden by 43%, 42% and 37% 
for OE33, OE19 and OE21 xenografts compared to control (figure 5.23). 
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Figure 5.23 Oral Deferasirox significantly reduces xenograft tumour burden in a murine 
model of oesophageal cancer 
Mean OE33, OE19 and OE21 cell line xenograft weight (Figure A) and representative 
images (Figure B) after orally administered Deferasirox (20mg/Kg) on alternate days for 
three weeks compared to vehicle alone. (*p=0.0061, p=0.05 and p=0.025 for OE33, OE19 
and OE21 respectively). Error bars denote ± SEM. 
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5.3.7.2 Oral administration of Deferasirox (20mg/Kg) does not adversely affect mouse 
weight 
Mouse weight, as a proxy of well being and general physiological condition was 
monitored over the three week period of oral Deferasirox administration436. 
Oral Deferasirox did not show a statistical difference, in average mouse weight, 
compared to vehicle alone (p=0.8) (figure 5.24). 
 
 
 
Figure 5.24 Oral administration of Deferasirox (20mg/Kg) does not adversely affect 
mouse weight 
Mice were gavaged with either Deferasirox 20mg/Kg or vehicle alone for 21 days. No 
difference in average weight was observed between the control and treatment cohorts 
(p=0.08). Control n=33; Deferasirox n=27. Error bars denote ± SEM. 
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5.3.7.3 Oral administration of Deferasirox (20mg/Kg) does not impact on murine 
systemic haematological and biochemical indices 
Mice were gavaged with either Deferasirox 20mg/Kg or vehicle alone for 21 days. Blood 
samples were obtained by direct cardiac puncture, at the time of culling, for FBC and 
biochemical analysis (urea, creatinine, ALT, AST, albumin, total bilirubin, serum iron, and 
total iron binding capacity). 
No statistically significant difference was noted between the haematological and 
biochemical indices of vehicle alone and Deferasirox treated murine cohorts. Orally 
administered Deferasirox (20mg/Kg over 21 days) does not appear to cause significant 
systemic iron stripping or derange liver or renal function in mice. Unfortunately, serum 
samples were not large enough for creatinine and AST calculation and therefore could 
not be analysed (table 5.1). 
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Table 5.1 Oral administration of Deferasirox (20mg/Kg) does not impact on systemic 
haematological and biochemical indices in murine models 
Mice were gavaged with either Deferasirox 20mg/Kg or vehicle alone for 21 days. 
Deferasirox treatment does not impact on haematological (Table A) or biochemical (Table 
B) parameters with no evidence of systemic iron stripping or derangement of liver and 
renal function. (Hb: haemoglobin; HCT: haematocrit; MCV: mean cell volume; MCH: mean 
cell haemoglobin; MCHC: mean cell haemoglobin concentration; PLT: platelets; WBC: 
total white cell count; RET: reticulocyte count; NEUT: neutrophil count; TIBC: total iron 
binding capacity; ALP: alkaline phosphatise; ALT: alanine transferase; ALB: albumin; TP: 
total protein). (All p-values >0.5). 
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5.3.7.4 Oral administration of Deferasirox (20mg/Kg) does not alter major organ weight 
or iron content in murine models 
Mice were gavaged with either Deferasirox 20mg/Kg or vehicle alone for 21 days. After 
culling, major organs (liver, spleen and heart) were harvested and average weights 
compared between the control and treatment cohorts. No significant difference in 
average liver, spleen or heart weight was noted between the treatment groups. 
Harvested organs (liver, spleen and heart) were then processed to derive gross iron 
content (ferrozine assay). No significant difference in average iron content was observed 
between the Deferasirox treated cohort and vehicle alone controls (figure 5.25). 
 
 
Table 5.2 Oral administration of Deferasirox (20mg/Kg) does not alter major organ 
weights in murine models 
Mice were gavaged with either Deferasirox 20mg/Kg or vehicle alone for 21 days. Major 
organs (liver, spleen and heart) were harvested and average weights (mg) compared (all 
p-values >0.5) 
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Figure 5.25 Oral administration of Deferasirox (20mg/Kg) does not alter major organ 
iron content in murine models 
Mice were gavaged with either Deferasirox 20mg/Kg or vehicle alone for 21 days. Major 
organs (liver, spleen and heart) were harvested and average iron content (nM/mg 
protein) compared (all p-values >0.5). Error bars denote ± SEM. 
 
5.3.7.5 Oral administration of Deferasirox (20mg/Kg) does not alter iron transport 
protein immunoreactivity in murine major organs (liver, spleen and heart) 
Mice were gavaged with either Deferasirox 20mg/Kg or vehicle alone for 21 days. Major 
organs (liver, spleen and heart) were harvested and processed for TfR1, ferritin and FPN 
immunohistochemistry. No difference in immunoreactivity was observed for TfR1, ferritin 
or FPN in any organ after Deferasirox administration when compared to vehicle alone 
controls (figure 5.26). 
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Figure 5.26 Representative images of major organ immunoreactivity following oral administration of Deferasirox or control vehicle alone 
NOD-SCID mice were gavarged with Deferasirox (20mg/Kg) or vehicle alone for 21 days. Immunoreactivity for TfR1, ferritin and FPN in liver, spleen and heart (magnification 
x20; inset box extrapolated to x60). 
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5.3.7.6 Characterisation of the in-vivo effects of iron chelation on xenograft iron 
content and alterations in iron transport proteins 
OE33, OE19 and OE21 cell xenografts were harvested after a 21-day period of orally 
gavaged Deferasirox and compared to vehicle alone controls. Harvested xenograft 
material was divided and processed for iron transport protein mRNA expression, 
immunohistochemistry and iron content. 
 
5.3.7.7 Oral administration of Deferasirox (20mg/Kg) for 21 days significantly reduces 
iron content in oesophageal cancer xenografts 
OE33, OE19 and OE21 xenografts were harvested at the time of culling after 21 days of 
oral Deferasirox or vehicle alone. Xenograft tissue was processed for gross iron content, 
utilising the ferrozine assay, and expressed as nM/mg protein. In contrast to the native 
major intra-abdominal organs, xenograft tissue from mice receiving Deferasirox showed 
marked and statistically significant reductions in iron content when compared to control. 
This observation was consistent across all three cell lines (OE33: p=0.0046; OE19: p=0.05; 
OE21: p=0.048) (figure 5.27). 
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Figure 5.27 Oral administration of Deferasirox (20mg/Kg) for 21 days significantly 
reduces iron content in oesophageal cancer xenografts 
Gross iron content (nM/mg protein) of xenografted oesophageal cell lines after orally 
administered Deferasirox or control vehicle alone. A significant reduction in average iron 
content was evident in the Deferasirox cohort compared to control. (*p=0.0046, p=0.05 
and p=0.048 for OE33, OE19 and OE21 cell lines respectively). Error bars denote ± SEM. 
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5.3.7.8 Oral administration of Deferasirox (20mg/Kg) for 21 days significantly alters 
mRNA expression of iron transport proteins in oesophageal cancer xenografts 
NOD-SCID mice bearing OE33, OE19 and OE21 xenografts were subject to oral 
Deferasirox (20mg/Kg) or control vehicle alone for 21 days. Upon culling, xenograft tissue 
was analysed for TfR1, ferritin and FPN mRNA expression using qRT-PCR (figure 5.28). 
Marked up-regulation of TfR1 mRNA expression was observed in the xenograft tissue 
exposed to Deferasirox, compared to control, across all lineages (fold change: 4.26±0.95 
p=0.0012; 2.04±0.3 p=0.048; 3.61±0.89 p=0.041 for OE33, OE19 and OE21 cell lines, 
respectively). mRNA of the iron storage protein ferritin, was significantly reduced in the 
Deferasirox cohort, compared to control and again was consistent across the cell lines 
(0.79±0.2 p=0.05; 0.64±0.1 p=0.006; 0.74±0.08 p=0.05 for OE33, OE19 and OE21 cell lines 
respectively). FPN mRNA expression was similarly significantly reduced in all cell lines 
(0.32±012 p=0.021; 0.57±0.04 p=0.05; 0.38±0.08 p=0.041 for OE33, OE19 and OE21, 
respectively). 
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Figure 5.28 Oral administration of Deferasirox significantly alters mRNA expression of 
the iron transport proteins in oesophageal cancer xenografts 
NOD-SCID mice bearing OE33, OE19 and OE21 xenografts were subjected to oral 
Deferasirox (20mg/Kg) or control vehicle alone for 21 days. Upon culling, xenograft tissue 
was analysed for TfR1, ferritin and FPN mRNA expression using qRT-PCR (*p=<0.05 fold 
change compared to vehicle alone). 
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5.3.7.9 Oral administration of Deferasirox (20mg/Kg) for 21 days significantly alters iron 
transport protein expression (immunohistochemistry) in oesophageal cancer xenografts 
Mice bearing OE33, OE19 and OE21 xenografts were subjected to oral Deferasirox 
(20mg/Kg) or control vehicle alone for 21 days. Immediately after culling, xenograft tissue 
was analysed for TfR1, ferritin and FPN protein localisation and semi-quantitative 
expression utilising immunohistochemistry as previously described (2.2.2) (figures 5.29 
and 5.30). 
Changes in immunohistochemistry reactivity scores for TfR1, ferritin and FPN mirrored 
observed changes in mRNA expression. TfR1 immunoreactivity was significantly elevated 
in the Deferasirox exposed cohort for all three cell lines (OE33: 2.66±0.33 vs 10±1, 
p=0.0022; OE19: 2.66±0.33 vs 11±1.0, p=0.0014; OE21: 3.33±0.33 vs 11±1.0, p=0.0019 for 
control and Deferasirox cohorts respectively). TfR1 immunoreactivity appeared 
principally to be membranous with a degree of cytoplasmic reactivity. Similar TfR1 
protein localisation was noted between cell lines, varying only in immunoreactivity 
intensity between control and Deferasirox cohorts (figure 5.30). Xenograft ferritin 
immunoreactivity was significantly reduced in mice gavaged with Deferasirox compared 
to vehicle alone (OE33: 8.0±1.0 vs 4.66±0.66, p=0.05; OE19: 10±1.0 vs 2.66±0.33, 
p=0.0022; OE21: 9.66±1.2 vs 3.33±0.33, p=0.0017 for control and Deferasirox cohorts 
respectively). Ferritin localisation was cytoplasmic in both Deferasirox and control 
cohorts across all cell lines (figure 5.30). FPN immunoreactivity was significantly reduced 
in xenografts exposed to Deferasirox compared to vehicle alone (OE33: 5.33±0.66 vs 
2.33±0.33, p=0.016; OE19: 8.66±0.33 vs 2.66±0.0.33, p=0.0022; OE21: 8.33±0.33 vs 
3.33±0.33, p=0.0004 for control and Deferasirox cohorts respectively). FPN localisation 
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varied little between treatment cohorts and cell lines with immunoreactivity presenting 
mixed cytoplasmic and membranous distributions (figure 5.30). 
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Figure 5.29 Oral administration of Deferasirox alters iron transport protein expression 
(immunohistochemistry) in oesophageal cancer xenografts 
NOD-SCID mice bearing OE33, OE19 and OE21 cell line xenografts were gavaged with 
Deferasirox (20mg/Kg) or vehicle alone for 21 days. Immunoreactivity for TfR1, ferritin 
and FPN was analysed with a semi-quantitative technique. (*p=<0.05 compared to 
vehicle alone). Error bars denote ± SEM. 
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Figure 5.30 Representative images of xenograft immunoreactivity following oral administration of Deferasirox or control vehicle alone 
NOD-SCID mice bearing OE33, OE19 and OE21 cell line xenografts were gavarged with Deferasirox (20mg/Kg) or vehicle alone for 21 days. Immunoreactivity for TfR1, 
ferritin and FPN (magnification x20; inset box extrapolated to x60). 
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5.3.8 Exploration of the anti-neoplastic potential of iron chelators in combination with 
standard chemotherapeutic agents for oesophageal cancer treatment and possible 
action on chemoresistant lineages 
The current standard chemotherapeutic regime for the treatment of OAC and SCC is a 
combination of Cisplatin, 5-FU and Epirubicin (ECF)437. In order to assess the potential of 
iron chelators to enhance the response to standard chemotherapy, OE33, OE19 and OE21 
cell lines were cultured with Cisplatin, 5-FU or Epirubicin, at IC50 concentration and 
challenged with titrated doses of Dp44mT, Deferasirox or DFO. The effect on cellular 
viability and proliferation was assessed by MTT and BrdU assays after 48 hours of 
incubation under experimental conditions. IC50 values for chemotherapy agents were 
derived by viability (MTT) and proliferation (BrdU) assays and determined as: Cisplatin 
8µM, 5-FU 8µM and Epirubicin 1µM. 
 
5.3.8.1 Iron chelators confer additive anti-neoplastic action in combination with 
standard chemotherapeutic agents on oesophageal cancers 
Results were consistent across all three cell lineages representing OAC and SCC 
malignancies. Even at low doses (0.25µM) Dp44mT could markedly suppress the level of 
viability and proliferation in the presence of Cisplatin, 5-FU or Epirubicin. Suppression of 
viability and proliferation was also evident for the clinically established chelators DFO and 
Deferasirox in combination with any of the three chemotherapeutic agents. In the 
majority of Deferasirox, DFO and chemotherapy agent combinations, additional chelator 
induced cytotoxic action occurred at concentrations below calculated IC50 values (figures 
5.31 and 5.32). Furthermore, irrespective of the iron chelator and chemotherapy agent 
 248 
 
used, the effect of combining these two classes of drugs was significantly more cytotoxic 
than that expected with one agent alone. This positive interaction appeared to be 
chelator and concentration dependent in all cases (table 5.3 and 5.4). 
  
 249 
 
 
 
 250 
 
 
 
Figure 5.31 Effect of iron chelators and standard chemotherapeutic agents on 
oesophageal cancer cellular viability 
Figure A: OE33, figure B: OE19 and figure C: OE21. 
Cellular viability was assessed in OE33, OE19 and OE21 cell lines following 48 hours of 
incubation with a titrated dose of Dp44mT, Deferasirox and DFO alone or in the presence 
of Cisplatin (8 µM), 5-FU (8 µM) or Epirubicin (1 µM). Error bars denote ± SEM. 
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Figure 5.32 Effect of iron chelators and standard chemotherapeutic agents on 
oesophageal cancer cellular proliferation 
Figure A: OE33, figure B: OE19 and figure C: OE21. 
Cellular proliferation was assessed in OE33, OE19 and OE21 cell lines following 48 hours 
of incubation with a titrated dose of Dp44mT, Deferasirox and DFO alone or in the 
presence of Cisplatin (8 µM), 5-FU (8 µM) or Epirubicin (1 µM). Error bars denote ± SEM. 
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   p-value 
Cell Line Iron Chelator Chemotherapeutic agent Viability 
(MTT) 
Proliferation 
(BrdU) 
OE33 Deferasirox Cisplatin 0.002 0.005 
  5-FU 0.004 0.002 
  Epirubicin 0.003 0.022 
 DFO Cisplatin 0.002 0.008 
  5-FU 0.020 0.001 
  Epirubicin 0.003 0.026 
 Dp44mT Cisplatin 0.024 0.036 
  5-FU 0.036 0.024 
  Epirubicin 0.016 0.317 
 
OE19 Deferasirox Cisplatin 0.001 0.008 
  5-FU 0.001 0.006 
  Epirubicin <0.001 0.004 
 DFO Cisplatin 0.001 0.013 
  5-FU 0.005 0.020 
  Epirubicin 0.004 0.004 
 Dp44mT Cisplatin 0.008 0.045 
  5-FU 0.021 0.020 
  Epirubicin 0.009 0.012 
 
OE21 Deferasirox Cisplatin 0.007 0.002 
  5-FU 0.004 <0.001 
  Epirubicin 0.002 0.002 
 DFO Cisplatin 0.003 0.046 
  5-FU 0.023 0.001 
  Epirubicin 0.003 <0.001 
 Dp44mT Cisplatin 0.015 0.037 
  5-FU 0.024 0.014 
  Epirubicin 0.002 0.015 
 
Table 5.3  Assessment of the statistical significance of treating oesophageal cancer cell 
lines with chelator alone compared to a combination of chelator and standard 
chemotherapeutic agent 
OE33, OE19 and OE21 cell lines were challenged with a titrated dose of Dp44mT, 
Deferasirox or DFO in the presence or absence of Cisplatin (8 µM), 5-FU (8 µM) or 
Epirubicin (1 µM) for 48 hours and assessed for viability and proliferation. Mean cell 
counts were then assessed across each regimen and statistical analysis performed 
between different regimes and p-values derived (Kindly calculated by statistician Dr 
Roger Holder – see statistical methods 2.2.18). 
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Cell line Chelating Agent 5-Fu Cisplatin Epirubicin 
OE19 Deferasirox 10µM 5-10µM 5-80µM 
 DFO 2.5-5µM 2.5-10µM 2.5-40µM 
 Dp44MT 0.25µM 0.25µM-1µM 0.25-1µM 
OE21 Deferasirox 5-10µM 5-10µM 5-40µM 
 DFO nil nil 2.5-20µM 
 Dp44MT 0.25µM 0.25µM 0.25-0.5µM 
OE33 Deferasirox 5-10µM 5-20µM 10µM 
 DFO 2.5-5µM 2.5-5µM -20µM 2.5-5µM 
 Dp44MT 0.25µM 0.25-0.5µM 0.25µM 
 
Table 5.4 Concentration/range of iron chelators indicating a chemo-sensitising potential 
in the presence of standard chemotherapeutic agents 
Concentration ranges were derived by MTT and or BrdU assays (kindly calculated by 
statistician Dr Roger Holder) for OE19, OE33 and OE21 cell lines and iron chelators 
Dp44mT, Deferasirox or DFO in the presence of chemotherapeutic agents 5-FU (8µM), 
Cisplatin (8µM) or Epirubicin (1µM). 
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5.3.8.2 Deferasirox and DFO can overcome Cisplatin chemo-resistance in-vitro 
To further investigate the action of Deferasirox and DFO to enhance chemotherapeutic 
effects and potentially over come chemo-resistance, the oesophageal SCC Cisplatin-
resistant cell line TE-4 was utilised438. As expected there was no loss in cellular viability 
when culturing TE-4 cells with 2µM Cisplatin relative to untreated controls. However, 
culturing TE-4 cells with even a very low concentration of Deferasirox (5µM) together 
with 2µM Cisplatin resulted in a significant decrease in cellular viability compared to 
Cisplatin alone (p<0.05). Notably, the same low concentration of Deferasirox did not 
induce any loss of viability compared to untreated control cells when used in isolation. 
Similarly when DFO was used at a non-toxic concentration (2.5 µM) and co-cultured with 
Cisplatin, a marked suppression of cellular viability compared to Cisplatin alone was 
observed (figure 5.33).  
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Figure 5.33 The effect of iron chelators on TE-4 cellular viability 
TE-4 cells were challenged with Cisplatin (2µM) in the presence or absence of Deferasirox 
(figure A; 5-20µM) or DFO (figure B; 2.5-10µM) and cellular viability assessed utilising an 
MTT assay. (*p=<0.05 compared to control unchallenged cells; † Denotes p=<0.05 
compared to Cisplatin alone). Error bars denote ± SEM. 
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5.4 Conclusions 
This study is the first to provide evidence that iron chelators may be of use in the 
treatment of oesophageal cancer. 
Deferasirox was the most effective clinically established agent in blocking up-take and 
extraction of iron from the panel of oesophageal cancer cells in-vitro. The promising 
experimental chelator Dp44mT is vastly superior to Deferasirox and DFO in chelating iron, 
however, it is too toxic to be trialled in humans in its present form. Interestingly, both 
Deferasirox and DFO delivered significant chelating capability at a fraction of the 
calculated IC50 values suggesting that in-vivo activity could still be achieved at relatively 
low doses. 
The chelating action of Deferasirox and DFO, on intracellular iron, resulted in a classical 
IRE-IRP mediated response to iron deprivation250. TfR1 was consistently up-regulated at 
the mRNA and protein levels, reflecting the increase in inorganic iron endocytosis. 
Correspondingly, iron storage capacity and efflux were curtailed. Proteins capable of 
haem import or export generally responded in a manner expected of a cell depleted of 
iron. However, the responses were not consistent or statistically significant in all cell 
lineages. LRP1 protein was significantly elevated in OAC cells but not the squamous OE21 
line. Conversely, HCP1 was not significantly elevated in OAC lines but was in OE21 cells. 
Logically, elevated expression of the haem importing protein LRP1 would fit with an 
increased need for cellular iron. However in chapter four, it was apparent that LRP1 did 
not seem to be regulated by intracellular iron concentration, although the exact 
mechanism of expression is yet to be elucidated. mRNA and protein expression of HCP1 
may not reflect iron requirements of the cell as HCP1 is post-translationally regulated by 
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intracellular iron concentration,  shuffling between the cytosolic and membranous 
compartments as required274,285,295. The expression of haem export proteins, BCRP and 
FLVCR, was generally down at the mRNA and protein levels, most likely reflecting the 
reduced levels of oxidative stress in the iron depleted cell as part of a detoxifying role 
rather than responding directly to intracellular iron concentration. 
Cellular iron deprivation, induced by exposure to Deferasirox and DFO, had a significant 
impact on cellular viability and proliferation. Viability and proliferation were both reduced 
by approximately fifty percent, in line with application at their respective predetermined 
IC50 concentrations. Supplementary iron sulphate and haem induced significant increases 
in viability and proliferation as previously observed in chapter four. The addition of iron 
chelators to media spiked with either inorganic or haem nullified the mitogenic action of 
supplementary iron. The anti-proliferative effect of iron chelators, in the presence of both 
inorganic and organic iron, is particularly encouraging given the recognised contribution 
of haem to the intracellular iron pool of oesophageal cancer cells. Importantly, these in-
vitro effects were observed across all three oesophageal cell lines (OAC and SCC lines), 
suggesting that the effect of modulating cellular iron levels is not cell lineage dependent. 
Indeed, the indiscriminate action of iron chelators on malignant cell lineages is consistent 
with the existing literature involving experimental chelators323,325,439-441. In this study, the 
experimental chelator Dp44mT demonstrated aggressive in-vitro anti-neoplastic effects 
which were not reversed by the addition of iron. This interesting observation is likely to 
be mediated by the novel mechanism of action of Dp44mT. Dp44mT is capable of prolific 
ROS generation by free radical cycling with iron and subsequent induction of pro-
apoptotic pathways323,400. 
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Further evidence of the anti-neoplastic effects of iron chelators on cellular phenotype was 
demonstrated by the impaired ability of all three cell lines to form viable independent 
colonies (as a surrogate for metastatic potential) and inhibit cell migration. Deferasirox 
and DFO significantly reduced colony formation and migratory potential which was 
subsequently reversed by the addition of supplementary iron. Again, Dp44mT 
demonstrated marked impairment of the malignant activities of colony formation and 
migration which was robustly maintained with the addition of supplementary iron. As 
expected, iron alone significantly enhanced colony formation and migratory activity, 
potentially mediated by iron-induced down-regulation of the adhesion molecule E-
cadherin. Dp44mT is also known to up-regulate expression of the tumour growth and 
metastasis suppressor, Ndrg1 in pancreatic cancer cells and may mediate the same 
effects in malignant oesophageal lineages408. 
Cell cycle analysis demonstrated a clear stimulatory effect of supplementary iron in all cell 
lines, significantly decreasing the percentage of cells in G0/G1 and boosting percentages 
passing through S and into G2/M. A similar effect was seen with supplementary haem, 
although the response was more muted and reached statistical significance in the OE19 
cell line only. The most startling changes were observed in the presence of Deferasirox 
which appeared to arrest the cell cycle in S phase. S phase arrest of the cell cycle was an 
unexpected finding as iron chelators have classically been observed to cause cycle arrest 
at the G1/S interface. The action of DFO has been studied in great detail in other 
malignant lineages and conforms to the expected G1/S arrest, mediated by a series of 
complex interactions which culminate in a decrease of the hyperphosphorylated form of 
pRb and G1/S arrest
189,194,371. DFO does not appear to directly inhibit the iron dependent 
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enzyme RNR, or it at least mediates cell cycle arrest before this becomes significantly 
important371. DFO failed to consistently alter the cell cycle in oesophageal cancer cells 
although it did show statistically significant evidence of G1/S hold-up in the OE33 cell line. 
Deferasirox mediated cell cycle arrest in S phase is likely to represent functional loss of 
RNR through iron deprivation, preventing the cell from completing the task of DNA 
replication, rather than disrupting G1/S. The potential inhibition of RNR by Deferasirox 
was further investigated by Western blotting for nuclear levels of CDC45L protein, as a 
proxy marker of cellular arrest in S phase434,435. CDC45L protein levels were significantly 
higher in cells exposed to Deferasirox and comparable to the degree of CDC45L protein 
accumulation seen with the application of HU to formally block RNR activity. Co-culture of 
iron with Deferasirox returned CDC45L levels back to those of control. Recently published 
data detailing the anti-neoplastic effects of Deferasirox on human hepatoma cells has also 
shown blockade of the cell cycle in S phase, potentially attributed to iron depletion and 
reduced polyamine metabolism387. Iron chelators are likely to interact in subtly different 
ways with the complex control mechanisms of the cell cycle and clearly an in-depth 
evaluation of the effects of Deferasirox on the cell cycle is required. 
A murine xenograft model of human oesophageal cancer was developed to assess the in-
vivo anti-neoplastic effects of Deferasirox as the agent of choice in a future clinical trial. 
Over a three week period, oral Deferasirox administration had a remarkable impact on 
xenograft tumour burden, reducing the mean average xenograft weight by approximately 
forty percent for OAC and SCC lineages. Such a reduction is on a par with the actions of 
experimental iron chelators in other non-gastrointestinal xenografts323. The average gross 
iron content of the xenografts exposed to Deferasirox was significantly reduced compared 
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to control, strongly supporting iron deprivation as an important mechanism of anti-
neoplastic action. Furthermore, the mice tolerated Deferasirox treatment extremely well 
maintaining a normal growth trajectory and organ weight compared to control. Despite 
extracting iron from the xenograft, importantly, there was no evidence of systemic and 
solid organ iron stripping or biochemical derangement. Changes seen in IRE-IRP 
responsive iron transport proteins were more consistent and marked than those 
observed in-vitro. Xenografts exposed to Deferasirox uniformly demonstrated significant 
up-regulation of TfR1 mRNA expression in response to iron deprivation to increase 
inorganic iron endocytosis. Similarly, iron storage capacity and efflux was reduced with 
significant suppression of ferritin and FPN mRNA expression in response to Deferasirox. 
Semi-quantitative immunohistochemistry was again concordant with xenograft iron 
deprivation. No changes in IRE-IRP responsive iron transport proteins were observed in 
the solid organs of mice administered Deferasirox, further supporting the tumour specific 
action of Deferasirox; at least at this low dose and relatively short duration. Deferasirox 
was administered at the standard starting dose for patients treated for iron overload 
(20mg/Kg). Even considering the differences between human and mouse biochemistry 
and pharmacodynamics, 20mg/Kg is a low dose and may reflect the ability of Deferasirox 
to chelate the majority of iron from malignant cells at very low concentrations, as seen in-
vitro. The apparent sparing of healthy benign cells has been noted in all studies assessing 
the potential anti-neoplastic effects of iron chelators323,325,328. This fascinating observation 
may represent the relative sensitivity of malignant cells to iron deprivation or subtle 
changes in the metabolism of iron by cancer cells rendering them more accessible to 
chelation. One such mechanism may be inhibition of the canonical Wnt/β-catenin 
oncogenic signalling pathway which is well known to be active in gastrointestinal 
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epithelial cancers176. DFO and Deferasirox are both potent iron dependent inhibitors of 
Wnt signalling in malignant colorectal lineages331. However, it is likely that iron chelators 
mediate cytotoxic activity by several pathways that may not be iron dependent. Indeed, 
the cytotoxic action of Deferasirox in myelodysplastic syndromes may be mediated 
through inhibition of the NF– κB pathway, which was not influenced by the addition of 
iron and is highly active in oesophageal cancers386,442. In addition, Deferasirox may 
mediate anti-proliferative effects on myeloid leukaemia cells by suppression of signalling 
through the mTOR pathway, which is again active in oesophageal malignancy396,443. 
Chemotherapy is the key to enhancing overall survival and prolonging life in patients 
receiving palliative care for oesophageal malignancy444. Perhaps the most encouraging 
aspect of the anti-neoplastic effects of DFO and Deferasirox are their apparent chemo-
sensitising properties in combination with the standard chemotherapeutic agents 
currently utilised in the treatment of oesophageal malignancies. The combination of 
chelators and chemotherapy agents demonstrated significantly greater cytotoxicity than 
observed with one agent alone in both OAC and SCC lineages. Pertinently for potential 
translation into clinical trials, Deferasirox and DFO showed marked additional cytotoxic 
action at doses well below IC50 values when in combination with chemotherapeutic 
agents, affording the possibility of dose reduction to minimise toxicity. The chemo-
sensitising action of Deferasirox and DFO was further highlighted when applied to the 
Cisplatin-resistant cell line TE-4, which became responsive to Cisplatin in the background 
of small doses of Deferasirox or DFO. These observations are consistent with other 
studies utilising the experimental iron chelator Dp44mT, which has been shown to 
overcome both etoposide and vinblastine resistance323. Similar data has been generated 
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in a leukaemic cell line, K562, where pre-incubation of cells with Deferasirox and 
subsequent incubation with etoposide, led to increased apoptosis above that expected 
with either agent alone396. Chemo-resistance is of major concern in the treatment OAC 
and many patients with non-responsive tumours are subject to unnecessary 
chemotherapy induced toxicity and subsequent delay in oesophagectomy445,446. At the 
present time, it is not possible to identify subtle differences in tumour biology that could 
robustly guide more selective treatment, therefore the introduction of a chemo-
sensitising agent that possesses independent anti-neoplastic properties is likely to benefit 
the majority of patients. 
Iron chelators show potential as anti-neoplastic and chemo-sensitising agents. This 
chapter provides a platform for assessing the utility of clinically established agents, such 
as Deferasirox, in the treatment of patients with oesophageal cancer. 
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CHAPTER 6: DISCUSSION 
 
6.1 Conclusions 
The cumulative evidence implicating iron in the pathogenesis and propagation of 
oesophageal malignancy is compelling. Understanding of the regulatory and metabolic 
pathways controlling iron homeostasis is now largely established and this knowledge can 
now be applied to delineate the pathological derangement in iron metabolism seen in 
malignancy. 
Ex-vivo samples of OAC are iron loaded in a progressive manner from benign BM to 
dysplastic BM and finally malignant transformation171. This continuing iron acquisition in 
oesophageal malignancies is paradoxical, given the high intracellular iron levels, and is 
clearly demonstrated by the ability of OAC cells to sequester more iron, through up-
regulation of TfR1 mediated endocytosis of transferrin bound iron and functional loss of 
iron export processes, in the background of an iron replete state171. The elegant and 
finely tuned homeostatic mechanism for controlling intracellular iron concentration, 
based on the IRE-IRP system, appears to have been abandoned at some point in the 
evolutionary paradigm of oesophageal carcinogenesis120,248,249. The exact trigger for this 
phenomenon remains elusive, although, it has been postulated that increased expression 
of the oncogene c-Myc induces inappropriate up-regulation of TfR1 in the background 
loss of APC function176. 
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However, there exists a pool of systemic haem that is constantly re-cycled in the process 
of erythrocyte regeneration, which is potentially available to cancer cells as a major 
source of iron accumulation270,290. This thesis provides, for the first time, evidence that 
both OAC and oesophageal SCC are able to capture haem in a manner akin to inorganic 
iron acquisition171. Ex-vivo OAC resection specimens, matched with adjacent dysplastic 
BM, demonstrate progressive up-regulation of the two recently discovered haem 
importing proteins LRP1 and HCP1. The membranous location of LRP1 and HCP1, 
demonstrated by immunohistochemistry in oesophageal cancer specimens, is highly 
suggestive of a functional role in capturing systemic haem. Haem, both free and bound to 
haemopexin, is likely to be relatively abundant in the substance of the tumour due to 
friable neovascularisation, direct vessel invasion and ulceration.  Once within the cell, 
iron is liberated from haem and enters a common inorganic iron metabolic pathway to 
create a more aggressive cellular phenotype171,270. Supplementary haem significantly 
enhances cellular proliferation, viability, migration and colony forming ability in-vitro 
compared to control. Abrogation of LRP1 or HCP1 expression reverses the stimulatory 
action of supplementary haem and induces a compensatory overexpression of TfR1, 
potentially mediated by the IRE-IRP regulatory mechanism in response to relative iron 
deprivation. The dramatic in-vivo contribution of LRP1 and HCP1 to tumourigenicity was 
highlighted here for the first time in a xenograft model of OAC where tumour burden was 
significantly reduced by up to seventy percent after loss of LRP1 or HCP1 expression. 
Intriguingly, the expression of haem exporting proteins, FLVCR and BCRP, was 
significantly up-regulated in OAC compared to adjacent dysplastic BM. These proteins are 
known to protect developing erythrocytes from excessive haem toxicity and enterocytes 
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from dietary derived toxins273,279. It is probable that the overexpression of FLVCR and 
BCRP in OAC could protect cancer cells from haem induced oxidative stress, especially 
within the hypoxic environment encountered in fast growing tumours285. 
LRP1 and HCP1 should be considered as novel targets for therapeutic monoclonal 
antibodies in the treatment of oesophageal malignancy. However, neither LRP1 nor HCP1 
are solely importers of haem. LRP1 is ubiquitously expressed as a general scavenger 
receptor with multiple ligands and HCP1 is putatively regarded to actively transport folate 
as well as haem296,298. With this in mind, the mechanism of anti-neoplastic action of 
blocking LRP1 or HCP1 could be multi-factorial and currently clinically unpredictable. 
The outcome from oesophageal cancer is notoriously dismal with an overall five-year-
survival figure quoted at just ten percent2,3. Despite the addition of neoadjuvant 
chemotherapy and refinement of surgical technique, the vast majority of patients still die 
from overwhelming malignant disease progression3. Oesophageal cancer cells have now 
been shown to acquire both organic and inorganic iron by the action of several transport 
proteins which helps explain why targeting TfR1 alone with monoclonal antibodies fails to 
produce a robust anti-neoplastic effect in a variety of malignant lineages208. Clearly 
simultaneous therapeutic functional blockade of multiple targets is not practical and 
likely to be prohibitively expensive and unpredictable. An alternative would be to deprive 
the cancer cell of iron by use of a chelating agent. This approach is particularly appealing 
as iron chelators have shown considerable anti-neoplastic properties in other 
malignancies and appear to exhibit cancer specific action without systemic iron 
stripping319,322,323,325,328. In addition, a number of iron chelators, including DFO and 
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Deferasirox are already in clinical use for the treatment of iron overload disorders and 
have excellent safety profiles357,379. 
This thesis details for the first time that iron chelators show potent anti-neoplastic action 
on OAC and oesophageal SCC both in-vitro and in-vivo. Experimental and clinically 
established iron chelators are able to extract significant amounts of iron from 
oesophageal cancer cells and prevent the up-take of ambient iron. The action of iron 
chelators significantly reduces proliferation, viability, migration and colony forming in-
vitro and reverses the stimulatory effect of supplementary iron. The experimental iron 
chelator Dp44mT displays the most aggressive anti-neoplastic action, however its 
potential systemic toxicity prohibits clinical application at the present time. Excitingly, the 
clinically established and orally administered iron chelator Deferasirox exhibited potent 
anti-cancer properties in-vitro and was taken forward to assess in-vivo performance in a 
mouse xenograft model. Orally administered Deferasirox significantly inhibited 
oesophageal cancer xenograft growth by up to forty percent and was extremely well 
tolerated without evidence of systemic or visceral iron stripping. The observed anti-
neoplastic action of Deferasirox is directly translatable into clinical research and should 
be considered for clinical trials in oesophageal cancer patients. Furthermore, iron 
chelators including Deferasirox, demonstrated an additive anti-neoplastic action in 
combination with current standard chemotherapy agents used in the treatment of 
oesophageal malignancy and were able to overcome chemo-resistance at very low 
concentrations. Chemo-resistance is of major concern in the treatment of OAC and many 
patients with non-responsive tumours are subject to unnecessary chemotherapy induced 
toxicity and subsequent delay in oesophagectomy445,446. At the present time, it is not 
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possible to identify subtle differences in tumour biology that could robustly guide more 
selective treatment; therefore the introduction of a chemo-sensitising agent that 
possesses independent anti-neoplastic properties is likely to benefit the majority of 
patients445. 
Oesophageal adenocarcinoma incidence is increasing at an alarming rate in Western 
populations and is principally associated with obesity, gastro-oesophageal reflux and 
Barrett's metaplasia1,42,45,46,55,58,120. Understanding the genetic and molecular events 
involved in the development of this disease is paramount to improving survival. This 
thesis contributes to the growing evidence implicating iron in the pathogenesis of 
oesophageal cancer and provides a platform to assess the utility of iron chelators as 
clinically therapeutic agents. 
 
6.2 Future work 
6.2.1 Laboratory experimental work 
Current understanding of the complex nature of systemic and cellular iron acquisition is 
not at a stage where targeted therapy, in the form of monoclonal antibodies to iron and 
haem transporting proteins, could be attempted in clinical trials. Regulatory interplay 
between LRP1 and HCP1 and cellular iron status is not clear and the ubiquitous 
expression of LRP1 in particular, creates an element of uncertainty as to the likely clinical 
effect of blocking these receptors298. 
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In contrast, iron chelation therapy, as an adjunct to current clinical management of 
patients with oesophageal malignancies, represents a far safer, cheaper, and more 
achievable alternative. The clinically licensed, well tolerated and orally administered 
chelator Deferasirox is the obvious agent of choice. Although there is little doubt that the 
principal mode of action of this drug is the chelation of iron, the exact pathways through 
which the cytotoxic action is mediated remain to be clarified. A reasonable place to start 
would be the NF– κB, mTOR and canonical Wnt/β-catenin signalling pathways that 
appear to be inhibited by Deferasirox in other cell lineages and are known to be active in 
oesophageal malignancies176,331,386,396,442,443. A more comprehensive assessment of the 
interplay between the complex mechanisms controlling the cell cycle and the action of 
Deferasirox would be appropriate especially considering the apparent induced cell cycle 
arrest in S phase, rather than G1/S more classically associated with iron chelators
189,371. 
The exciting in-vitro evidence of the chemo-sensitising capabilities of Deferasirox should 
be further explored and validated in murine models using a combination of chelator, 
standard chemotherapy agents and multiple cell lineages. Furthermore, the dose and 
timing of Deferasirox administration, as a pre-sensitising dose or in combination with 
chemotherapy agents, needs to be addressed. 
 
6.2.2 Clinical experimental work 
Work is currently underway to design and obtain funding and ethical approval for the 
assessment of Deferasirox in human clinical trials. In the first instance, safety, tolerability 
and proof of concept are paramount. Assuming murine studies are successful in 
validating the in-vitro evidence of the chemo-sensitising action of Deferasirox and provide 
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guidance on the most appropriate dosing regimen, these data can be used to finalise the 
proposed protocol for the application of Deferasirox in patients receiving palliative 
chemotherapy. The ultimate goal would be to combine Deferasirox with neoadjuvant 
chemotherapy in patients deemed potentially curable with a view to improving overall 
survival and prolonging life in the palliative setting. 
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